The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident implant combination for total hip arthroplasty (THA) was 1.18 percent at 1 year following the primary procedure. The 95% confidence interval was (1.04, 1.34). This estimate is based on 20558 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident implant combination for total hip arthroplasty (THA) was 1.62 percent at 2 years following the primary procedure. The 95% confidence interval was (1.46, 1.81). This estimate is based on 20229 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident implant combination for total hip arthroplasty (THA) was 1.92 percent at 3 years following the primary procedure. The 95% confidence interval was (1.74, 2.11). This estimate is based on 19712 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident implant combination for total hip arthroplasty (THA) was 2.20 percent at 4 years following the primary procedure. The 95% confidence interval was (2.01, 2.41). This estimate is based on 17402 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident implant combination for total hip arthroplasty (THA) was 2.43 percent at 5 years following the primary procedure. The 95% confidence interval was (2.23, 2.66). This estimate is based on 13756 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident implant combination for total hip arthroplasty (THA) was 2.68 percent at 6 years following the primary procedure. The 95% confidence interval was (2.46, 2.92). This estimate is based on 9612 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident implant combination for total hip arthroplasty (THA) was 2.92 percent at 7 years following the primary procedure. The 95% confidence interval was (2.67, 3.18). This estimate is based on 5704 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident implant combination for total hip arthroplasty (THA) was 3.12 percent at 8 years following the primary procedure. The 95% confidence interval was (2.84, 3.43). This estimate is based on 2953 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident implant combination for total hip arthroplasty (THA) was 3.62 percent at 9 years following the primary procedure. The 95% confidence interval was (3.20, 4.11). This estimate is based on 1084 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident implant combination for total hip arthroplasty (THA) was 3.72 percent at 10 years following the primary procedure. The 95% confidence interval was (3.26, 4.24). This estimate is based on 186 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident II implant combination for total hip arthroplasty (THA) was 1.58 percent at 1 year following the primary procedure. The 95% confidence interval was (1.40, 1.80). This estimate is based on 11752 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident II implant combination for total hip arthroplasty (THA) was 1.82 percent at 2 years following the primary procedure. The 95% confidence interval was (1.62, 2.06). This estimate is based on 7578 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident II implant combination for total hip arthroplasty (THA) was 2.13 percent at 3 years following the primary procedure. The 95% confidence interval was (1.88, 2.41). This estimate is based on 3967 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident II implant combination for total hip arthroplasty (THA) was 2.23 percent at 4 years following the primary procedure. The 95% confidence interval was (1.96, 2.53). This estimate is based on 1213 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident II implant combination for total hip arthroplasty (THA) was 2.55 percent at 5 years following the primary procedure. The 95% confidence interval was (1.94, 3.35). This estimate is based on 176 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II/Trident II implant combination for total hip arthroplasty (THA) was 2.55 percent at 6 years following the primary procedure. The 95% confidence interval was (1.94, 3.35). This estimate is based on 13 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C/Trident II implant combination for total hip arthroplasty (THA) was 0.97 percent at 1 year following the primary procedure. The 95% confidence interval was (0.40, 2.33). This estimate is based on 335 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C/Trident II implant combination for total hip arthroplasty (THA) was 1.84 percent at 2 years following the primary procedure. The 95% confidence interval was (0.81, 4.14). This estimate is based on 162 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C/Trident II implant combination for total hip arthroplasty (THA) was 1.84 percent at 3 years following the primary procedure. The 95% confidence interval was (0.81, 4.14). This estimate is based on 56 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C/Trident II implant combination for total hip arthroplasty (THA) was 1.84 percent at 4 years following the primary procedure. The 95% confidence interval was (0.81, 4.14). This estimate is based on 15 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C/Trident II implant combination for total hip arthroplasty (THA) was 1.84 percent at 5 years following the primary procedure. The 95% confidence interval was (0.81, 4.14). This estimate is based on 2 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF/Trident implant combination for total hip arthroplasty (THA) was 0.90 percent at 1 year following the primary procedure. The 95% confidence interval was (0.45, 1.79). This estimate is based on 883 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF/Trident implant combination for total hip arthroplasty (THA) was 1.57 percent at 2 years following the primary procedure. The 95% confidence interval was (0.93, 2.64). This estimate is based on 877 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF/Trident implant combination for total hip arthroplasty (THA) was 2.02 percent at 3 years following the primary procedure. The 95% confidence interval was (1.28, 3.19). This estimate is based on 873 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF/Trident implant combination for total hip arthroplasty (THA) was 2.81 percent at 4 years following the primary procedure. The 95% confidence interval was (1.90, 4.12). This estimate is based on 865 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF/Trident implant combination for total hip arthroplasty (THA) was 2.81 percent at 5 years following the primary procedure. The 95% confidence interval was (1.90, 4.12). This estimate is based on 854 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF/Trident implant combination for total hip arthroplasty (THA) was 2.81 percent at 6 years following the primary procedure. The 95% confidence interval was (1.90, 4.12). This estimate is based on 822 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF/Trident implant combination for total hip arthroplasty (THA) was 3.32 percent at 7 years following the primary procedure. The 95% confidence interval was (2.31, 4.74). This estimate is based on 704 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF/Trident implant combination for total hip arthroplasty (THA) was 3.91 percent at 8 years following the primary procedure. The 95% confidence interval was (2.76, 5.52). This estimate is based on 431 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF/Trident implant combination for total hip arthroplasty (THA) was 3.91 percent at 9 years following the primary procedure. The 95% confidence interval was (2.76, 5.52). This estimate is based on 215 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF/Trident implant combination for total hip arthroplasty (THA) was 3.91 percent at 10 years following the primary procedure. The 95% confidence interval was (2.76, 5.52). This estimate is based on 58 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Actis DuoFix/Pinnacle implant combination for total hip arthroplasty (THA) was 0.67 percent at 1 year following the primary procedure. The 95% confidence interval was (0.48, 0.93). This estimate is based on 4043 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Actis DuoFix/Pinnacle implant combination for total hip arthroplasty (THA) was 0.84 percent at 2 years following the primary procedure. The 95% confidence interval was (0.61, 1.14). This estimate is based on 2679 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Actis DuoFix/Pinnacle implant combination for total hip arthroplasty (THA) was 0.89 percent at 3 years following the primary procedure. The 95% confidence interval was (0.65, 1.22). This estimate is based on 1605 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Actis DuoFix/Pinnacle implant combination for total hip arthroplasty (THA) was 0.89 percent at 4 years following the primary procedure. The 95% confidence interval was (0.65, 1.22). This estimate is based on 608 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Actis DuoFix/Pinnacle implant combination for total hip arthroplasty (THA) was 1.05 percent at 5 years following the primary procedure. The 95% confidence interval was (0.70, 1.58). This estimate is based on 40 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML/Pinnacle implant combination for total hip arthroplasty (THA) was 1.28 percent at 1 year following the primary procedure. The 95% confidence interval was (0.69, 2.36). This estimate is based on 750 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML/Pinnacle implant combination for total hip arthroplasty (THA) was 1.70 percent at 2 years following the primary procedure. The 95% confidence interval was (0.99, 2.90). This estimate is based on 672 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML/Pinnacle implant combination for total hip arthroplasty (THA) was 2.15 percent at 3 years following the primary procedure. The 95% confidence interval was (1.32, 3.49). This estimate is based on 603 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML/Pinnacle implant combination for total hip arthroplasty (THA) was 2.67 percent at 4 years following the primary procedure. The 95% confidence interval was (1.71, 4.17). This estimate is based on 509 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML/Pinnacle implant combination for total hip arthroplasty (THA) was 3.06 percent at 5 years following the primary procedure. The 95% confidence interval was (2.00, 4.69). This estimate is based on 374 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML/Pinnacle implant combination for total hip arthroplasty (THA) was 3.36 percent at 6 years following the primary procedure. The 95% confidence interval was (2.20, 5.13). This estimate is based on 270 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML/Pinnacle implant combination for total hip arthroplasty (THA) was 3.36 percent at 7 years following the primary procedure. The 95% confidence interval was (2.20, 5.13). This estimate is based on 172 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML/Pinnacle implant combination for total hip arthroplasty (THA) was 3.36 percent at 8 years following the primary procedure. The 95% confidence interval was (2.20, 5.13). This estimate is based on 90 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML/Pinnacle implant combination for total hip arthroplasty (THA) was 3.36 percent at 9 years following the primary procedure. The 95% confidence interval was (2.20, 5.13). This estimate is based on 24 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML/Pinnacle implant combination for total hip arthroplasty (THA) was 3.36 percent at 10 years following the primary procedure. The 95% confidence interval was (2.20, 5.13). This estimate is based on 6 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/PolarCup implant combination for total hip arthroplasty (THA) was 0.55 percent at 1 year following the primary procedure. The 95% confidence interval was (0.18, 1.69). This estimate is based on 539 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/PolarCup implant combination for total hip arthroplasty (THA) was 1.29 percent at 2 years following the primary procedure. The 95% confidence interval was (0.62, 2.69). This estimate is based on 521 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/PolarCup implant combination for total hip arthroplasty (THA) was 1.49 percent at 3 years following the primary procedure. The 95% confidence interval was (0.75, 2.95). This estimate is based on 460 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/PolarCup implant combination for total hip arthroplasty (THA) was 1.72 percent at 4 years following the primary procedure. The 95% confidence interval was (0.90, 3.28). This estimate is based on 386 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/PolarCup implant combination for total hip arthroplasty (THA) was 2.00 percent at 5 years following the primary procedure. The 95% confidence interval was (1.07, 3.71). This estimate is based on 294 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/PolarCup implant combination for total hip arthroplasty (THA) was 2.00 percent at 6 years following the primary procedure. The 95% confidence interval was (1.07, 3.71). This estimate is based on 183 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/PolarCup implant combination for total hip arthroplasty (THA) was 2.00 percent at 7 years following the primary procedure. The 95% confidence interval was (1.07, 3.71). This estimate is based on 71 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/Reflection 3 implant combination for total hip arthroplasty (THA) was 2.01 percent at 1 year following the primary procedure. The 95% confidence interval was (1.65, 2.44). This estimate is based on 4262 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/Reflection 3 implant combination for total hip arthroplasty (THA) was 2.60 percent at 2 years following the primary procedure. The 95% confidence interval was (2.18, 3.10). This estimate is based on 3579 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/Reflection 3 implant combination for total hip arthroplasty (THA) was 2.91 percent at 3 years following the primary procedure. The 95% confidence interval was (2.46, 3.45). This estimate is based on 2905 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/Reflection 3 implant combination for total hip arthroplasty (THA) was 3.14 percent at 4 years following the primary procedure. The 95% confidence interval was (2.65, 3.71). This estimate is based on 2306 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/Reflection 3 implant combination for total hip arthroplasty (THA) was 3.38 percent at 5 years following the primary procedure. The 95% confidence interval was (2.86, 3.99). This estimate is based on 1789 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/Reflection 3 implant combination for total hip arthroplasty (THA) was 3.91 percent at 6 years following the primary procedure. The 95% confidence interval was (3.29, 4.64). This estimate is based on 1381 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/Reflection 3 implant combination for total hip arthroplasty (THA) was 3.91 percent at 7 years following the primary procedure. The 95% confidence interval was (3.29, 4.64). This estimate is based on 886 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/Reflection 3 implant combination for total hip arthroplasty (THA) was 4.16 percent at 8 years following the primary procedure. The 95% confidence interval was (3.47, 4.98). This estimate is based on 456 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/Reflection 3 implant combination for total hip arthroplasty (THA) was 4.16 percent at 9 years following the primary procedure. The 95% confidence interval was (3.47, 4.98). This estimate is based on 128 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology/Reflection 3 implant combination for total hip arthroplasty (THA) was 4.16 percent at 10 years following the primary procedure. The 95% confidence interval was (3.47, 4.98). This estimate is based on 33 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented)/G7 implant combination for total hip arthroplasty (THA) was 0.87 percent at 1 year following the primary procedure. The 95% confidence interval was (0.41, 1.83). This estimate is based on 514 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented)/G7 implant combination for total hip arthroplasty (THA) was 1.08 percent at 2 years following the primary procedure. The 95% confidence interval was (0.53, 2.20). This estimate is based on 279 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented)/G7 implant combination for total hip arthroplasty (THA) was 1.08 percent at 3 years following the primary procedure. The 95% confidence interval was (0.53, 2.20). This estimate is based on 165 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented)/G7 implant combination for total hip arthroplasty (THA) was 1.73 percent at 4 years following the primary procedure. The 95% confidence interval was (0.73, 4.05). This estimate is based on 60 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented)/G7 implant combination for total hip arthroplasty (THA) was 1.73 percent at 5 years following the primary procedure. The 95% confidence interval was (0.73, 4.05). This estimate is based on 19 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented)/G7 implant combination for total hip arthroplasty (THA) was 1.73 percent at 6 years following the primary procedure. The 95% confidence interval was (0.73, 4.05). This estimate is based on 1 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/Continuum implant combination for total hip arthroplasty (THA) was 1.34 percent at 1 year following the primary procedure. The 95% confidence interval was (0.64, 2.80). This estimate is based on 514 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/Continuum implant combination for total hip arthroplasty (THA) was 1.54 percent at 2 years following the primary procedure. The 95% confidence interval was (0.77, 3.05). This estimate is based on 507 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/Continuum implant combination for total hip arthroplasty (THA) was 1.92 percent at 3 years following the primary procedure. The 95% confidence interval was (1.04, 3.55). This estimate is based on 503 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/Continuum implant combination for total hip arthroplasty (THA) was 1.92 percent at 4 years following the primary procedure. The 95% confidence interval was (1.04, 3.55). This estimate is based on 497 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/Continuum implant combination for total hip arthroplasty (THA) was 2.13 percent at 5 years following the primary procedure. The 95% confidence interval was (1.18, 3.81). This estimate is based on 481 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/Continuum implant combination for total hip arthroplasty (THA) was 2.13 percent at 6 years following the primary procedure. The 95% confidence interval was (1.18, 3.81). This estimate is based on 414 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/Continuum implant combination for total hip arthroplasty (THA) was 2.66 percent at 7 years following the primary procedure. The 95% confidence interval was (1.55, 4.57). This estimate is based on 318 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/Continuum implant combination for total hip arthroplasty (THA) was 2.66 percent at 8 years following the primary procedure. The 95% confidence interval was (1.55, 4.57). This estimate is based on 189 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/Continuum implant combination for total hip arthroplasty (THA) was 2.66 percent at 9 years following the primary procedure. The 95% confidence interval was (1.55, 4.57). This estimate is based on 27 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/G7 implant combination for total hip arthroplasty (THA) was 1.94 percent at 1 year following the primary procedure. The 95% confidence interval was (1.13, 3.31). This estimate is based on 572 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/G7 implant combination for total hip arthroplasty (THA) was 1.94 percent at 2 years following the primary procedure. The 95% confidence interval was (1.13, 3.31). This estimate is based on 502 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/G7 implant combination for total hip arthroplasty (THA) was 2.13 percent at 3 years following the primary procedure. The 95% confidence interval was (1.27, 3.58). This estimate is based on 441 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/G7 implant combination for total hip arthroplasty (THA) was 2.13 percent at 4 years following the primary procedure. The 95% confidence interval was (1.27, 3.58). This estimate is based on 302 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/G7 implant combination for total hip arthroplasty (THA) was 2.13 percent at 5 years following the primary procedure. The 95% confidence interval was (1.27, 3.58). This estimate is based on 186 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless)/G7 implant combination for total hip arthroplasty (THA) was 2.13 percent at 6 years following the primary procedure. The 95% confidence interval was (1.27, 3.58). This estimate is based on 82 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir Complete/G7 implant combination for total hip arthroplasty (THA) was 0.88 percent at 1 year following the primary procedure. The 95% confidence interval was (0.55, 1.39). This estimate is based on 952 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir Complete/G7 implant combination for total hip arthroplasty (THA) was 0.88 percent at 2 years following the primary procedure. The 95% confidence interval was (0.55, 1.39). This estimate is based on 175 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir Complete/G7 implant combination for total hip arthroplasty (THA) was 0.88 percent at 3 years following the primary procedure. The 95% confidence interval was (0.55, 1.39). This estimate is based on 11 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail/Pinnacle implant combination for total hip arthroplasty (THA) was 1.22 percent at 1 year following the primary procedure. The 95% confidence interval was (0.90, 1.65). This estimate is based on 3071 primary cases at risk.t
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail/Pinnacle implant combination for total hip arthroplasty (THA) was 1.59 percent at 2 years following the primary procedure. The 95% confidence interval was (1.22, 2.09). This estimate is based on 2686 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail/Pinnacle implant combination for total hip arthroplasty (THA) was 1.86 percent at 3 years following the primary procedure. The 95% confidence interval was (1.44, 2.40). This estimate is based on 2450 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail/Pinnacle implant combination for total hip arthroplasty (THA) was 1.86 percent at 4 years following the primary procedure. The 95% confidence interval was (1.44, 2.40). This estimate is based on 2184 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail/Pinnacle implant combination for total hip arthroplasty (THA) was 1.92 percent at 5 years following the primary procedure. The 95% confidence interval was (1.49, 2.47). This estimate is based on 1753 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail/Pinnacle implant combination for total hip arthroplasty (THA) was 1.97 percent at 6 years following the primary procedure. The 95% confidence interval was (1.53, 2.54). This estimate is based on 1159 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail/Pinnacle implant combination for total hip arthroplasty (THA) was 2.06 percent at 7 years following the primary procedure. The 95% confidence interval was (1.59, 2.65). This estimate is based on 686 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail/Pinnacle implant combination for total hip arthroplasty (THA) was 2.66 percent at 8 years following the primary procedure. The 95% confidence interval was (1.92, 3.68). This estimate is based on 347 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail/Pinnacle implant combination for total hip arthroplasty (THA) was 2.66 percent at 9 years following the primary procedure. The 95% confidence interval was (1.92, 3.68). This estimate is based on 64 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail/Pinnacle implant combination for total hip arthroplasty (THA) was 2.66 percent at 10 years following the primary procedure. The 95% confidence interval was (1.92, 3.68). This estimate is based on 2 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara/Pinnacle implant combination for total hip arthroplasty (THA) was 0.14 percent at 1 year following the primary procedure. The 95% confidence interval was (0.02, 0.96). This estimate is based on 661 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara/Pinnacle implant combination for total hip arthroplasty (THA) was 0.60 percent at 2 years following the primary procedure. The 95% confidence interval was (0.23, 1.60). This estimate is based on 587 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara/Pinnacle implant combination for total hip arthroplasty (THA) was 0.78 percent at 3 years following the primary procedure. The 95% confidence interval was (0.33, 1.88). This estimate is based on 526 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara/Pinnacle implant combination for total hip arthroplasty (THA) was 0.98 percent at 4 years following the primary procedure. The 95% confidence interval was (0.44, 2.19). This estimate is based on 434 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara/Pinnacle implant combination for total hip arthroplasty (THA) was 0.98 percent at 5 years following the primary procedure. The 95% confidence interval was (0.44, 2.19). This estimate is based on 344 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara/Pinnacle implant combination for total hip arthroplasty (THA) was 0.98 percent at 6 years following the primary procedure. The 95% confidence interval was (0.44, 2.19). This estimate is based on 225 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara/Pinnacle implant combination for total hip arthroplasty (THA) was 0.98 percent at 7 years following the primary procedure. The 95% confidence interval was (0.44, 2.19). This estimate is based on 134 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara/Pinnacle implant combination for total hip arthroplasty (THA) was 0.98 percent at 8 years following the primary procedure. The 95% confidence interval was (0.44, 2.19). This estimate is based on 63 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara/Pinnacle implant combination for total hip arthroplasty (THA) was 0.98 percent at 9 years following the primary procedure. The 95% confidence interval was (0.44, 2.19). This estimate is based on 22 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara/Pinnacle implant combination for total hip arthroplasty (THA) was 0.98 percent at 10 years following the primary procedure. The 95% confidence interval was (0.44, 2.19). This estimate is based on 1 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric/G7 implant combination for total hip arthroplasty (THA) was 2.78 percent at 1 year following the primary procedure. The 95% confidence interval was (2.08, 3.71). This estimate is based on 1505 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric/G7 implant combination for total hip arthroplasty (THA) was 3.31 percent at 2 years following the primary procedure. The 95% confidence interval was (2.54, 4.31). This estimate is based on 1360 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric/G7 implant combination for total hip arthroplasty (THA) was 3.54 percent at 3 years following the primary procedure. The 95% confidence interval was (2.73, 4.58). This estimate is based on 1140 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric/G7 implant combination for total hip arthroplasty (THA) was 3.83 percent at 4 years following the primary procedure. The 95% confidence interval was (2.97, 4.93). This estimate is based on 749 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric/G7 implant combination for total hip arthroplasty (THA) was 3.83 percent at 5 years following the primary procedure. The 95% confidence interval was (2.97, 4.93). This estimate is based on 366 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric/G7 implant combination for total hip arthroplasty (THA) was 3.83 percent at 6 years following the primary procedure. The 95% confidence interval was (2.97, 4.93). This estimate is based on 152 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric/G7 implant combination for total hip arthroplasty (THA) was 3.83 percent at 7 years following the primary procedure. The 95% confidence interval was (2.97, 4.93). This estimate is based on 44 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric/G7 implant combination for total hip arthroplasty (THA) was 3.83 percent at 8 years following the primary procedure. The 95% confidence interval was (2.97, 4.93). This estimate is based on 3 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty/G7 implant combination for total hip arthroplasty (THA) was 2.01 percent at 1 year following the primary procedure. The 95% confidence interval was (1.45, 2.77). This estimate is based on 1617 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty/G7 implant combination for total hip arthroplasty (THA) was 2.46 percent at 2 years following the primary procedure. The 95% confidence interval was (1.83, 3.31). This estimate is based on 1306 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty/G7 implant combination for total hip arthroplasty (THA) was 2.64 percent at 3 years following the primary procedure. The 95% confidence interval was (1.97, 3.52). This estimate is based on 920 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty/G7 implant combination for total hip arthroplasty (THA) was 3.06 percent at 4 years following the primary procedure. The 95% confidence interval was (2.28, 4.10). This estimate is based on 580 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty/G7 implant combination for total hip arthroplasty (THA) was 3.06 percent at 5 years following the primary procedure. The 95% confidence interval was (2.28, 4.10). This estimate is based on 328 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty/G7 implant combination for total hip arthroplasty (THA) was 3.06 percent at 6 years following the primary procedure. The 95% confidence interval was (2.28, 4.10). This estimate is based on 84 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty/G7 implant combination for total hip arthroplasty (THA) was 3.06 percent at 7 years following the primary procedure. The 95% confidence interval was (2.28, 4.10). This estimate is based on 3 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/Continuum implant combination for total hip arthroplasty (THA) was 1.32 percent at 1 year following the primary procedure. The 95% confidence interval was (0.96, 1.82). This estimate is based on 2763 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/Continuum implant combination for total hip arthroplasty (THA) was 1.68 percent at 2 years following the primary procedure. The 95% confidence interval was (1.26, 2.23). This estimate is based on 2731 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/Continuum implant combination for total hip arthroplasty (THA) was 2.00 percent at 3 years following the primary procedure. The 95% confidence interval was (1.55, 2.60). This estimate is based on 2668 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/Continuum implant combination for total hip arthroplasty (THA) was 2.19 percent at 4 years following the primary procedure. The 95% confidence interval was (1.71, 2.81). This estimate is based on 2580 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/Continuum implant combination for total hip arthroplasty (THA) was 2.35 percent at 5 years following the primary procedure. The 95% confidence interval was (1.85, 2.99). This estimate is based on 2331 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/Continuum implant combination for total hip arthroplasty (THA) was 2.39 percent at 6 years following the primary procedure. The 95% confidence interval was (1.89, 3.04). This estimate is based on 1827 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/Continuum implant combination for total hip arthroplasty (THA) was 2.86 percent at 7 years following the primary procedure. The 95% confidence interval was (2.27, 3.59). This estimate is based on 1309 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/Continuum implant combination for total hip arthroplasty (THA) was 2.86 percent at 8 years following the primary procedure. The 95% confidence interval was (2.27, 3.59). This estimate is based on 651 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/Continuum implant combination for total hip arthroplasty (THA) was 2.86 percent at 9 years following the primary procedure. The 95% confidence interval was (2.27, 3.59). This estimate is based on 167 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/Continuum implant combination for total hip arthroplasty (THA) was 2.86 percent at 10 years following the primary procedure. The 95% confidence interval was (2.27, 3.59). This estimate is based on 2 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/G7 implant combination for total hip arthroplasty (THA) was 1.36 percent at 1 year following the primary procedure. The 95% confidence interval was (0.98, 1.88). This estimate is based on 2427 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/G7 implant combination for total hip arthroplasty (THA) was 1.66 percent at 2 years following the primary procedure. The 95% confidence interval was (1.23, 2.23). This estimate is based on 2088 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/G7 implant combination for total hip arthroplasty (THA) was 1.76 percent at 3 years following the primary procedure. The 95% confidence interval was (1.31, 2.35). This estimate is based on 1515 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/G7 implant combination for total hip arthroplasty (THA) was 1.94 percent at 4 years following the primary procedure. The 95% confidence interval was (1.44, 2.60). This estimate is based on 852 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/G7 implant combination for total hip arthroplasty (THA) was 1.94 percent at 5 years following the primary procedure. The 95% confidence interval was (1.44, 2.60). This estimate is based on 436 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/G7 implant combination for total hip arthroplasty (THA) was 1.94 percent at 6 years following the primary procedure. The 95% confidence interval was (1.44, 2.60). This estimate is based on 200 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore/G7 implant combination for total hip arthroplasty (THA) was 1.94 percent at 7 years following the primary procedure. The 95% confidence interval was (1.44, 2.60). This estimate is based on 39 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Continuum implant combination for total hip arthroplasty (THA) was 1.71 percent at 1 year following the primary procedure. The 95% confidence interval was (1.45, 2.02). This estimate is based on 7586 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Continuum implant combination for total hip arthroplasty (THA) was 2.02 percent at 2 years following the primary procedure. The 95% confidence interval was (1.73, 2.35). This estimate is based on 7092 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Continuum implant combination for total hip arthroplasty (THA) was 2.39 percent at 3 years following the primary procedure. The 95% confidence interval was (2.07, 2.75). This estimate is based on 6620 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Continuum implant combination for total hip arthroplasty (THA) was 2.67 percent at 4 years following the primary procedure. The 95% confidence interval was (2.33, 3.05). This estimate is based on 6074 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Continuum implant combination for total hip arthroplasty (THA) was 2.82 percent at 5 years following the primary procedure. The 95% confidence interval was (2.47, 3.22). This estimate is based on 5463 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Continuum implant combination for total hip arthroplasty (THA) was 2.95 percent at 6 years following the primary procedure. The 95% confidence interval was (2.59, 3.36). This estimate is based on 4780 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Continuum implant combination for total hip arthroplasty (THA) was 3.06 percent at 7 years following the primary procedure. The 95% confidence interval was (2.69, 3.48). This estimate is based on 3854 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Continuum implant combination for total hip arthroplasty (THA) was 3.18 percent at 8 years following the primary procedure. The 95% confidence interval was (2.79, 3.62). This estimate is based on 2648 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Continuum implant combination for total hip arthroplasty (THA) was 3.22 percent at 9 years following the primary procedure. The 95% confidence interval was (2.82, 3.67). This estimate is based on 1267 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Continuum implant combination for total hip arthroplasty (THA) was 3.65 percent at 10 years following the primary procedure. The 95% confidence interval was (3.02, 4.40). This estimate is based on 366 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/G7 implant combination for total hip arthroplasty (THA) was 1.62 percent at 1 year following the primary procedure. The 95% confidence interval was (1.26, 2.08). This estimate is based on 2981 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/G7 implant combination for total hip arthroplasty (THA) was 2.10 percent at 2 years following the primary procedure. The 95% confidence interval was (1.67, 2.64). This estimate is based on 2361 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/G7 implant combination for total hip arthroplasty (THA) was 2.32 percent at 3 years following the primary procedure. The 95% confidence interval was (1.86, 2.90). This estimate is based on 1953 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/G7 implant combination for total hip arthroplasty (THA) was 2.38 percent at 4 years following the primary procedure. The 95% confidence interval was (1.91, 2.97). This estimate is based on 1407 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/G7 implant combination for total hip arthroplasty (THA) was 2.48 percent at 5 years following the primary procedure. The 95% confidence interval was (1.98, 3.12). This estimate is based on 941 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/G7 implant combination for total hip arthroplasty (THA) was 2.48 percent at 6 years following the primary procedure. The 95% confidence interval was (1.98, 3.12). This estimate is based on 453 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/G7 implant combination for total hip arthroplasty (THA) was 2.89 percent at 7 years following the primary procedure. The 95% confidence interval was (2.06, 4.04). This estimate is based on 76 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trabecular Metal implant combination for total hip arthroplasty (THA) was 2.51 percent at 1 year following the primary procedure. The 95% confidence interval was (1.71, 3.66). This estimate is based on 999 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trabecular Metal implant combination for total hip arthroplasty (THA) was 3.01 percent at 2 years following the primary procedure. The 95% confidence interval was (2.12, 4.25). This estimate is based on 897 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trabecular Metal implant combination for total hip arthroplasty (THA) was 3.35 percent at 3 years following the primary procedure. The 95% confidence interval was (2.40, 4.66). This estimate is based on 809 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trabecular Metal implant combination for total hip arthroplasty (THA) was 3.60 percent at 4 years following the primary procedure. The 95% confidence interval was (2.60, 4.96). This estimate is based on 707 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trabecular Metal implant combination for total hip arthroplasty (THA) was 3.90 percent at 5 years following the primary procedure. The 95% confidence interval was (2.84, 5.34). This estimate is based on 598 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trabecular Metal implant combination for total hip arthroplasty (THA) was 3.90 percent at 6 years following the primary procedure. The 95% confidence interval was (2.84, 5.34). This estimate is based on 473 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trabecular Metal implant combination for total hip arthroplasty (THA) was 4.23 percent at 7 years following the primary procedure. The 95% confidence interval was (3.05, 5.86). This estimate is based on 269 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trabecular Metal implant combination for total hip arthroplasty (THA) was 4.23 percent at 8 years following the primary procedure. The 95% confidence interval was (3.05, 5.86). This estimate is based on 184 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trabecular Metal implant combination for total hip arthroplasty (THA) was 4.23 percent at 9 years following the primary procedure. The 95% confidence interval was (3.05, 5.86). This estimate is based on 100 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trabecular Metal implant combination for total hip arthroplasty (THA) was 4.23 percent at 10 years following the primary procedure. The 95% confidence interval was (3.05, 5.86). This estimate is based on 45 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trilogy implant combination for total hip arthroplasty (THA) was 1.58 percent at 1 year following the primary procedure. The 95% confidence interval was (1.04, 2.42). This estimate is based on 1304 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trilogy implant combination for total hip arthroplasty (THA) was 2.35 percent at 2 years following the primary procedure. The 95% confidence interval was (1.66, 3.32). This estimate is based on 1262 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trilogy implant combination for total hip arthroplasty (THA) was 2.99 percent at 3 years following the primary procedure. The 95% confidence interval was (2.19, 4.07). This estimate is based on 1175 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trilogy implant combination for total hip arthroplasty (THA) was 3.07 percent at 4 years following the primary procedure. The 95% confidence interval was (2.26, 4.17). This estimate is based on 1083 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trilogy implant combination for total hip arthroplasty (THA) was 3.54 percent at 5 years following the primary procedure. The 95% confidence interval was (2.65, 4.71). This estimate is based on 999 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trilogy implant combination for total hip arthroplasty (THA) was 3.95 percent at 6 years following the primary procedure. The 95% confidence interval was (3.00, 5.21). This estimate is based on 895 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trilogy implant combination for total hip arthroplasty (THA) was 4.45 percent at 7 years following the primary procedure. The 95% confidence interval was (3.40, 5.82). This estimate is based on 691 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trilogy implant combination for total hip arthroplasty (THA) was 4.60 percent at 8 years following the primary procedure. The 95% confidence interval was (3.52, 5.99). This estimate is based on 494 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trilogy implant combination for total hip arthroplasty (THA) was 4.60 percent at 9 years following the primary procedure. The 95% confidence interval was (3.52, 5.99). This estimate is based on 298 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper/Trilogy implant combination for total hip arthroplasty (THA) was 4.60 percent at 10 years following the primary procedure. The 95% confidence interval was (3.52, 5.99). This estimate is based on 109 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem/Reflection 3 implant combination for total hip arthroplasty (THA) was 1.59 percent at 1 year following the primary procedure. The 95% confidence interval was (1.18, 2.15). This estimate is based on 2210 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem/Reflection 3 implant combination for total hip arthroplasty (THA) was 1.79 percent at 2 years following the primary procedure. The 95% confidence interval was (1.34, 2.39). This estimate is based on 1764 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem/Reflection 3 implant combination for total hip arthroplasty (THA) was 1.91 percent at 3 years following the primary procedure. The 95% confidence interval was (1.44, 2.53). This estimate is based on 1413 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem/Reflection 3 implant combination for total hip arthroplasty (THA) was 2.25 percent at 4 years following the primary procedure. The 95% confidence interval was (1.70, 2.99). This estimate is based on 971 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem/Reflection 3 implant combination for total hip arthroplasty (THA) was 2.61 percent at 5 years following the primary procedure. The 95% confidence interval was (1.96, 3.48). This estimate is based on 599 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem/Reflection 3 implant combination for total hip arthroplasty (THA) was 2.61 percent at 6 years following the primary procedure. The 95% confidence interval was (1.96, 3.48). This estimate is based on 314 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem/Reflection 3 implant combination for total hip arthroplasty (THA) was 2.61 percent at 7 years following the primary procedure. The 95% confidence interval was (1.96, 3.48). This estimate is based on 47 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem/Reflection 3 implant combination for total hip arthroplasty (THA) was 2.61 percent at 8 years following the primary procedure. The 95% confidence interval was (1.96, 3.48). This estimate is based on 6 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident implant combination for total hip arthroplasty (THA) was 3.76 percent at 1 year following the primary procedure. The 95% confidence interval was (2.78, 5.07). This estimate is based on 1049 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident implant combination for total hip arthroplasty (THA) was 4.50 percent at 2 years following the primary procedure. The 95% confidence interval was (3.42, 5.90). This estimate is based on 1041 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident implant combination for total hip arthroplasty (THA) was 4.96 percent at 3 years following the primary procedure. The 95% confidence interval was (3.82, 6.42). This estimate is based on 1030 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident implant combination for total hip arthroplasty (THA) was 5.14 percent at 4 years following the primary procedure. The 95% confidence interval was (3.98, 6.63). This estimate is based on 993 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident implant combination for total hip arthroplasty (THA) was 5.65 percent at 5 years following the primary procedure. The 95% confidence interval was (4.42, 7.20). This estimate is based on 855 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident implant combination for total hip arthroplasty (THA) was 5.90 percent at 6 years following the primary procedure. The 95% confidence interval was (4.63, 7.49). This estimate is based on 655 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident implant combination for total hip arthroplasty (THA) was 6.22 percent at 7 years following the primary procedure. The 95% confidence interval was (4.90, 7.89). This estimate is based on 415 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident implant combination for total hip arthroplasty (THA) was 6.77 percent at 8 years following the primary procedure. The 95% confidence interval was (5.30, 8.64). This estimate is based on 213 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident implant combination for total hip arthroplasty (THA) was 6.77 percent at 9 years following the primary procedure. The 95% confidence interval was (5.30, 8.64). This estimate is based on 44 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident II implant combination for total hip arthroplasty (THA) was 3.06 percent at 1 year following the primary procedure. The 95% confidence interval was (1.99, 4.71). This estimate is based on 498 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident II implant combination for total hip arthroplasty (THA) was 3.06 percent at 2 years following the primary procedure. The 95% confidence interval was (1.99, 4.71). This estimate is based on 345 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident II implant combination for total hip arthroplasty (THA) was 3.06 percent at 3 years following the primary procedure. The 95% confidence interval was (1.99, 4.71). This estimate is based on 224 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident II implant combination for total hip arthroplasty (THA) was 3.59 percent at 4 years following the primary procedure. The 95% confidence interval was (2.25, 5.69). This estimate is based on 64 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit/Trident II implant combination for total hip arthroplasty (THA) was 3.59 percent at 5 years following the primary procedure. The 95% confidence interval was (2.25, 5.69). This estimate is based on 1 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max/Trident implant combination for total hip arthroplasty (THA) was 2.10 percent at 1 year following the primary procedure. The 95% confidence interval was (1.64, 2.68). This estimate is based on 2822 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max/Trident implant combination for total hip arthroplasty (THA) was 2.57 percent at 2 years following the primary procedure. The 95% confidence interval was (2.05, 3.20). This estimate is based on 2662 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max/Trident implant combination for total hip arthroplasty (THA) was 2.91 percent at 3 years following the primary procedure. The 95% confidence interval was (2.36, 3.58). This estimate is based on 2493 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max/Trident implant combination for total hip arthroplasty (THA) was 3.35 percent at 4 years following the primary procedure. The 95% confidence interval was (2.75, 4.08). This estimate is based on 2297 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max/Trident implant combination for total hip arthroplasty (THA) was 3.49 percent at 5 years following the primary procedure. The 95% confidence interval was (2.87, 4.23). This estimate is based on 1906 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max/Trident implant combination for total hip arthroplasty (THA) was 3.66 percent at 6 years following the primary procedure. The 95% confidence interval was (3.02, 4.44). This estimate is based on 1440 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max/Trident implant combination for total hip arthroplasty (THA) was 4.06 percent at 7 years following the primary procedure. The 95% confidence interval was (3.34, 4.92). This estimate is based on 996 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max/Trident implant combination for total hip arthroplasty (THA) was 4.19 percent at 8 years following the primary procedure. The 95% confidence interval was (3.44, 5.10). This estimate is based on 605 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max/Trident implant combination for total hip arthroplasty (THA) was 4.35 percent at 9 years following the primary procedure. The 95% confidence interval was (3.55, 5.32). This estimate is based on 341 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max/Trident implant combination for total hip arthroplasty (THA) was 4.35 percent at 10 years following the primary procedure. The 95% confidence interval was (3.55, 5.32). This estimate is based on 127 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max/Trident implant combination for total hip arthroplasty (THA) was 1.71 percent at 1 year following the primary procedure. The 95% confidence interval was (1.23, 2.39). This estimate is based on 1950 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max/Trident implant combination for total hip arthroplasty (THA) was 1.97 percent at 2 years following the primary procedure. The 95% confidence interval was (1.44, 2.68). This estimate is based on 1943 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max/Trident implant combination for total hip arthroplasty (THA) was 2.12 percent at 3 years following the primary procedure. The 95% confidence interval was (1.57, 2.85). This estimate is based on 1936 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max/Trident implant combination for total hip arthroplasty (THA) was 2.27 percent at 4 years following the primary procedure. The 95% confidence interval was (1.70, 3.03). This estimate is based on 1918 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max/Trident implant combination for total hip arthroplasty (THA) was 2.53 percent at 5 years following the primary procedure. The 95% confidence interval was (1.92, 3.33). This estimate is based on 1823 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max/Trident implant combination for total hip arthroplasty (THA) was 2.76 percent at 6 years following the primary procedure. The 95% confidence interval was (2.12, 3.58). This estimate is based on 1606 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max/Trident implant combination for total hip arthroplasty (THA) was 2.96 percent at 7 years following the primary procedure. The 95% confidence interval was (2.29, 3.82). This estimate is based on 1240 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max/Trident implant combination for total hip arthroplasty (THA) was 3.47 percent at 8 years following the primary procedure. The 95% confidence interval was (2.69, 4.46). This estimate is based on 882 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max/Trident implant combination for total hip arthroplasty (THA) was 3.47 percent at 9 years following the primary procedure. The 95% confidence interval was (2.69, 4.46). This estimate is based on 538 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max/Trident implant combination for total hip arthroplasty (THA) was 3.47 percent at 10 years following the primary procedure. The 95% confidence interval was (2.69, 4.46). This estimate is based on 223 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM/Pinnacle implant combination for total hip arthroplasty (THA) was 1.27 percent at 1 year following the primary procedure. The 95% confidence interval was (0.75, 2.13). This estimate is based on 1086 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM/Pinnacle implant combination for total hip arthroplasty (THA) was 2.18 percent at 2 years following the primary procedure. The 95% confidence interval was (1.47, 3.24). This estimate is based on 1062 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM/Pinnacle implant combination for total hip arthroplasty (THA) was 2.55 percent at 3 years following the primary procedure. The 95% confidence interval was (1.77, 3.68). This estimate is based on 1036 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM/Pinnacle implant combination for total hip arthroplasty (THA) was 2.95 percent at 4 years following the primary procedure. The 95% confidence interval was (2.10, 4.15). This estimate is based on 962 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM/Pinnacle implant combination for total hip arthroplasty (THA) was 3.16 percent at 5 years following the primary procedure. The 95% confidence interval was (2.27, 4.39). This estimate is based on 893 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM/Pinnacle implant combination for total hip arthroplasty (THA) was 3.38 percent at 6 years following the primary procedure. The 95% confidence interval was (2.45, 4.66). This estimate is based on 785 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM/Pinnacle implant combination for total hip arthroplasty (THA) was 3.79 percent at 7 years following the primary procedure. The 95% confidence interval was (2.77, 5.16). This estimate is based on 641 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM/Pinnacle implant combination for total hip arthroplasty (THA) was 3.96 percent at 8 years following the primary procedure. The 95% confidence interval was (2.91, 5.39). This estimate is based on 434 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM/Pinnacle implant combination for total hip arthroplasty (THA) was 3.96 percent at 9 years following the primary procedure. The 95% confidence interval was (2.91, 5.39). This estimate is based on 202 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM/Pinnacle implant combination for total hip arthroplasty (THA) was 3.96 percent at 10 years following the primary procedure. The 95% confidence interval was (2.91, 5.39). This estimate is based on 13 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit/Pinnacle implant combination for total hip arthroplasty (THA) was 1.47 percent at 1 year following the primary procedure. The 95% confidence interval was (1.22, 1.77). This estimate is based on 6794 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit/Pinnacle implant combination for total hip arthroplasty (THA) was 1.79 percent at 2 years following the primary procedure. The 95% confidence interval was (1.50, 2.12). This estimate is based on 6232 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit/Pinnacle implant combination for total hip arthroplasty (THA) was 1.98 percent at 3 years following the primary procedure. The 95% confidence interval was (1.68, 2.34). This estimate is based on 5740 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit/Pinnacle implant combination for total hip arthroplasty (THA) was 2.08 percent at 4 years following the primary procedure. The 95% confidence interval was (1.77, 2.44). This estimate is based on 5189 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit/Pinnacle implant combination for total hip arthroplasty (THA) was 2.14 percent at 5 years following the primary procedure. The 95% confidence interval was (1.82, 2.51). This estimate is based on 4532 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit/Pinnacle implant combination for total hip arthroplasty (THA) was 2.19 percent at 6 years following the primary procedure. The 95% confidence interval was (1.86, 2.57). This estimate is based on 3692 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit/Pinnacle implant combination for total hip arthroplasty (THA) was 2.29 percent at 7 years following the primary procedure. The 95% confidence interval was (1.95, 2.68). This estimate is based on 2712 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit/Pinnacle implant combination for total hip arthroplasty (THA) was 2.37 percent at 8 years following the primary procedure. The 95% confidence interval was (2.02, 2.79). This estimate is based on 1675 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit/Pinnacle implant combination for total hip arthroplasty (THA) was 2.55 percent at 9 years following the primary procedure. The 95% confidence interval was (2.13, 3.05). This estimate is based on 760 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit/Pinnacle implant combination for total hip arthroplasty (THA) was 2.86 percent at 10 years following the primary procedure. The 95% confidence interval was (2.19, 3.72). This estimate is based on 201 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy/Reflection 3 implant combination for total hip arthroplasty (THA) was 2.33 percent at 1 year following the primary procedure. The 95% confidence interval was (1.63, 3.34). This estimate is based on 1124 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy/Reflection 3 implant combination for total hip arthroplasty (THA) was 2.97 percent at 2 years following the primary procedure. The 95% confidence interval was (2.15, 4.09). This estimate is based on 1010 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy/Reflection 3 implant combination for total hip arthroplasty (THA) was 3.35 percent at 3 years following the primary procedure. The 95% confidence interval was (2.47, 4.55). This estimate is based on 920 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy/Reflection 3 implant combination for total hip arthroplasty (THA) was 3.59 percent at 4 years following the primary procedure. The 95% confidence interval was (2.66, 4.83). This estimate is based on 804 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy/Reflection 3 implant combination for total hip arthroplasty (THA) was 3.72 percent at 5 years following the primary procedure. The 95% confidence interval was (2.76, 5.00). This estimate is based on 669 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy/Reflection 3 implant combination for total hip arthroplasty (THA) was 4.37 percent at 6 years following the primary procedure. The 95% confidence interval was (3.27, 5.84). This estimate is based on 528 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy/Reflection 3 implant combination for total hip arthroplasty (THA) was 4.59 percent at 7 years following the primary procedure. The 95% confidence interval was (3.43, 6.13). This estimate is based on 386 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy/Reflection 3 implant combination for total hip arthroplasty (THA) was 4.87 percent at 8 years following the primary procedure. The 95% confidence interval was (3.62, 6.53). This estimate is based on 246 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy/Reflection 3 implant combination for total hip arthroplasty (THA) was 4.87 percent at 9 years following the primary procedure. The 95% confidence interval was (3.62, 6.53). This estimate is based on 92 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy/Reflection 3 implant combination for total hip arthroplasty (THA) was 4.87 percent at 10 years following the primary procedure. The 95% confidence interval was (3.62, 6.53). This estimate is based on 30 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/Continuum implant combination for total hip arthroplasty (THA) was 3.06 percent at 1 year following the primary procedure. The 95% confidence interval was (2.06, 4.53). This estimate is based on 737 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/Continuum implant combination for total hip arthroplasty (THA) was 3.59 percent at 2 years following the primary procedure. The 95% confidence interval was (2.49, 5.16). This estimate is based on 716 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/Continuum implant combination for total hip arthroplasty (THA) was 4.95 percent at 3 years following the primary procedure. The 95% confidence interval was (3.62, 6.74). This estimate is based on 685 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/Continuum implant combination for total hip arthroplasty (THA) was 5.38 percent at 4 years following the primary procedure. The 95% confidence interval was (3.99, 7.24). This estimate is based on 597 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/Continuum implant combination for total hip arthroplasty (THA) was 5.78 percent at 5 years following the primary procedure. The 95% confidence interval was (4.31, 7.73). This estimate is based on 435 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/Continuum implant combination for total hip arthroplasty (THA) was 5.78 percent at 6 years following the primary procedure. The 95% confidence interval was (4.31, 7.73). This estimate is based on 230 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/Continuum implant combination for total hip arthroplasty (THA) was 5.78 percent at 7 years following the primary procedure. The 95% confidence interval was (4.31, 7.73). This estimate is based on 61 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/G7 implant combination for total hip arthroplasty (THA) was 1.62 percent at 1 year following the primary procedure. The 95% confidence interval was (1.38, 1.89). This estimate is based on 8336 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/G7 implant combination for total hip arthroplasty (THA) was 2.11 percent at 2 years following the primary procedure. The 95% confidence interval was (1.83, 2.42). This estimate is based on 6484 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/G7 implant combination for total hip arthroplasty (THA) was 2.23 percent at 3 years following the primary procedure. The 95% confidence interval was (1.94, 2.56). This estimate is based on 4952 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/G7 implant combination for total hip arthroplasty (THA) was 2.44 percent at 4 years following the primary procedure. The 95% confidence interval was (2.12, 2.80). This estimate is based on 3285 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/G7 implant combination for total hip arthroplasty (THA) was 2.62 percent at 5 years following the primary procedure. The 95% confidence interval was (2.27, 3.02). This estimate is based on 2003 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/G7 implant combination for total hip arthroplasty (THA) was 2.68 percent at 6 years following the primary procedure. The 95% confidence interval was (2.31, 3.09). This estimate is based on 971 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/G7 implant combination for total hip arthroplasty (THA) was 2.68 percent at 7 years following the primary procedure. The 95% confidence interval was (2.31, 3.09). This estimate is based on 365 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/G7 implant combination for total hip arthroplasty (THA) was 3.33 percent at 8 years following the primary procedure. The 95% confidence interval was (2.23, 4.98). This estimate is based on 110 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/RingLoc implant combination for total hip arthroplasty (THA) was 1.73 percent at 1 year following the primary procedure. The 95% confidence interval was (1.20, 2.48). This estimate is based on 1648 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/RingLoc implant combination for total hip arthroplasty (THA) was 2.27 percent at 2 years following the primary procedure. The 95% confidence interval was (1.65, 3.10). This estimate is based on 1633 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/RingLoc implant combination for total hip arthroplasty (THA) was 2.45 percent at 3 years following the primary procedure. The 95% confidence interval was (1.81, 3.31). This estimate is based on 1600 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/RingLoc implant combination for total hip arthroplasty (THA) was 2.64 percent at 4 years following the primary procedure. The 95% confidence interval was (1.97, 3.53). This estimate is based on 1486 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/RingLoc implant combination for total hip arthroplasty (THA) was 2.64 percent at 5 years following the primary procedure. The 95% confidence interval was (1.97, 3.53). This estimate is based on 1349 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/RingLoc implant combination for total hip arthroplasty (THA) was 2.72 percent at 6 years following the primary procedure. The 95% confidence interval was (2.03, 3.62). This estimate is based on 1203 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/RingLoc implant combination for total hip arthroplasty (THA) was 2.72 percent at 7 years following the primary procedure. The 95% confidence interval was (2.03, 3.62). This estimate is based on 974 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/RingLoc implant combination for total hip arthroplasty (THA) was 2.72 percent at 8 years following the primary procedure. The 95% confidence interval was (2.03, 3.62). This estimate is based on 566 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/RingLoc implant combination for total hip arthroplasty (THA) was 2.94 percent at 9 years following the primary procedure. The 95% confidence interval was (2.17, 3.99). This estimate is based on 206 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133/RingLoc implant combination for total hip arthroplasty (THA) was 2.94 percent at 10 years following the primary procedure. The 95% confidence interval was (2.17, 3.99). This estimate is based on 18 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/Continuum implant combination for total hip arthroplasty (THA) was 2.18 percent at 1 year following the primary procedure. The 95% confidence interval was (1.21, 3.91). This estimate is based on 398 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/Continuum implant combination for total hip arthroplasty (THA) was 2.45 percent at 2 years following the primary procedure. The 95% confidence interval was (1.39, 4.28). This estimate is based on 292 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/Continuum implant combination for total hip arthroplasty (THA) was 2.45 percent at 3 years following the primary procedure. The 95% confidence interval was (1.39, 4.28). This estimate is based on 178 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/Continuum implant combination for total hip arthroplasty (THA) was 3.20 percent at 4 years following the primary procedure. The 95% confidence interval was (1.70, 5.98). This estimate is based on 64 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/Continuum implant combination for total hip arthroplasty (THA) was 3.20 percent at 5 years following the primary procedure. The 95% confidence interval was (1.70, 5.98). This estimate is based on 20 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/Continuum implant combination for total hip arthroplasty (THA) was 3.20 percent at 6 years following the primary procedure. The 95% confidence interval was (1.70, 5.98). This estimate is based on 12 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/Continuum implant combination for total hip arthroplasty (THA) was 3.20 percent at 7 years following the primary procedure. The 95% confidence interval was (1.70, 5.98). This estimate is based on 5 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/G7 implant combination for total hip arthroplasty (THA) was 1.14 percent at 1 year following the primary procedure. The 95% confidence interval was (0.84, 1.56). This estimate is based on 3099 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/G7 implant combination for total hip arthroplasty (THA) was 1.32 percent at 2 years following the primary procedure. The 95% confidence interval was (0.99, 1.78). This estimate is based on 2572 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/G7 implant combination for total hip arthroplasty (THA) was 1.36 percent at 3 years following the primary procedure. The 95% confidence interval was (1.02, 1.83). This estimate is based on 2139 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/G7 implant combination for total hip arthroplasty (THA) was 1.67 percent at 4 years following the primary procedure. The 95% confidence interval was (1.26, 2.21). This estimate is based on 1689 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/G7 implant combination for total hip arthroplasty (THA) was 1.95 percent at 5 years following the primary procedure. The 95% confidence interval was (1.48, 2.57). This estimate is based on 1227 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/G7 implant combination for total hip arthroplasty (THA) was 2.03 percent at 6 years following the primary procedure. The 95% confidence interval was (1.54, 2.68). This estimate is based on 747 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/G7 implant combination for total hip arthroplasty (THA) was 2.03 percent at 7 years following the primary procedure. The 95% confidence interval was (1.54, 2.68). This estimate is based on 335 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty/G7 implant combination for total hip arthroplasty (THA) was 2.03 percent at 8 years following the primary procedure. The 95% confidence interval was (1.54, 2.68). This estimate is based on 92 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal/Continuum implant combination for total hip arthroplasty (THA) was 2.19 percent at 1 year following the primary procedure. The 95% confidence interval was (1.36, 3.49). This estimate is based on 723 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal/Continuum implant combination for total hip arthroplasty (THA) was 2.32 percent at 2 years following the primary procedure. The 95% confidence interval was (1.47, 3.67). This estimate is based on 677 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal/Continuum implant combination for total hip arthroplasty (THA) was 2.92 percent at 3 years following the primary procedure. The 95% confidence interval was (1.93, 4.40). This estimate is based on 644 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal/Continuum implant combination for total hip arthroplasty (THA) was 3.07 percent at 4 years following the primary procedure. The 95% confidence interval was (2.05, 4.59). This estimate is based on 618 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal/Continuum implant combination for total hip arthroplasty (THA) was 3.07 percent at 5 years following the primary procedure. The 95% confidence interval was (2.05, 4.59). This estimate is based on 572 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal/Continuum implant combination for total hip arthroplasty (THA) was 3.07 percent at 6 years following the primary procedure. The 95% confidence interval was (2.05, 4.59). This estimate is based on 502 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal/Continuum implant combination for total hip arthroplasty (THA) was 3.07 percent at 7 years following the primary procedure. The 95% confidence interval was (2.05, 4.59). This estimate is based on 388 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal/Continuum implant combination for total hip arthroplasty (THA) was 3.07 percent at 8 years following the primary procedure. The 95% confidence interval was (2.05, 4.59). This estimate is based on 220 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal/Continuum implant combination for total hip arthroplasty (THA) was 3.07 percent at 9 years following the primary procedure. The 95% confidence interval was (2.05, 4.59). This estimate is based on 73 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal/Continuum implant combination for total hip arthroplasty (THA) was 3.07 percent at 10 years following the primary procedure. The 95% confidence interval was (2.05, 4.59). This estimate is based on 8 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS/Pinnacle implant combination for total hip arthroplasty (THA) was 0.65 percent at 1 year following the primary procedure. The 95% confidence interval was (0.44, 0.96). This estimate is based on 3574 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS/Pinnacle implant combination for total hip arthroplasty (THA) was 0.89 percent at 2 years following the primary procedure. The 95% confidence interval was (0.63, 1.25). This estimate is based on 3104 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS/Pinnacle implant combination for total hip arthroplasty (THA) was 1.24 percent at 3 years following the primary procedure. The 95% confidence interval was (0.92, 1.68). This estimate is based on 2565 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS/Pinnacle implant combination for total hip arthroplasty (THA) was 1.41 percent at 4 years following the primary procedure. The 95% confidence interval was (1.06, 1.89). This estimate is based on 2060 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS/Pinnacle implant combination for total hip arthroplasty (THA) was 1.63 percent at 5 years following the primary procedure. The 95% confidence interval was (1.23, 2.16). This estimate is based on 1603 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS/Pinnacle implant combination for total hip arthroplasty (THA) was 1.70 percent at 6 years following the primary procedure. The 95% confidence interval was (1.28, 2.25). This estimate is based on 1187 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS/Pinnacle implant combination for total hip arthroplasty (THA) was 1.70 percent at 7 years following the primary procedure. The 95% confidence interval was (1.28, 2.25). This estimate is based on 810 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS/Pinnacle implant combination for total hip arthroplasty (THA) was 1.84 percent at 8 years following the primary procedure. The 95% confidence interval was (1.36, 2.47). This estimate is based on 373 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS/Pinnacle implant combination for total hip arthroplasty (THA) was 1.84 percent at 9 years following the primary procedure. The 95% confidence interval was (1.36, 2.47). This estimate is based on 85 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS/Pinnacle implant combination for total hip arthroplasty (THA) was 1.84 percent at 10 years following the primary procedure. The 95% confidence interval was (1.36, 2.47). This estimate is based on 8 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C implant for total hip arthroplasty (THA) was 0.88 percent at 1 year following the primary procedure. The 95% confidence interval was (0.42, 1.83). This estimate is based on 611 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C implant for total hip arthroplasty (THA) was 1.47 percent at 2 years following the primary procedure. The 95% confidence interval was (0.78, 2.76). This estimate is based on 437 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C implant for total hip arthroplasty (THA) was 1.47 percent at 3 years following the primary procedure. The 95% confidence interval was (0.78, 2.76). This estimate is based on 326 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C implant for total hip arthroplasty (THA) was 1.77 percent at 4 years following the primary procedure. The 95% confidence interval was (0.95, 3.30). This estimate is based on 230 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C implant for total hip arthroplasty (THA) was 1.77 percent at 5 years following the primary procedure. The 95% confidence interval was (0.95, 3.30). This estimate is based on 140 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C implant for total hip arthroplasty (THA) was 1.77 percent at 6 years following the primary procedure. The 95% confidence interval was (0.95, 3.30). This estimate is based on 69 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C implant for total hip arthroplasty (THA) was 4.00 percent at 7 years following the primary procedure. The 95% confidence interval was (1.30, 11.95). This estimate is based on 43 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C implant for total hip arthroplasty (THA) was 4.00 percent at 8 years following the primary procedure. The 95% confidence interval was (1.30, 11.95). This estimate is based on 32 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade C implant for total hip arthroplasty (THA) was 4.00 percent at 9 years following the primary procedure. The 95% confidence interval was (1.30, 11.95). This estimate is based on 9 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II implant for total hip arthroplasty (THA) was 1.35 percent at 1 year following the primary procedure. The 95% confidence interval was (1.23, 1.47). This estimate is based on 32905 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II implant for total hip arthroplasty (THA) was 1.73 percent at 2 years following the primary procedure. The 95% confidence interval was (1.60, 1.87). This estimate is based on 28391 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II implant for total hip arthroplasty (THA) was 2.03 percent at 3 years following the primary procedure. The 95% confidence interval was (1.88, 2.18). This estimate is based on 24252 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II implant for total hip arthroplasty (THA) was 2.29 percent at 4 years following the primary procedure. The 95% confidence interval was (2.13, 2.46). This estimate is based on 19173 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II implant for total hip arthroplasty (THA) was 2.53 percent at 5 years following the primary procedure. The 95% confidence interval was (2.36, 2.72). This estimate is based on 14470 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II implant for total hip arthroplasty (THA) was 2.77 percent at 6 years following the primary procedure. The 95% confidence interval was (2.57, 2.97). This estimate is based on 10072 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II implant for total hip arthroplasty (THA) was 3.00 percent at 7 years following the primary procedure. The 95% confidence interval was (2.79, 3.24). This estimate is based on 6037 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II implant for total hip arthroplasty (THA) was 3.19 percent at 8 years following the primary procedure. The 95% confidence interval was (2.94, 3.47). This estimate is based on 3161 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II implant for total hip arthroplasty (THA) was 3.67 percent at 9 years following the primary procedure. The 95% confidence interval was (3.27, 4.12). This estimate is based on 1146 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade II implant for total hip arthroplasty (THA) was 3.76 percent at 10 years following the primary procedure. The 95% confidence interval was (3.33, 4.24). This estimate is based on 200 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF implant for total hip arthroplasty (THA) was 0.90 percent at 1 year following the primary procedure. The 95% confidence interval was (0.45, 1.78). This estimate is based on 885 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF implant for total hip arthroplasty (THA) was 1.57 percent at 2 years following the primary procedure. The 95% confidence interval was (0.93, 2.63). This estimate is based on 879 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF implant for total hip arthroplasty (THA) was 2.02 percent at 3 years following the primary procedure. The 95% confidence interval was (1.27, 3.18). This estimate is based on 875 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF implant for total hip arthroplasty (THA) was 2.80 percent at 4 years following the primary procedure. The 95% confidence interval was (1.90, 4.12). This estimate is based on 867 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF implant for total hip arthroplasty (THA) was 2.80 percent at 5 years following the primary procedure. The 95% confidence interval was (1.90, 4.12). This estimate is based on 855 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF implant for total hip arthroplasty (THA) was 2.80 percent at 6 years following the primary procedure. The 95% confidence interval was (1.90, 4.12). This estimate is based on 823 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF implant for total hip arthroplasty (THA) was 3.31 percent at 7 years following the primary procedure. The 95% confidence interval was (2.31, 4.73). This estimate is based on 705 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF implant for total hip arthroplasty (THA) was 3.90 percent at 8 years following the primary procedure. The 95% confidence interval was (2.75, 5.51). This estimate is based on 432 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF implant for total hip arthroplasty (THA) was 3.90 percent at 9 years following the primary procedure. The 95% confidence interval was (2.75, 5.51). This estimate is based on 216 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Accolade TMZF implant for total hip arthroplasty (THA) was 3.90 percent at 10 years following the primary procedure. The 95% confidence interval was (2.75, 5.51). This estimate is based on 58 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Actis DuoFix implant for total hip arthroplasty (THA) was 0.71 percent at 1 year following the primary procedure. The 95% confidence interval was (0.51, 0.98). This estimate is based on 4140 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Actis DuoFix implant for total hip arthroplasty (THA) was 0.87 percent at 2 years following the primary procedure. The 95% confidence interval was (0.64, 1.18). This estimate is based on 2731 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Actis DuoFix implant for total hip arthroplasty (THA) was 0.92 percent at 3 years following the primary procedure. The 95% confidence interval was (0.68, 1.26). This estimate is based on 1623 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Actis DuoFix implant for total hip arthroplasty (THA) was 0.92 percent at 4 years following the primary procedure. The 95% confidence interval was (0.68, 1.26). This estimate is based on 608 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Actis DuoFix implant for total hip arthroplasty (THA) was 1.09 percent at 5 years following the primary procedure. The 95% confidence interval was (0.73, 1.61). This estimate is based on 40 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML implant for total hip arthroplasty (THA) was 1.27 percent at 1 year following the primary procedure. The 95% confidence interval was (0.69, 2.36). This estimate is based on 753 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML implant for total hip arthroplasty (THA) was 1.69 percent at 2 years following the primary procedure. The 95% confidence interval was (0.98, 2.89). This estimate is based on 675 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML implant for total hip arthroplasty (THA) was 2.14 percent at 3 years following the primary procedure. The 95% confidence interval was (1.31, 3.47). This estimate is based on 606 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML implant for total hip arthroplasty (THA) was 2.66 percent at 4 years following the primary procedure. The 95% confidence interval was (1.70, 4.15). This estimate is based on 512 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML implant for total hip arthroplasty (THA) was 3.05 percent at 5 years following the primary procedure. The 95% confidence interval was (1.99, 4.67). This estimate is based on 377 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML implant for total hip arthroplasty (THA) was 3.35 percent at 6 years following the primary procedure. The 95% confidence interval was (2.18, 5.11). This estimate is based on 273 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML implant for total hip arthroplasty (THA) was 3.35 percent at 7 years following the primary procedure. The 95% confidence interval was (2.18, 5.11). This estimate is based on 174 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML implant for total hip arthroplasty (THA) was 3.35 percent at 8 years following the primary procedure. The 95% confidence interval was (2.18, 5.11). This estimate is based on 91 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML implant for total hip arthroplasty (THA) was 3.35 percent at 9 years following the primary procedure. The 95% confidence interval was (2.18, 5.11). This estimate is based on 25 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the AML implant for total hip arthroplasty (THA) was 3.35 percent at 10 years following the primary procedure. The 95% confidence interval was (2.18, 5.11). This estimate is based on 7 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology implant for total hip arthroplasty (THA) was 1.86 percent at 1 year following the primary procedure. The 95% confidence interval was (1.54, 2.26). This estimate is based on 4844 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology implant for total hip arthroplasty (THA) was 2.47 percent at 2 years following the primary procedure. The 95% confidence interval was (2.08, 2.93). This estimate is based on 4138 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology implant for total hip arthroplasty (THA) was 2.76 percent at 3 years following the primary procedure. The 95% confidence interval was (2.34, 3.25). This estimate is based on 3398 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology implant for total hip arthroplasty (THA) was 2.98 percent at 4 years following the primary procedure. The 95% confidence interval was (2.54, 3.50). This estimate is based on 2723 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology implant for total hip arthroplasty (THA) was 3.27 percent at 5 years following the primary procedure. The 95% confidence interval was (2.78, 3.83). This estimate is based on 2113 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology implant for total hip arthroplasty (THA) was 3.72 percent at 6 years following the primary procedure. The 95% confidence interval was (3.16, 4.38). This estimate is based on 1594 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology implant for total hip arthroplasty (THA) was 3.72 percent at 7 years following the primary procedure. The 95% confidence interval was (3.16, 4.38). This estimate is based on 985 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology implant for total hip arthroplasty (THA) was 3.95 percent at 8 years following the primary procedure. The 95% confidence interval was (3.32, 4.70). This estimate is based on 470 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology implant for total hip arthroplasty (THA) was 3.95 percent at 9 years following the primary procedure. The 95% confidence interval was (3.32, 4.70). This estimate is based on 134 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Anthology implant for total hip arthroplasty (THA) was 3.95 percent at 10 years following the primary procedure. The 95% confidence interval was (3.32, 4.70). This estimate is based on 33 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented) implant for total hip arthroplasty (THA) was 0.90 percent at 1 year following the primary procedure. The 95% confidence interval was (0.45, 1.80). This estimate is based on 606 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented) implant for total hip arthroplasty (THA) was 1.07 percent at 2 years following the primary procedure. The 95% confidence interval was (0.55, 2.08). This estimate is based on 365 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented) implant for total hip arthroplasty (THA) was 1.07 percent at 3 years following the primary procedure. The 95% confidence interval was (0.55, 2.08). This estimate is based on 238 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented) implant for total hip arthroplasty (THA) was 1.52 percent at 4 years following the primary procedure. The 95% confidence interval was (0.72, 3.18). This estimate is based on 117 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented) implant for total hip arthroplasty (THA) was 1.52 percent at 5 years following the primary procedure. The 95% confidence interval was (0.72, 3.18). This estimate is based on 61 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented) implant for total hip arthroplasty (THA) was 1.52 percent at 6 years following the primary procedure. The 95% confidence interval was (0.72, 3.18). This estimate is based on 19 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented) implant for total hip arthroplasty (THA) was 1.52 percent at 7 years following the primary procedure. The 95% confidence interval was (0.72, 3.18). This estimate is based on 8 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cemented) implant for total hip arthroplasty (THA) was 1.52 percent at 8 years following the primary procedure. The 95% confidence interval was (0.72, 3.18). This estimate is based on 1 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless) implant for total hip arthroplasty (THA) was 1.83 percent at 1 year following the primary procedure. The 95% confidence interval was (1.21, 2.76). This estimate is based on 1106 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless) implant for total hip arthroplasty (THA) was 1.92 percent at 2 years following the primary procedure. The 95% confidence interval was (1.28, 2.87). This estimate is based on 1028 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless) implant for total hip arthroplasty (THA) was 2.21 percent at 3 years following the primary procedure. The 95% confidence interval was (1.51, 3.23). This estimate is based on 962 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless) implant for total hip arthroplasty (THA) was 2.21 percent at 4 years following the primary procedure. The 95% confidence interval was (1.51, 3.23). This estimate is based on 816 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless) implant for total hip arthroplasty (THA) was 2.35 percent at 5 years following the primary procedure. The 95% confidence interval was (1.61, 3.42). This estimate is based on 684 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless) implant for total hip arthroplasty (THA) was 2.35 percent at 6 years following the primary procedure. The 95% confidence interval was (1.61, 3.42). This estimate is based on 510 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless) implant for total hip arthroplasty (THA) was 2.84 percent at 7 years following the primary procedure. The 95% confidence interval was (1.92, 4.18). This estimate is based on 327 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless) implant for total hip arthroplasty (THA) was 2.84 percent at 8 years following the primary procedure. The 95% confidence interval was (1.92, 4.18). This estimate is based on 192 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir (Cementless) implant for total hip arthroplasty (THA) was 2.84 percent at 9 years following the primary procedure. The 95% confidence interval was (1.92, 4.18). This estimate is based on 30 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir Complete implant for total hip arthroplasty (THA) was 0.91 percent at 1 year following the primary procedure. The 95% confidence interval was (0.58, 1.43). This estimate is based on 960 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir Complete implant for total hip arthroplasty (THA) was 0.91 percent at 2 years following the primary procedure. The 95% confidence interval was (0.58, 1.43). This estimate is based on 177 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Avenir Complete implant for total hip arthroplasty (THA) was 0.91 percent at 3 years following the primary procedure. The 95% confidence interval was (0.58, 1.43). This estimate is based on 11 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara implant for total hip arthroplasty (THA) was 0.14 percent at 1 year following the primary procedure. The 95% confidence interval was (0.02, 0.96). This estimate is based on 666 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara implant for total hip arthroplasty (THA) was 0.60 percent at 2 years following the primary procedure. The 95% confidence interval was (0.22, 1.59). This estimate is based on 592 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara implant for total hip arthroplasty (THA) was 0.78 percent at 3 years following the primary procedure. The 95% confidence interval was (0.32, 1.87). This estimate is based on 528 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara implant for total hip arthroplasty (THA) was 0.98 percent at 4 years following the primary procedure. The 95% confidence interval was (0.44, 2.18). This estimate is based on 434 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara implant for total hip arthroplasty (THA) was 0.98 percent at 5 years following the primary procedure. The 95% confidence interval was (0.44, 2.18). This estimate is based on 344 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara implant for total hip arthroplasty (THA) was 0.98 percent at 6 years following the primary procedure. The 95% confidence interval was (0.44, 2.18). This estimate is based on 225 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara implant for total hip arthroplasty (THA) was 0.98 percent at 7 years following the primary procedure. The 95% confidence interval was (0.44, 2.18). This estimate is based on 134 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara implant for total hip arthroplasty (THA) was 0.98 percent at 8 years following the primary procedure. The 95% confidence interval was (0.44, 2.18). This estimate is based on 63 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara implant for total hip arthroplasty (THA) was 0.98 percent at 9 years following the primary procedure. The 95% confidence interval was (0.44, 2.18). This estimate is based on 22 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail Coxa Vara implant for total hip arthroplasty (THA) was 0.98 percent at 10 years following the primary procedure. The 95% confidence interval was (0.44, 2.18). This estimate is based on 1 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail implant for total hip arthroplasty (THA) was 1.24 percent at 1 year following the primary procedure. The 95% confidence interval was (0.92, 1.68). This estimate is based on 3081 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail implant for total hip arthroplasty (THA) was 1.62 percent at 2 years following the primary procedure. The 95% confidence interval was (1.24, 2.11). This estimate is based on 2695 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail implant for total hip arthroplasty (THA) was 1.89 percent at 3 years following the primary procedure. The 95% confidence interval was (1.46, 2.43). This estimate is based on 2455 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail implant for total hip arthroplasty (THA) was 1.89 percent at 4 years following the primary procedure. The 95% confidence interval was (1.46, 2.43). This estimate is based on 2188 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail implant for total hip arthroplasty (THA) was 1.94 percent at 5 years following the primary procedure. The 95% confidence interval was (1.51, 2.49). This estimate is based on 1757 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail implant for total hip arthroplasty (THA) was 1.99 percent at 6 years following the primary procedure. The 95% confidence interval was (1.55, 2.56). This estimate is based on 1162 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail implant for total hip arthroplasty (THA) was 2.08 percent at 7 years following the primary procedure. The 95% confidence interval was (1.61, 2.68). This estimate is based on 687 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail implant for total hip arthroplasty (THA) was 2.68 percent at 8 years following the primary procedure. The 95% confidence interval was (1.94, 3.70). This estimate is based on 348 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail implant for total hip arthroplasty (THA) was 2.68 percent at 9 years following the primary procedure. The 95% confidence interval was (1.94, 3.70). This estimate is based on 65 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Corail implant for total hip arthroplasty (THA) was 2.68 percent at 10 years following the primary procedure. The 95% confidence interval was (1.94, 3.70). This estimate is based on 2 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echelon implant for total hip arthroplasty (THA) was 2.61 percent at 1 year following the primary procedure. The 95% confidence interval was (1.52, 4.45). This estimate is based on 471 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echelon implant for total hip arthroplasty (THA) was 3.25 percent at 2 years following the primary procedure. The 95% confidence interval was (2.00, 5.26). This estimate is based on 440 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echelon implant for total hip arthroplasty (THA) was 3.72 percent at 3 years following the primary procedure. The 95% confidence interval was (2.36, 5.84). This estimate is based on 408 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echelon implant for total hip arthroplasty (THA) was 3.72 percent at 4 years following the primary procedure. The 95% confidence interval was (2.36, 5.84). This estimate is based on 354 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echelon implant for total hip arthroplasty (THA) was 3.72 percent at 5 years following the primary procedure. The 95% confidence interval was (2.36, 5.84). This estimate is based on 308 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echelon implant for total hip arthroplasty (THA) was 4.35 percent at 6 years following the primary procedure. The 95% confidence interval was (2.81, 6.71). This estimate is based on 281 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echelon implant for total hip arthroplasty (THA) was 4.35 percent at 7 years following the primary procedure. The 95% confidence interval was (2.81, 6.71). This estimate is based on 198 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echelon implant for total hip arthroplasty (THA) was 4.35 percent at 8 years following the primary procedure. The 95% confidence interval was (2.81, 6.71). This estimate is based on 112 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echelon implant for total hip arthroplasty (THA) was 4.35 percent at 9 years following the primary procedure. The 95% confidence interval was (2.81, 6.71). This estimate is based on 39 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty implant for total hip arthroplasty (THA) was 2.01 percent at 1 year following the primary procedure. The 95% confidence interval was (1.45, 2.77). This estimate is based on 1618 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty implant for total hip arthroplasty (THA) was 2.46 percent at 2 years following the primary procedure. The 95% confidence interval was (1.83, 3.31). This estimate is based on 1307 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty implant for total hip arthroplasty (THA) was 2.64 percent at 3 years following the primary procedure. The 95% confidence interval was (1.97, 3.52). This estimate is based on 921 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty implant for total hip arthroplasty (THA) was 3.05 percent at 4 years following the primary procedure. The 95% confidence interval was (2.27, 4.09). This estimate is based on 581 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty implant for total hip arthroplasty (THA) was 3.05 percent at 5 years following the primary procedure. The 95% confidence interval was (2.27, 4.09). This estimate is based on 329 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty implant for total hip arthroplasty (THA) was 3.05 percent at 6 years following the primary procedure. The 95% confidence interval was (2.27, 4.09). This estimate is based on 85 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric Microplasty implant for total hip arthroplasty (THA) was 3.05 percent at 7 years following the primary procedure. The 95% confidence interval was (2.27, 4.09). This estimate is based on 3 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric implant for total hip arthroplasty (THA) was 2.66 percent at 1 year following the primary procedure. The 95% confidence interval was (2.03, 3.48). This estimate is based on 1833 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric implant for total hip arthroplasty (THA) was 3.15 percent at 2 years following the primary procedure. The 95% confidence interval was (2.46, 4.02). This estimate is based on 1686 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric implant for total hip arthroplasty (THA) was 3.39 percent at 3 years following the primary procedure. The 95% confidence interval was (2.67, 4.31). This estimate is based on 1465 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric implant for total hip arthroplasty (THA) was 3.68 percent at 4 years following the primary procedure. The 95% confidence interval was (2.91, 4.64). This estimate is based on 1072 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric implant for total hip arthroplasty (THA) was 3.68 percent at 5 years following the primary procedure. The 95% confidence interval was (2.91, 4.64). This estimate is based on 689 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric implant for total hip arthroplasty (THA) was 3.82 percent at 6 years following the primary procedure. The 95% confidence interval was (3.02, 4.83). This estimate is based on 469 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric implant for total hip arthroplasty (THA) was 3.82 percent at 7 years following the primary procedure. The 95% confidence interval was (3.02, 4.83). This estimate is based on 224 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric implant for total hip arthroplasty (THA) was 3.82 percent at 8 years following the primary procedure. The 95% confidence interval was (3.02, 4.83). This estimate is based on 70 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric implant for total hip arthroplasty (THA) was 3.82 percent at 9 years following the primary procedure. The 95% confidence interval was (3.02, 4.83). This estimate is based on 37 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Echo Bi-Metric implant for total hip arthroplasty (THA) was 3.82 percent at 10 years following the primary procedure. The 95% confidence interval was (3.02, 4.83). This estimate is based on 14 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore implant for total hip arthroplasty (THA) was 1.32 percent at 1 year following the primary procedure. The 95% confidence interval was (1.06, 1.65). This estimate is based on 5575 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore implant for total hip arthroplasty (THA) was 1.70 percent at 2 years following the primary procedure. The 95% confidence interval was (1.40, 2.07). This estimate is based on 5200 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore implant for total hip arthroplasty (THA) was 1.94 percent at 3 years following the primary procedure. The 95% confidence interval was (1.61, 2.34). This estimate is based on 4563 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore implant for total hip arthroplasty (THA) was 2.12 percent at 4 years following the primary procedure. The 95% confidence interval was (1.78, 2.54). This estimate is based on 3810 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore implant for total hip arthroplasty (THA) was 2.27 percent at 5 years following the primary procedure. The 95% confidence interval was (1.90, 2.70). This estimate is based on 3143 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore implant for total hip arthroplasty (THA) was 2.30 percent at 6 years following the primary procedure. The 95% confidence interval was (1.93, 2.74). This estimate is based on 2393 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore implant for total hip arthroplasty (THA) was 2.70 percent at 7 years following the primary procedure. The 95% confidence interval was (2.26, 3.23). This estimate is based on 1644 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore implant for total hip arthroplasty (THA) was 2.70 percent at 8 years following the primary procedure. The 95% confidence interval was (2.26, 3.23). This estimate is based on 920 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore implant for total hip arthroplasty (THA) was 3.09 percent at 9 years following the primary procedure. The 95% confidence interval was (2.44, 3.91). This estimate is based on 366 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Fitmore implant for total hip arthroplasty (THA) was 3.09 percent at 10 years following the primary procedure. The 95% confidence interval was (2.44, 3.91). This estimate is based on 89 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Integral X implant for total hip arthroplasty (THA) was 2.62 percent at 1 year following the primary procedure. The 95% confidence interval was (1.59, 4.31). This estimate is based on 532 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Integral X implant for total hip arthroplasty (THA) was 3.01 percent at 2 years following the primary procedure. The 95% confidence interval was (1.88, 4.79). This estimate is based on 487 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Integral X implant for total hip arthroplasty (THA) was 3.21 percent at 3 years following the primary procedure. The 95% confidence interval was (2.03, 5.05). This estimate is based on 447 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Integral X implant for total hip arthroplasty (THA) was 3.67 percent at 4 years following the primary procedure. The 95% confidence interval was (2.38, 5.65). This estimate is based on 394 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Integral X implant for total hip arthroplasty (THA) was 3.67 percent at 5 years following the primary procedure. The 95% confidence interval was (2.38, 5.65). This estimate is based on 321 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Integral X implant for total hip arthroplasty (THA) was 3.67 percent at 6 years following the primary procedure. The 95% confidence interval was (2.38, 5.65). This estimate is based on 253 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Integral X implant for total hip arthroplasty (THA) was 3.67 percent at 7 years following the primary procedure. The 95% confidence interval was (2.38, 5.65). This estimate is based on 208 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Integral X implant for total hip arthroplasty (THA) was 4.13 percent at 8 years following the primary procedure. The 95% confidence interval was (2.66, 6.41). This estimate is based on 137 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Integral X implant for total hip arthroplasty (THA) was 4.13 percent at 9 years following the primary procedure. The 95% confidence interval was (2.66, 6.41). This estimate is based on 59 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Integral X implant for total hip arthroplasty (THA) was 6.13 percent at 10 years following the primary procedure. The 95% confidence interval was (3.04, 12.17). This estimate is based on 24 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper Kinectiv implant for total hip arthroplasty (THA) was 2.03 percent at 1 year following the primary procedure. The 95% confidence interval was (1.29, 3.21). This estimate is based on 842 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper Kinectiv implant for total hip arthroplasty (THA) was 3.11 percent at 2 years following the primary procedure. The 95% confidence interval was (2.15, 4.51). This estimate is based on 784 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper Kinectiv implant for total hip arthroplasty (THA) was 3.50 percent at 3 years following the primary procedure. The 95% confidence interval was (2.46, 4.97). This estimate is based on 724 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper Kinectiv implant for total hip arthroplasty (THA) was 3.78 percent at 4 years following the primary procedure. The 95% confidence interval was (2.68, 5.31). This estimate is based on 637 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper Kinectiv implant for total hip arthroplasty (THA) was 4.27 percent at 5 years following the primary procedure. The 95% confidence interval was (3.08, 5.92). This estimate is based on 547 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper Kinectiv implant for total hip arthroplasty (THA) was 4.27 percent at 6 years following the primary procedure. The 95% confidence interval was (3.08, 5.92). This estimate is based on 469 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper Kinectiv implant for total hip arthroplasty (THA) was 4.27 percent at 7 years following the primary procedure. The 95% confidence interval was (3.08, 5.92). This estimate is based on 383 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper Kinectiv implant for total hip arthroplasty (THA) was 4.27 percent at 8 years following the primary procedure. The 95% confidence interval was (3.08, 5.92). This estimate is based on 276 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper Kinectiv implant for total hip arthroplasty (THA) was 4.27 percent at 9 years following the primary procedure. The 95% confidence interval was (3.08, 5.92). This estimate is based on 162 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper Kinectiv implant for total hip arthroplasty (THA) was 4.27 percent at 10 years following the primary procedure. The 95% confidence interval was (3.08, 5.92). This estimate is based on 54 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper implant for total hip arthroplasty (THA) was 1.73 percent at 1 year following the primary procedure. The 95% confidence interval was (1.53, 1.96). This estimate is based on 13303 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper implant for total hip arthroplasty (THA) was 2.13 percent at 2 years following the primary procedure. The 95% confidence interval was (1.91, 2.38). This estimate is based on 11920 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper implant for total hip arthroplasty (THA) was 2.50 percent at 3 years following the primary procedure. The 95% confidence interval was (2.25, 2.77). This estimate is based on 10667 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper implant for total hip arthroplasty (THA) was 2.71 percent at 4 years following the primary procedure. The 95% confidence interval was (2.45, 3.00). This estimate is based on 9368 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper implant for total hip arthroplasty (THA) was 2.91 percent at 5 years following the primary procedure. The 95% confidence interval was (2.64, 3.22). This estimate is based on 8097 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper implant for total hip arthroplasty (THA) was 3.06 percent at 6 years following the primary procedure. The 95% confidence interval was (2.77, 3.38). This estimate is based on 6693 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper implant for total hip arthroplasty (THA) was 3.24 percent at 7 years following the primary procedure. The 95% confidence interval was (2.94, 3.58). This estimate is based on 4976 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper implant for total hip arthroplasty (THA) was 3.36 percent at 8 years following the primary procedure. The 95% confidence interval was (3.04, 3.71). This estimate is based on 3357 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper implant for total hip arthroplasty (THA) was 3.39 percent at 9 years following the primary procedure. The 95% confidence interval was (3.06, 3.75). This estimate is based on 1686 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the M/L Taper implant for total hip arthroplasty (THA) was 3.70 percent at 10 years following the primary procedure. The 95% confidence interval was (3.22, 4.25). This estimate is based on 521 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem implant for total hip arthroplasty (THA) was 1.63 percent at 1 year following the primary procedure. The 95% confidence interval was (1.22, 2.19). This estimate is based on 2244 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem implant for total hip arthroplasty (THA) was 1.83 percent at 2 years following the primary procedure. The 95% confidence interval was (1.38, 2.43). This estimate is based on 1789 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem implant for total hip arthroplasty (THA) was 1.95 percent at 3 years following the primary procedure. The 95% confidence interval was (1.48, 2.57). This estimate is based on 1433 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem implant for total hip arthroplasty (THA) was 2.29 percent at 4 years following the primary procedure. The 95% confidence interval was (1.74, 3.02). This estimate is based on 984 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem implant for total hip arthroplasty (THA) was 2.64 percent at 5 years following the primary procedure. The 95% confidence interval was (1.99, 3.50). This estimate is based on 609 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem implant for total hip arthroplasty (THA) was 2.64 percent at 6 years following the primary procedure. The 95% confidence interval was (1.99, 3.50). This estimate is based on 323 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem implant for total hip arthroplasty (THA) was 2.64 percent at 7 years following the primary procedure. The 95% confidence interval was (1.99, 3.50). This estimate is based on 53 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Polarstem implant for total hip arthroplasty (THA) was 2.64 percent at 8 years following the primary procedure. The 95% confidence interval was (1.99, 3.50). This estimate is based on 6 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max implant for total hip arthroplasty (THA) was 2.11 percent at 1 year following the primary procedure. The 95% confidence interval was (1.66, 2.67). This estimate is based on 2956 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max implant for total hip arthroplasty (THA) was 2.56 percent at 2 years following the primary procedure. The 95% confidence interval was (2.06, 3.18). This estimate is based on 2760 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max implant for total hip arthroplasty (THA) was 2.89 percent at 3 years following the primary procedure. The 95% confidence interval was (2.35, 3.54). This estimate is based on 2552 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max implant for total hip arthroplasty (THA) was 3.32 percent at 4 years following the primary procedure. The 95% confidence interval was (2.74, 4.03). This estimate is based on 2317 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max implant for total hip arthroplasty (THA) was 3.46 percent at 5 years following the primary procedure. The 95% confidence interval was (2.86, 4.18). This estimate is based on 1913 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max implant for total hip arthroplasty (THA) was 3.63 percent at 6 years following the primary procedure. The 95% confidence interval was (3.01, 4.39). This estimate is based on 1446 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max implant for total hip arthroplasty (THA) was 4.03 percent at 7 years following the primary procedure. The 95% confidence interval was (3.33, 4.87). This estimate is based on 1002 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max implant for total hip arthroplasty (THA) was 4.16 percent at 8 years following the primary procedure. The 95% confidence interval was (3.42, 5.05). This estimate is based on 610 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max implant for total hip arthroplasty (THA) was 4.32 percent at 9 years following the primary procedure. The 95% confidence interval was (3.53, 5.27). This estimate is based on 344 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Max implant for total hip arthroplasty (THA) was 4.32 percent at 10 years following the primary procedure. The 95% confidence interval was (3.53, 5.27). This estimate is based on 129 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max implant for total hip arthroplasty (THA) was 1.76 percent at 1 year following the primary procedure. The 95% confidence interval was (1.28, 2.42). This estimate is based on 2049 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max implant for total hip arthroplasty (THA) was 2.00 percent at 2 years following the primary procedure. The 95% confidence interval was (1.48, 2.70). This estimate is based on 2010 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max implant for total hip arthroplasty (THA) was 2.15 percent at 3 years following the primary procedure. The 95% confidence interval was (1.61, 2.87). This estimate is based on 1983 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max implant for total hip arthroplasty (THA) was 2.30 percent at 4 years following the primary procedure. The 95% confidence interval was (1.74, 3.04). This estimate is based on 1942 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max implant for total hip arthroplasty (THA) was 2.56 percent at 5 years following the primary procedure. The 95% confidence interval was (1.96, 3.33). This estimate is based on 1829 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max implant for total hip arthroplasty (THA) was 2.78 percent at 6 years following the primary procedure. The 95% confidence interval was (2.15, 3.59). This estimate is based on 1612 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max implant for total hip arthroplasty (THA) was 2.98 percent at 7 years following the primary procedure. The 95% confidence interval was (2.32, 3.83). This estimate is based on 1245 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max implant for total hip arthroplasty (THA) was 3.49 percent at 8 years following the primary procedure. The 95% confidence interval was (2.72, 4.47). This estimate is based on 886 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max implant for total hip arthroplasty (THA) was 3.49 percent at 9 years following the primary procedure. The 95% confidence interval was (2.72, 4.47). This estimate is based on 540 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit Plus Max implant for total hip arthroplasty (THA) was 3.49 percent at 10 years following the primary procedure. The 95% confidence interval was (2.72, 4.47). This estimate is based on 225 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit implant for total hip arthroplasty (THA) was 3.51 percent at 1 year following the primary procedure. The 95% confidence interval was (2.74, 4.49). This estimate is based on 1551 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit implant for total hip arthroplasty (THA) was 4.02 percent at 2 years following the primary procedure. The 95% confidence interval was (3.19, 5.07). This estimate is based on 1390 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit implant for total hip arthroplasty (THA) was 4.39 percent at 3 years following the primary procedure. The 95% confidence interval was (3.51, 5.48). This estimate is based on 1258 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit implant for total hip arthroplasty (THA) was 4.63 percent at 4 years following the primary procedure. The 95% confidence interval was (3.71, 5.76). This estimate is based on 1061 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit implant for total hip arthroplasty (THA) was 5.13 percent at 5 years following the primary procedure. The 95% confidence interval was (4.13, 6.35). This estimate is based on 859 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit implant for total hip arthroplasty (THA) was 5.37 percent at 6 years following the primary procedure. The 95% confidence interval was (4.34, 6.65). This estimate is based on 658 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit implant for total hip arthroplasty (THA) was 5.70 percent at 7 years following the primary procedure. The 95% confidence interval was (4.59, 7.07). This estimate is based on 416 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit implant for total hip arthroplasty (THA) was 6.25 percent at 8 years following the primary procedure. The 95% confidence interval was (4.96, 7.87). This estimate is based on 214 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Secur-Fit implant for total hip arthroplasty (THA) was 6.25 percent at 9 years following the primary procedure. The 95% confidence interval was (4.96, 7.87). This estimate is based on 45 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM implant for total hip arthroplasty (THA) was 1.22 percent at 1 year following the primary procedure. The 95% confidence interval was (0.72, 2.05). This estimate is based on 1130 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM implant for total hip arthroplasty (THA) was 2.27 percent at 2 years following the primary procedure. The 95% confidence interval was (1.55, 3.32). This estimate is based on 1103 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM implant for total hip arthroplasty (THA) was 2.63 percent at 3 years following the primary procedure. The 95% confidence interval was (1.85, 3.74). This estimate is based on 1073 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM implant for total hip arthroplasty (THA) was 3.11 percent at 4 years following the primary procedure. The 95% confidence interval was (2.24, 4.30). This estimate is based on 996 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM implant for total hip arthroplasty (THA) was 3.31 percent at 5 years following the primary procedure. The 95% confidence interval was (2.41, 4.54). This estimate is based on 923 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM implant for total hip arthroplasty (THA) was 3.52 percent at 6 years following the primary procedure. The 95% confidence interval was (2.58, 4.79). This estimate is based on 812 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM implant for total hip arthroplasty (THA) was 3.91 percent at 7 years following the primary procedure. The 95% confidence interval was (2.90, 5.27). This estimate is based on 662 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM implant for total hip arthroplasty (THA) was 4.08 percent at 8 years following the primary procedure. The 95% confidence interval was (3.03, 5.49). This estimate is based on 445 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM implant for total hip arthroplasty (THA) was 4.08 percent at 9 years following the primary procedure. The 95% confidence interval was (3.03, 5.49). This estimate is based on 208 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the SROM implant for total hip arthroplasty (THA) was 4.08 percent at 10 years following the primary procedure. The 95% confidence interval was (3.03, 5.49). This estimate is based on 15 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit implant for total hip arthroplasty (THA) was 1.48 percent at 1 year following the primary procedure. The 95% confidence interval was (1.22, 1.78). This estimate is based on 6827 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit implant for total hip arthroplasty (THA) was 1.82 percent at 2 years following the primary procedure. The 95% confidence interval was (1.54, 2.16). This estimate is based on 6262 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit implant for total hip arthroplasty (THA) was 2.03 percent at 3 years following the primary procedure. The 95% confidence interval was (1.73, 2.39). This estimate is based on 5765 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit implant for total hip arthroplasty (THA) was 2.13 percent at 4 years following the primary procedure. The 95% confidence interval was (1.81, 2.49). This estimate is based on 5211 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit implant for total hip arthroplasty (THA) was 2.19 percent at 5 years following the primary procedure. The 95% confidence interval was (1.87, 2.56). This estimate is based on 4554 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit implant for total hip arthroplasty (THA) was 2.24 percent at 6 years following the primary procedure. The 95% confidence interval was (1.91, 2.62). This estimate is based on 3714 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit implant for total hip arthroplasty (THA) was 2.33 percent at 7 years following the primary procedure. The 95% confidence interval was (1.99, 2.73). This estimate is based on 2730 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit implant for total hip arthroplasty (THA) was 2.48 percent at 8 years following the primary procedure. The 95% confidence interval was (2.10, 2.91). This estimate is based on 1688 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit implant for total hip arthroplasty (THA) was 2.65 percent at 9 years following the primary procedure. The 95% confidence interval was (2.22, 3.17). This estimate is based on 766 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Summit implant for total hip arthroplasty (THA) was 2.95 percent at 10 years following the primary procedure. The 95% confidence interval was (2.29, 3.81). This estimate is based on 203 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy implant for total hip arthroplasty (THA) was 2.26 percent at 1 year following the primary procedure. The 95% confidence interval was (1.61, 3.17). This estimate is based on 1334 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy implant for total hip arthroplasty (THA) was 2.94 percent at 2 years following the primary procedure. The 95% confidence interval was (2.18, 3.97). This estimate is based on 1213 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy implant for total hip arthroplasty (THA) was 3.27 percent at 3 years following the primary procedure. The 95% confidence interval was (2.46, 4.34). This estimate is based on 1120 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy implant for total hip arthroplasty (THA) was 3.45 percent at 4 years following the primary procedure. The 95% confidence interval was (2.61, 4.56). This estimate is based on 1000 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy implant for total hip arthroplasty (THA) was 3.67 percent at 5 years following the primary procedure. The 95% confidence interval was (2.78, 4.82). This estimate is based on 851 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy implant for total hip arthroplasty (THA) was 4.17 percent at 6 years following the primary procedure. The 95% confidence interval was (3.19, 5.45). This estimate is based on 687 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy implant for total hip arthroplasty (THA) was 4.48 percent at 7 years following the primary procedure. The 95% confidence interval was (3.43, 5.84). This estimate is based on 507 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy implant for total hip arthroplasty (THA) was 4.69 percent at 8 years following the primary procedure. The 95% confidence interval was (3.59, 6.13). This estimate is based on 324 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy implant for total hip arthroplasty (THA) was 4.69 percent at 9 years following the primary procedure. The 95% confidence interval was (3.59, 6.13). This estimate is based on 133 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Synergy implant for total hip arthroplasty (THA) was 4.69 percent at 10 years following the primary procedure. The 95% confidence interval was (3.59, 6.13). This estimate is based on 43 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty implant for total hip arthroplasty (THA) was 1.29 percent at 1 year following the primary procedure. The 95% confidence interval was (1.00, 1.67). This estimate is based on 4140 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty implant for total hip arthroplasty (THA) was 1.51 percent at 2 years following the primary procedure. The 95% confidence interval was (1.19, 1.91). This estimate is based on 3502 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty implant for total hip arthroplasty (THA) was 1.54 percent at 3 years following the primary procedure. The 95% confidence interval was (1.21, 1.95). This estimate is based on 2950 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty implant for total hip arthroplasty (THA) was 1.79 percent at 4 years following the primary procedure. The 95% confidence interval was (1.43, 2.25). This estimate is based on 2318 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty implant for total hip arthroplasty (THA) was 1.99 percent at 5 years following the primary procedure. The 95% confidence interval was (1.59, 2.50). This estimate is based on 1739 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty implant for total hip arthroplasty (THA) was 2.05 percent at 6 years following the primary procedure. The 95% confidence interval was (1.63, 2.57). This estimate is based on 1146 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty implant for total hip arthroplasty (THA) was 2.05 percent at 7 years following the primary procedure. The 95% confidence interval was (1.63, 2.57). This estimate is based on 631 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty implant for total hip arthroplasty (THA) was 2.05 percent at 8 years following the primary procedure. The 95% confidence interval was (1.63, 2.57). This estimate is based on 246 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 Microplasty implant for total hip arthroplasty (THA) was 3.97 percent at 9 years following the primary procedure. The 95% confidence interval was (1.53, 10.09). This estimate is based on 36 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 implant for total hip arthroplasty (THA) was 1.71 percent at 1 year following the primary procedure. The 95% confidence interval was (1.50, 1.94). This estimate is based on 11930 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 implant for total hip arthroplasty (THA) was 2.20 percent at 2 years following the primary procedure. The 95% confidence interval was (1.96, 2.47). This estimate is based on 10035 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 implant for total hip arthroplasty (THA) was 2.43 percent at 3 years following the primary procedure. The 95% confidence interval was (2.17, 2.71). This estimate is based on 8420 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 implant for total hip arthroplasty (THA) was 2.67 percent at 4 years following the primary procedure. The 95% confidence interval was (2.40, 2.98). This estimate is based on 6460 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 implant for total hip arthroplasty (THA) was 2.83 percent at 5 years following the primary procedure. The 95% confidence interval was (2.54, 3.16). This estimate is based on 4767 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 implant for total hip arthroplasty (THA) was 2.88 percent at 6 years following the primary procedure. The 95% confidence interval was (2.58, 3.22). This estimate is based on 3206 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 implant for total hip arthroplasty (THA) was 2.91 percent at 7 years following the primary procedure. The 95% confidence interval was (2.61, 3.25). This estimate is based on 2014 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 implant for total hip arthroplasty (THA) was 2.99 percent at 8 years following the primary procedure. The 95% confidence interval was (2.65, 3.37). This estimate is based on 1049 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 implant for total hip arthroplasty (THA) was 3.33 percent at 9 years following the primary procedure. The 95% confidence interval was (2.78, 3.99). This estimate is based on 345 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc 133 implant for total hip arthroplasty (THA) was 3.33 percent at 10 years following the primary procedure. The 95% confidence interval was (2.78, 3.99). This estimate is based on 25 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc implant for total hip arthroplasty (THA) was 1.55 percent at 1 year following the primary procedure. The 95% confidence interval was (0.78, 3.07). This estimate is based on 509 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc implant for total hip arthroplasty (THA) was 1.55 percent at 2 years following the primary procedure. The 95% confidence interval was (0.78, 3.07). This estimate is based on 508 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc implant for total hip arthroplasty (THA) was 2.13 percent at 3 years following the primary procedure. The 95% confidence interval was (1.18, 3.81). This estimate is based on 504 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc implant for total hip arthroplasty (THA) was 2.52 percent at 4 years following the primary procedure. The 95% confidence interval was (1.47, 4.30). This estimate is based on 491 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc implant for total hip arthroplasty (THA) was 2.52 percent at 5 years following the primary procedure. The 95% confidence interval was (1.47, 4.30). This estimate is based on 456 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc implant for total hip arthroplasty (THA) was 2.52 percent at 6 years following the primary procedure. The 95% confidence interval was (1.47, 4.30). This estimate is based on 420 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc implant for total hip arthroplasty (THA) was 2.79 percent at 7 years following the primary procedure. The 95% confidence interval was (1.66, 4.68). This estimate is based on 353 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc implant for total hip arthroplasty (THA) was 2.79 percent at 8 years following the primary procedure. The 95% confidence interval was (1.66, 4.68). This estimate is based on 274 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc implant for total hip arthroplasty (THA) was 2.79 percent at 9 years following the primary procedure. The 95% confidence interval was (1.66, 4.68). This estimate is based on 177 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Taperloc implant for total hip arthroplasty (THA) was 2.79 percent at 10 years following the primary procedure. The 95% confidence interval was (1.66, 4.68). This estimate is based on 109 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 1.84 percent at 1 year following the primary procedure. The 95% confidence interval was (1.24, 2.74). This estimate is based on 1232 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 1.92 percent at 2 years following the primary procedure. The 95% confidence interval was (1.30, 2.83). This estimate is based on 1147 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 2.47 percent at 3 years following the primary procedure. The 95% confidence interval was (1.74, 3.49). This estimate is based on 1047 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 2.57 percent at 4 years following the primary procedure. The 95% confidence interval was (1.82, 3.61). This estimate is based on 944 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 2.57 percent at 5 years following the primary procedure. The 95% confidence interval was (1.82, 3.61). This estimate is based on 816 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 2.57 percent at 6 years following the primary procedure. The 95% confidence interval was (1.82, 3.61). This estimate is based on 657 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 2.57 percent at 7 years following the primary procedure. The 95% confidence interval was (1.82, 3.61). This estimate is based on 446 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 2.57 percent at 8 years following the primary procedure. The 95% confidence interval was (1.82, 3.61). This estimate is based on 237 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 2.57 percent at 9 years following the primary procedure. The 95% confidence interval was (1.82, 3.61). This estimate is based on 80 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 2.57 percent at 10 years following the primary procedure. The 95% confidence interval was (1.82, 3.61). This estimate is based on 9 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS implant for total hip arthroplasty (THA) was 0.66 percent at 1 year following the primary procedure. The 95% confidence interval was (0.46, 0.94). This estimate is based on 4102 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS implant for total hip arthroplasty (THA) was 0.97 percent at 2 years following the primary procedure. The 95% confidence interval was (0.71, 1.32). This estimate is based on 3592 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS implant for total hip arthroplasty (THA) was 1.27 percent at 3 years following the primary procedure. The 95% confidence interval was (0.97, 1.68). This estimate is based on 3002 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS implant for total hip arthroplasty (THA) was 1.42 percent at 4 years following the primary procedure. The 95% confidence interval was (1.09, 1.85). This estimate is based on 2429 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS implant for total hip arthroplasty (THA) was 1.60 percent at 5 years following the primary procedure. The 95% confidence interval was (1.23, 2.08). This estimate is based on 1916 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS implant for total hip arthroplasty (THA) was 1.66 percent at 6 years following the primary procedure. The 95% confidence interval was (1.28, 2.15). This estimate is based on 1452 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS implant for total hip arthroplasty (THA) was 1.75 percent at 7 years following the primary procedure. The 95% confidence interval was (1.34, 2.29). This estimate is based on 1004 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS implant for total hip arthroplasty (THA) was 1.86 percent at 8 years following the primary procedure. The 95% confidence interval was (1.41, 2.45). This estimate is based on 488 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS implant for total hip arthroplasty (THA) was 1.86 percent at 9 years following the primary procedure. The 95% confidence interval was (1.41, 2.45). This estimate is based on 136 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Tri-Lock BPS implant for total hip arthroplasty (THA) was 1.86 percent at 10 years following the primary procedure. The 95% confidence interval was (1.41, 2.45). This estimate is based on 19 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Advocate implant for total hip arthroplasty (THA) was 2.01 percent at 1 year following the primary procedure. The 95% confidence interval was (1.15, 3.52). This estimate is based on 495 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Advocate implant for total hip arthroplasty (THA) was 2.01 percent at 2 years following the primary procedure. The 95% confidence interval was (1.15, 3.52). This estimate is based on 395 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Advocate implant for total hip arthroplasty (THA) was 2.01 percent at 3 years following the primary procedure. The 95% confidence interval was (1.15, 3.52). This estimate is based on 276 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Advocate implant for total hip arthroplasty (THA) was 2.40 percent at 4 years following the primary procedure. The 95% confidence interval was (1.36, 4.22). This estimate is based on 204 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Advocate implant for total hip arthroplasty (THA) was 2.40 percent at 5 years following the primary procedure. The 95% confidence interval was (1.36, 4.22). This estimate is based on 154 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Advocate implant for total hip arthroplasty (THA) was 2.40 percent at 6 years following the primary procedure. The 95% confidence interval was (1.36, 4.22). This estimate is based on 124 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Advocate implant for total hip arthroplasty (THA) was 2.40 percent at 7 years following the primary procedure. The 95% confidence interval was (1.36, 4.22). This estimate is based on 94 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Advocate implant for total hip arthroplasty (THA) was 2.40 percent at 8 years following the primary procedure. The 95% confidence interval was (1.36, 4.22). This estimate is based on 59 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Advocate implant for total hip arthroplasty (THA) was 2.40 percent at 9 years following the primary procedure. The 95% confidence interval was (1.36, 4.22). This estimate is based on 31 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Advocate implant for total hip arthroplasty (THA) was 2.40 percent at 10 years following the primary procedure. The 95% confidence interval was (1.36, 4.22). This estimate is based on 11 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Heritage implant for total hip arthroplasty (THA) was 1.41 percent at 1 year following the primary procedure. The 95% confidence interval was (0.67, 2.93). This estimate is based on 436 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Heritage implant for total hip arthroplasty (THA) was 1.64 percent at 2 years following the primary procedure. The 95% confidence interval was (0.82, 3.27). This estimate is based on 367 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Heritage implant for total hip arthroplasty (THA) was 1.64 percent at 3 years following the primary procedure. The 95% confidence interval was (0.82, 3.27). This estimate is based on 308 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Heritage implant for total hip arthroplasty (THA) was 2.00 percent at 4 years following the primary procedure. The 95% confidence interval was (1.03, 3.86). This estimate is based on 223 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Heritage implant for total hip arthroplasty (THA) was 2.00 percent at 5 years following the primary procedure. The 95% confidence interval was (1.03, 3.86). This estimate is based on 149 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Heritage implant for total hip arthroplasty (THA) was 2.00 percent at 6 years following the primary procedure. The 95% confidence interval was (1.03, 3.86). This estimate is based on 101 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Heritage implant for total hip arthroplasty (THA) was 2.00 percent at 7 years following the primary procedure. The 95% confidence interval was (1.03, 3.86). This estimate is based on 70 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Heritage implant for total hip arthroplasty (THA) was 2.00 percent at 8 years following the primary procedure. The 95% confidence interval was (1.03, 3.86). This estimate is based on 46 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Heritage implant for total hip arthroplasty (THA) was 2.00 percent at 9 years following the primary procedure. The 95% confidence interval was (1.03, 3.86). This estimate is based on 33 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Versys Heritage implant for total hip arthroplasty (THA) was 2.00 percent at 10 years following the primary procedure. The 95% confidence interval was (1.03, 3.86). This estimate is based on 14 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Wagner Cone implant for total hip arthroplasty (THA) was 1.50 percent at 1 year following the primary procedure. The 95% confidence interval was (0.81, 2.77). This estimate is based on 621 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Wagner Cone implant for total hip arthroplasty (THA) was 3.00 percent at 2 years following the primary procedure. The 95% confidence interval was (1.92, 4.67). This estimate is based on 552 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Wagner Cone implant for total hip arthroplasty (THA) was 3.19 percent at 3 years following the primary procedure. The 95% confidence interval was (2.06, 4.90). This estimate is based on 476 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Wagner Cone implant for total hip arthroplasty (THA) was 3.67 percent at 4 years following the primary procedure. The 95% confidence interval was (2.42, 5.55). This estimate is based on 358 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Wagner Cone implant for total hip arthroplasty (THA) was 3.96 percent at 5 years following the primary procedure. The 95% confidence interval was (2.63, 5.96). This estimate is based on 291 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Wagner Cone implant for total hip arthroplasty (THA) was 4.76 percent at 6 years following the primary procedure. The 95% confidence interval was (3.15, 7.15). This estimate is based on 217 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Wagner Cone implant for total hip arthroplasty (THA) was 5.23 percent at 7 years following the primary procedure. The 95% confidence interval was (3.46, 7.87). This estimate is based on 138 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Wagner Cone implant for total hip arthroplasty (THA) was 5.23 percent at 8 years following the primary procedure. The 95% confidence interval was (3.46, 7.87). This estimate is based on 87 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Wagner Cone implant for total hip arthroplasty (THA) was 6.92 percent at 9 years following the primary procedure. The 95% confidence interval was (3.92, 12.08). This estimate is based on 45 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Wagner Cone implant for total hip arthroplasty (THA) was 6.92 percent at 10 years following the primary procedure. The 95% confidence interval was (3.92, 12.08). This estimate is based on 18 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Continuum implant for total hip arthroplasty (THA) was 1.80 percent at 1 year following the primary procedure. The 95% confidence interval was (1.60, 2.02). This estimate is based on 14675 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Continuum implant for total hip arthroplasty (THA) was 2.18 percent at 2 years following the primary procedure. The 95% confidence interval was (1.96, 2.42). This estimate is based on 13831 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Continuum implant for total hip arthroplasty (THA) was 2.59 percent at 3 years following the primary procedure. The 95% confidence interval was (2.35, 2.86). This estimate is based on 12972 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Continuum implant for total hip arthroplasty (THA) was 2.87 percent at 4 years following the primary procedure. The 95% confidence interval was (2.61, 3.15). This estimate is based on 11938 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Continuum implant for total hip arthroplasty (THA) was 3.03 percent at 5 years following the primary procedure. The 95% confidence interval was (2.76, 3.32). This estimate is based on 10665 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Continuum implant for total hip arthroplasty (THA) was 3.12 percent at 6 years following the primary procedure. The 95% confidence interval was (2.85, 3.42). This estimate is based on 8973 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Continuum implant for total hip arthroplasty (THA) was 3.31 percent at 7 years following the primary procedure. The 95% confidence interval was (3.02, 3.62). This estimate is based on 6962 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Continuum implant for total hip arthroplasty (THA) was 3.39 percent at 8 years following the primary procedure. The 95% confidence interval was (3.09, 3.71). This estimate is based on 4498 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Continuum implant for total hip arthroplasty (THA) was 3.49 percent at 9 years following the primary procedure. The 95% confidence interval was (3.18, 3.84). This estimate is based on 1998 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Continuum implant for total hip arthroplasty (THA) was 3.83 percent at 10 years following the primary procedure. The 95% confidence interval was (3.36, 4.36). This estimate is based on 534 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Converge implant for total hip arthroplasty (THA) was 0.78 percent at 1 year following the primary procedure. The 95% confidence interval was (0.29, 2.06). This estimate is based on 510 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Converge implant for total hip arthroplasty (THA) was 1.17 percent at 2 years following the primary procedure. The 95% confidence interval was (0.53, 2.58). This estimate is based on 508 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Converge implant for total hip arthroplasty (THA) was 1.36 percent at 3 years following the primary procedure. The 95% confidence interval was (0.65, 2.84). This estimate is based on 507 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Converge implant for total hip arthroplasty (THA) was 1.36 percent at 4 years following the primary procedure. The 95% confidence interval was (0.65, 2.84). This estimate is based on 507 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Converge implant for total hip arthroplasty (THA) was 1.56 percent at 5 years following the primary procedure. The 95% confidence interval was (0.78, 3.09). This estimate is based on 506 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Converge implant for total hip arthroplasty (THA) was 1.75 percent at 6 years following the primary procedure. The 95% confidence interval was (0.92, 3.34). This estimate is based on 442 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Converge implant for total hip arthroplasty (THA) was 1.75 percent at 7 years following the primary procedure. The 95% confidence interval was (0.92, 3.34). This estimate is based on 320 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Converge implant for total hip arthroplasty (THA) was 2.27 percent at 8 years following the primary procedure. The 95% confidence interval was (1.16, 4.42). This estimate is based on 179 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Converge implant for total hip arthroplasty (THA) was 2.27 percent at 9 years following the primary procedure. The 95% confidence interval was (1.16, 4.42). This estimate is based on 92 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Converge implant for total hip arthroplasty (THA) was 2.27 percent at 10 years following the primary procedure. The 95% confidence interval was (1.16, 4.42). This estimate is based on 16 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the G7 implant for total hip arthroplasty (THA) was 1.62 percent at 1 year following the primary procedure. The 95% confidence interval was (1.49, 1.77). This estimate is based on 24460 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the G7 implant for total hip arthroplasty (THA) was 2.02 percent at 2 years following the primary procedure. The 95% confidence interval was (1.86, 2.19). This estimate is based on 19151 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the G7 implant for total hip arthroplasty (THA) was 2.17 percent at 3 years following the primary procedure. The 95% confidence interval was (2.00, 2.35). This estimate is based on 14816 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the G7 implant for total hip arthroplasty (THA) was 2.40 percent at 4 years following the primary procedure. The 95% confidence interval was (2.21, 2.60). This estimate is based on 9971 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the G7 implant for total hip arthroplasty (THA) was 2.54 percent at 5 years following the primary procedure. The 95% confidence interval was (2.34, 2.76). This estimate is based on 6079 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the G7 implant for total hip arthroplasty (THA) was 2.59 percent at 6 years following the primary procedure. The 95% confidence interval was (2.38, 2.82). This estimate is based on 2938 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the G7 implant for total hip arthroplasty (THA) was 2.65 percent at 7 years following the primary procedure. The 95% confidence interval was (2.42, 2.91). This estimate is based on 914 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the G7 implant for total hip arthroplasty (THA) was 2.99 percent at 8 years following the primary procedure. The 95% confidence interval was (2.36, 3.78). This estimate is based on 219 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Pinnacle implant for total hip arthroplasty (THA) was 1.04 percent at 1 year following the primary procedure. The 95% confidence interval was (0.91, 1.18). This estimate is based on 20383 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Pinnacle implant for total hip arthroplasty (THA) was 1.36 percent at 2 years following the primary procedure. The 95% confidence interval was (1.22, 1.53). This estimate is based on 17339 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Pinnacle implant for total hip arthroplasty (THA) was 1.61 percent at 3 years following the primary procedure. The 95% confidence interval was (1.45, 1.79). This estimate is based on 14780 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Pinnacle implant for total hip arthroplasty (THA) was 1.74 percent at 4 years following the primary procedure. The 95% confidence interval was (1.57, 1.94). This estimate is based on 12152 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Pinnacle implant for total hip arthroplasty (THA) was 1.86 percent at 5 years following the primary procedure. The 95% confidence interval was (1.68, 2.06). This estimate is based on 9699 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Pinnacle implant for total hip arthroplasty (THA) was 1.94 percent at 6 years following the primary procedure. The 95% confidence interval was (1.75, 2.15). This estimate is based on 7421 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Pinnacle implant for total hip arthroplasty (THA) was 2.05 percent at 7 years following the primary procedure. The 95% confidence interval was (1.85, 2.28). This estimate is based on 5209 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Pinnacle implant for total hip arthroplasty (THA) was 2.22 percent at 8 years following the primary procedure. The 95% confidence interval was (1.98, 2.48). This estimate is based on 3008 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Pinnacle implant for total hip arthroplasty (THA) was 2.33 percent at 9 years following the primary procedure. The 95% confidence interval was (2.05, 2.64). This estimate is based on 1168 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Pinnacle implant for total hip arthroplasty (THA) was 2.59 percent at 10 years following the primary procedure. The 95% confidence interval was (2.06, 3.26). This estimate is based on 232 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the PolarCup implant for total hip arthroplasty (THA) was 0.86 percent at 1 year following the primary procedure. The 95% confidence interval was (0.36, 2.06). This estimate is based on 566 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the PolarCup implant for total hip arthroplasty (THA) was 1.57 percent at 2 years following the primary procedure. The 95% confidence interval was (0.82, 3.00). This estimate is based on 545 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the PolarCup implant for total hip arthroplasty (THA) was 1.76 percent at 3 years following the primary procedure. The 95% confidence interval was (0.95, 3.25). This estimate is based on 480 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the PolarCup implant for total hip arthroplasty (THA) was 1.98 percent at 4 years following the primary procedure. The 95% confidence interval was (1.10, 3.55). This estimate is based on 400 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the PolarCup implant for total hip arthroplasty (THA) was 2.25 percent at 5 years following the primary procedure. The 95% confidence interval was (1.28, 3.95). This estimate is based on 305 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the PolarCup implant for total hip arthroplasty (THA) was 2.25 percent at 6 years following the primary procedure. The 95% confidence interval was (1.28, 3.95). This estimate is based on 190 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the PolarCup implant for total hip arthroplasty (THA) was 2.25 percent at 7 years following the primary procedure. The 95% confidence interval was (1.28, 3.95). This estimate is based on 77 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the PolarCup implant for total hip arthroplasty (THA) was 2.25 percent at 8 years following the primary procedure. The 95% confidence interval was (1.28, 3.95). This estimate is based on 1 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the PolarCup implant for total hip arthroplasty (THA) was 2.25 percent at 9 years following the primary procedure. The 95% confidence interval was (1.28, 3.95). This estimate is based on 1 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the PolarCup implant for total hip arthroplasty (THA) was 2.25 percent at 10 years following the primary procedure. The 95% confidence interval was (1.28, 3.95). This estimate is based on 1 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Procotyl Prime implant for total hip arthroplasty (THA) was 1.76 percent at 1 year following the primary procedure. The 95% confidence interval was (1.00, 3.08). This estimate is based on 572 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Procotyl Prime implant for total hip arthroplasty (THA) was 1.97 percent at 2 years following the primary procedure. The 95% confidence interval was (1.15, 3.39). This estimate is based on 374 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Procotyl Prime implant for total hip arthroplasty (THA) was 1.97 percent at 3 years following the primary procedure. The 95% confidence interval was (1.15, 3.39). This estimate is based on 270 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Procotyl Prime implant for total hip arthroplasty (THA) was 2.98 percent at 4 years following the primary procedure. The 95% confidence interval was (1.66, 5.35). This estimate is based on 192 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Procotyl Prime implant for total hip arthroplasty (THA) was 2.98 percent at 5 years following the primary procedure. The 95% confidence interval was (1.66, 5.35). This estimate is based on 53 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection implant for total hip arthroplasty (THA) was 1.65 percent at 1 year following the primary procedure. The 95% confidence interval was (0.86, 3.14). This estimate is based on 538 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection implant for total hip arthroplasty (THA) was 2.19 percent at 2 years following the primary procedure. The 95% confidence interval was (1.25, 3.83). This estimate is based on 534 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection implant for total hip arthroplasty (THA) was 2.56 percent at 3 years following the primary procedure. The 95% confidence interval was (1.52, 4.29). This estimate is based on 531 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection implant for total hip arthroplasty (THA) was 2.56 percent at 4 years following the primary procedure. The 95% confidence interval was (1.52, 4.29). This estimate is based on 524 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection implant for total hip arthroplasty (THA) was 2.94 percent at 5 years following the primary procedure. The 95% confidence interval was (1.81, 4.75). This estimate is based on 501 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection implant for total hip arthroplasty (THA) was 3.33 percent at 6 years following the primary procedure. The 95% confidence interval was (2.11, 5.24). This estimate is based on 453 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection implant for total hip arthroplasty (THA) was 3.55 percent at 7 years following the primary procedure. The 95% confidence interval was (2.28, 5.51). This estimate is based on 351 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection implant for total hip arthroplasty (THA) was 3.55 percent at 8 years following the primary procedure. The 95% confidence interval was (2.28, 5.51). This estimate is based on 223 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection implant for total hip arthroplasty (THA) was 3.55 percent at 9 years following the primary procedure. The 95% confidence interval was (2.28, 5.51). This estimate is based on 107 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection implant for total hip arthroplasty (THA) was 3.55 percent at 10 years following the primary procedure. The 95% confidence interval was (2.28, 5.51). This estimate is based on 20 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection 3 implant for total hip arthroplasty (THA) was 2.01 percent at 1 year following the primary procedure. The 95% confidence interval was (1.75, 2.31). This estimate is based on 8584 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection 3 implant for total hip arthroplasty (THA) was 2.51 percent at 2 years following the primary procedure. The 95% confidence interval was (2.21, 2.85). This estimate is based on 7247 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection 3 implant for total hip arthroplasty (THA) was 2.84 percent at 3 years following the primary procedure. The 95% confidence interval was (2.52, 3.21). This estimate is based on 6061 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection 3 implant for total hip arthroplasty (THA) was 3.08 percent at 4 years following the primary procedure. The 95% confidence interval was (2.73, 3.47). This estimate is based on 4746 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection 3 implant for total hip arthroplasty (THA) was 3.29 percent at 5 years following the primary procedure. The 95% confidence interval was (2.92, 3.70). This estimate is based on 3576 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection 3 implant for total hip arthroplasty (THA) was 3.69 percent at 6 years following the primary procedure. The 95% confidence interval was (3.27, 4.17). This estimate is based on 2617 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection 3 implant for total hip arthroplasty (THA) was 3.74 percent at 7 years following the primary procedure. The 95% confidence interval was (3.31, 4.23). This estimate is based on 1525 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection 3 implant for total hip arthroplasty (THA) was 3.97 percent at 8 years following the primary procedure. The 95% confidence interval was (3.47, 4.52). This estimate is based on 805 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection 3 implant for total hip arthroplasty (THA) was 3.97 percent at 9 years following the primary procedure. The 95% confidence interval was (3.47, 4.52). This estimate is based on 262 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Reflection 3 implant for total hip arthroplasty (THA) was 3.97 percent at 10 years following the primary procedure. The 95% confidence interval was (3.47, 4.52). This estimate is based on 77 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Regenerex RingLoc+ implant for total hip arthroplasty (THA) was 1.69 percent at 1 year following the primary procedure. The 95% confidence interval was (1.06, 2.71). This estimate is based on 987 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Regenerex RingLoc+ implant for total hip arthroplasty (THA) was 2.09 percent at 2 years following the primary procedure. The 95% confidence interval was (1.37, 3.19). This estimate is based on 983 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Regenerex RingLoc+ implant for total hip arthroplasty (THA) was 2.19 percent at 3 years following the primary procedure. The 95% confidence interval was (1.45, 3.31). This estimate is based on 982 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Regenerex RingLoc+ implant for total hip arthroplasty (THA) was 2.49 percent at 4 years following the primary procedure. The 95% confidence interval was (1.69, 3.66). This estimate is based on 974 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Regenerex RingLoc+ implant for total hip arthroplasty (THA) was 2.59 percent at 5 years following the primary procedure. The 95% confidence interval was (1.77, 3.78). This estimate is based on 946 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Regenerex RingLoc+ implant for total hip arthroplasty (THA) was 2.69 percent at 6 years following the primary procedure. The 95% confidence interval was (1.86, 3.90). This estimate is based on 841 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Regenerex RingLoc+ implant for total hip arthroplasty (THA) was 2.69 percent at 7 years following the primary procedure. The 95% confidence interval was (1.86, 3.90). This estimate is based on 605 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Regenerex RingLoc+ implant for total hip arthroplasty (THA) was 2.86 percent at 8 years following the primary procedure. The 95% confidence interval was (1.98, 4.12). This estimate is based on 299 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Regenerex RingLoc+ implant for total hip arthroplasty (THA) was 2.86 percent at 9 years following the primary procedure. The 95% confidence interval was (1.98, 4.12). This estimate is based on 71 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Regenerex RingLoc+ implant for total hip arthroplasty (THA) was 2.86 percent at 10 years following the primary procedure. The 95% confidence interval was (1.98, 4.12). This estimate is based on 9 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Restoration ADM implant for total hip arthroplasty (THA) was 0.58 percent at 1 year following the primary procedure. The 95% confidence interval was (0.19, 1.78). This estimate is based on 516 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Restoration ADM implant for total hip arthroplasty (THA) was 1.16 percent at 2 years following the primary procedure. The 95% confidence interval was (0.52, 2.57). This estimate is based on 505 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Restoration ADM implant for total hip arthroplasty (THA) was 1.36 percent at 3 years following the primary procedure. The 95% confidence interval was (0.65, 2.83). This estimate is based on 496 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Restoration ADM implant for total hip arthroplasty (THA) was 1.56 percent at 4 years following the primary procedure. The 95% confidence interval was (0.78, 3.09). This estimate is based on 488 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Restoration ADM implant for total hip arthroplasty (THA) was 2.17 percent at 5 years following the primary procedure. The 95% confidence interval was (1.21, 3.89). This estimate is based on 441 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Restoration ADM implant for total hip arthroplasty (THA) was 2.17 percent at 6 years following the primary procedure. The 95% confidence interval was (1.21, 3.89). This estimate is based on 343 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Restoration ADM implant for total hip arthroplasty (THA) was 2.46 percent at 7 years following the primary procedure. The 95% confidence interval was (1.40, 4.32). This estimate is based on 239 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Restoration ADM implant for total hip arthroplasty (THA) was 2.46 percent at 8 years following the primary procedure. The 95% confidence interval was (1.40, 4.32). This estimate is based on 135 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Restoration ADM implant for total hip arthroplasty (THA) was 2.46 percent at 9 years following the primary procedure. The 95% confidence interval was (1.40, 4.32). This estimate is based on 33 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Restoration ADM implant for total hip arthroplasty (THA) was 2.46 percent at 10 years following the primary procedure. The 95% confidence interval was (1.40, 4.32). This estimate is based on 7 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RingLoc implant for total hip arthroplasty (THA) was 1.73 percent at 1 year following the primary procedure. The 95% confidence interval was (1.30, 2.31). This estimate is based on 2550 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RingLoc implant for total hip arthroplasty (THA) was 2.23 percent at 2 years following the primary procedure. The 95% confidence interval was (1.73, 2.88). This estimate is based on 2527 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RingLoc implant for total hip arthroplasty (THA) was 2.39 percent at 3 years following the primary procedure. The 95% confidence interval was (1.87, 3.06). This estimate is based on 2484 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RingLoc implant for total hip arthroplasty (THA) was 2.59 percent at 4 years following the primary procedure. The 95% confidence interval was (2.05, 3.28). This estimate is based on 2292 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RingLoc implant for total hip arthroplasty (THA) was 2.59 percent at 5 years following the primary procedure. The 95% confidence interval was (2.05, 3.28). This estimate is based on 2075 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RingLoc implant for total hip arthroplasty (THA) was 2.65 percent at 6 years following the primary procedure. The 95% confidence interval was (2.09, 3.35). This estimate is based on 1819 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RingLoc implant for total hip arthroplasty (THA) was 2.71 percent at 7 years following the primary procedure. The 95% confidence interval was (2.15, 3.42). This estimate is based on 1478 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RingLoc implant for total hip arthroplasty (THA) was 2.71 percent at 8 years following the primary procedure. The 95% confidence interval was (2.15, 3.42). This estimate is based on 817 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RingLoc implant for total hip arthroplasty (THA) was 3.11 percent at 9 years following the primary procedure. The 95% confidence interval was (2.37, 4.07). This estimate is based on 328 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RingLoc implant for total hip arthroplasty (THA) was 3.67 percent at 10 years following the primary procedure. The 95% confidence interval was (2.52, 5.33). This estimate is based on 58 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 2.04 percent at 1 year following the primary procedure. The 95% confidence interval was (1.49, 2.78). This estimate is based on 1854 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 2.85 percent at 2 years following the primary procedure. The 95% confidence interval was (2.19, 3.70). This estimate is based on 1729 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 3.19 percent at 3 years following the primary procedure. The 95% confidence interval was (2.49, 4.09). This estimate is based on 1614 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 3.56 percent at 4 years following the primary procedure. The 95% confidence interval was (2.81, 4.51). This estimate is based on 1473 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 3.97 percent at 5 years following the primary procedure. The 95% confidence interval was (3.16, 4.98). This estimate is based on 1315 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 4.05 percent at 6 years following the primary procedure. The 95% confidence interval was (3.23, 5.08). This estimate is based on 1123 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 4.25 percent at 7 years following the primary procedure. The 95% confidence interval was (3.40, 5.32). This estimate is based on 825 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 4.25 percent at 8 years following the primary procedure. The 95% confidence interval was (3.40, 5.32). This estimate is based on 646 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 4.65 percent at 9 years following the primary procedure. The 95% confidence interval was (3.67, 5.88). This estimate is based on 406 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trabecular Metal implant for total hip arthroplasty (THA) was 4.65 percent at 10 years following the primary procedure. The 95% confidence interval was (3.67, 5.88). This estimate is based on 170 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident implant for total hip arthroplasty (THA) was 1.43 percent at 1 year following the primary procedure. The 95% confidence interval was (1.30, 1.57). This estimate is based on 29500 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident implant for total hip arthroplasty (THA) was 1.89 percent at 2 years following the primary procedure. The 95% confidence interval was (1.74, 2.05). This estimate is based on 28816 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident implant for total hip arthroplasty (THA) was 2.18 percent at 3 years following the primary procedure. The 95% confidence interval was (2.02, 2.35). This estimate is based on 27839 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident implant for total hip arthroplasty (THA) was 2.48 percent at 4 years following the primary procedure. The 95% confidence interval was (2.31, 2.66). This estimate is based on 25044 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident implant for total hip arthroplasty (THA) was 2.70 percent at 5 years following the primary procedure. The 95% confidence interval was (2.52, 2.89). This estimate is based on 20514 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident implant for total hip arthroplasty (THA) was 2.92 percent at 6 years following the primary procedure. The 95% confidence interval was (2.73, 3.13). This estimate is based on 15210 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident implant for total hip arthroplasty (THA) was 3.21 percent at 7 years following the primary procedure. The 95% confidence interval was (3.00, 3.44). This estimate is based on 9862 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident implant for total hip arthroplasty (THA) was 3.54 percent at 8 years following the primary procedure. The 95% confidence interval was (3.29, 3.81). This estimate is based on 5568 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident implant for total hip arthroplasty (THA) was 3.80 percent at 9 years following the primary procedure. The 95% confidence interval was (3.51, 4.12). This estimate is based on 2432 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident implant for total hip arthroplasty (THA) was 3.84 percent at 10 years following the primary procedure. The 95% confidence interval was (3.54, 4.17). This estimate is based on 635 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident II implant for total hip arthroplasty (THA) was 1.62 percent at 1 year following the primary procedure. The 95% confidence interval was (1.44, 1.82). This estimate is based on 13181 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident II implant for total hip arthroplasty (THA) was 1.88 percent at 2 years following the primary procedure. The 95% confidence interval was (1.68, 2.10). This estimate is based on 8465 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident II implant for total hip arthroplasty (THA) was 2.15 percent at 3 years following the primary procedure. The 95% confidence interval was (1.92, 2.41). This estimate is based on 4439 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident II implant for total hip arthroplasty (THA) was 2.34 percent at 4 years following the primary procedure. The 95% confidence interval was (2.05, 2.66). This estimate is based on 1344 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident II implant for total hip arthroplasty (THA) was 2.65 percent at 5 years following the primary procedure. The 95% confidence interval was (2.05, 3.43). This estimate is based on 183 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trident II implant for total hip arthroplasty (THA) was 2.65 percent at 6 years following the primary procedure. The 95% confidence interval was (2.05, 3.43). This estimate is based on 13 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trilogy implant for total hip arthroplasty (THA) was 1.76 percent at 1 year following the primary procedure. The 95% confidence interval was (1.22, 2.54). This estimate is based on 1561 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trilogy implant for total hip arthroplasty (THA) was 2.52 percent at 2 years following the primary procedure. The 95% confidence interval was (1.86, 3.43). This estimate is based on 1517 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trilogy implant for total hip arthroplasty (THA) was 3.05 percent at 3 years following the primary procedure. The 95% confidence interval was (2.31, 4.03). This estimate is based on 1429 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trilogy implant for total hip arthroplasty (THA) was 3.19 percent at 4 years following the primary procedure. The 95% confidence interval was (2.43, 4.19). This estimate is based on 1330 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trilogy implant for total hip arthroplasty (THA) was 3.64 percent at 5 years following the primary procedure. The 95% confidence interval was (2.81, 4.71). This estimate is based on 1212 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trilogy implant for total hip arthroplasty (THA) was 4.07 percent at 6 years following the primary procedure. The 95% confidence interval was (3.18, 5.21). This estimate is based on 1075 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trilogy implant for total hip arthroplasty (THA) was 4.48 percent at 7 years following the primary procedure. The 95% confidence interval was (3.52, 5.70). This estimate is based on 853 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trilogy implant for total hip arthroplasty (THA) was 4.60 percent at 8 years following the primary procedure. The 95% confidence interval was (3.62, 5.84). This estimate is based on 615 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trilogy implant for total hip arthroplasty (THA) was 4.60 percent at 9 years following the primary procedure. The 95% confidence interval was (3.62, 5.84). This estimate is based on 388 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Trilogy implant for total hip arthroplasty (THA) was 4.60 percent at 10 years following the primary procedure. The 95% confidence interval was (3.62, 5.84). This estimate is based on 168 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the BHR/BHR implant combination for total hip arthroplasty (THA) was 1.25 percent at 1 year following the primary procedure. The 95% confidence interval was (0.76, 2.07). This estimate is based on 1154 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the BHR/BHR implant combination for total hip arthroplasty (THA) was 1.60 percent at 2 years following the primary procedure. The 95% confidence interval was (1.02, 2.50). This estimate is based on 1100 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the BHR/BHR implant combination for total hip arthroplasty (THA) was 2.06 percent at 3 years following the primary procedure. The 95% confidence interval was (1.39, 3.06). This estimate is based on 1017 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the BHR/BHR implant combination for total hip arthroplasty (THA) was 2.67 percent at 4 years following the primary procedure. The 95% confidence interval was (1.87, 3.81). This estimate is based on 857 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the BHR/BHR implant combination for total hip arthroplasty (THA) was 2.79 percent at 5 years following the primary procedure. The 95% confidence interval was (1.97, 3.95). This estimate is based on 698 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the BHR/BHR implant combination for total hip arthroplasty (THA) was 3.25 percent at 6 years following the primary procedure. The 95% confidence interval was (2.32, 4.56). This estimate is based on 539 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the BHR/BHR implant combination for total hip arthroplasty (THA) was 3.72 percent at 7 years following the primary procedure. The 95% confidence interval was (2.64, 5.24). This estimate is based on 333 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the BHR/BHR implant combination for total hip arthroplasty (THA) was 4.08 percent at 8 years following the primary procedure. The 95% confidence interval was (2.86, 5.81). This estimate is based on 132 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the BHR/BHR implant combination for total hip arthroplasty (THA) was 4.08 percent at 9 years following the primary procedure. The 95% confidence interval was (2.86, 5.81). This estimate is based on 61 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the BHR/BHR implant combination for total hip arthroplasty (THA) was 4.08 percent at 10 years following the primary procedure. The 95% confidence interval was (2.86, 5.81). This estimate is based on 17 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Attune/Attune implant combination for total knee arthroplasty (TKA) was 0.68 percent at 1 year following the primary procedure. The 95% confidence interval was (0.55, 0.83). This estimate is based on 12789 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Attune/Attune implant combination for total knee arthroplasty (TKA) was 1.64 percent at 2 years following the primary procedure. The 95% confidence interval was (1.44, 1.88). This estimate is based on 10906 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Attune/Attune implant combination for total knee arthroplasty (TKA) was 2.25 percent at 3 years following the primary procedure. The 95% confidence interval was (2.00, 2.53). This estimate is based on 9356 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Attune/Attune implant combination for total knee arthroplasty (TKA) was 2.90 percent at 4 years following the primary procedure. The 95% confidence interval was (2.60, 3.23). This estimate is based on 7906 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Attune/Attune implant combination for total knee arthroplasty (TKA) was 3.32 percent at 5 years following the primary procedure. The 95% confidence interval was (2.99, 3.68). This estimate is based on 6318 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Attune/Attune implant combination for total knee arthroplasty (TKA) was 3.76 percent at 6 years following the primary procedure. The 95% confidence interval was (3.40, 4.16). This estimate is based on 4620 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Attune/Attune implant combination for total knee arthroplasty (TKA) was 3.90 percent at 7 years following the primary procedure. The 95% confidence interval was (3.52, 4.32). This estimate is based on 2820 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Attune/Attune implant combination for total knee arthroplasty (TKA) was 4.16 percent at 8 years following the primary procedure. The 95% confidence interval was (3.72, 4.64). This estimate is based on 1079 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Attune/Attune implant combination for total knee arthroplasty (TKA) was 4.68 percent at 9 years following the primary procedure. The 95% confidence interval was (3.81, 5.74). This estimate is based on 227 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Attune/Attune implant combination for total knee arthroplasty (TKA) was 4.68 percent at 10 years following the primary procedure. The 95% confidence interval was (3.81, 5.74). This estimate is based on 2 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Evolution MP/Evolution MP implant combination for total knee arthroplasty (TKA) was 1.28 percent at 1 year following the primary procedure. The 95% confidence interval was (0.98, 1.67). This estimate is based on 3893 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Evolution MP/Evolution MP implant combination for total knee arthroplasty (TKA) was 2.43 percent at 2 years following the primary procedure. The 95% confidence interval was (1.99, 2.96). This estimate is based on 3178 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Evolution MP/Evolution MP implant combination for total knee arthroplasty (TKA) was 3.50 percent at 3 years following the primary procedure. The 95% confidence interval was (2.95, 4.16). This estimate is based on 2539 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Evolution MP/Evolution MP implant combination for total knee arthroplasty (TKA) was 4.09 percent at 4 years following the primary procedure. The 95% confidence interval was (3.46, 4.83). This estimate is based on 1725 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Evolution MP/Evolution MP implant combination for total knee arthroplasty (TKA) was 4.56 percent at 5 years following the primary procedure. The 95% confidence interval was (3.86, 5.39). This estimate is based on 997 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Evolution MP/Evolution MP implant combination for total knee arthroplasty (TKA) was 4.87 percent at 6 years following the primary procedure. The 95% confidence interval was (4.10, 5.78). This estimate is based on 549 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Evolution MP/Evolution MP implant combination for total knee arthroplasty (TKA) was 5.42 percent at 7 years following the primary procedure. The 95% confidence interval was (4.47, 6.56). This estimate is based on 343 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Evolution MP/Evolution MP implant combination for total knee arthroplasty (TKA) was 5.72 percent at 8 years following the primary procedure. The 95% confidence interval was (4.64, 7.04). This estimate is based on 251 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Evolution MP/Evolution MP implant combination for total knee arthroplasty (TKA) was 5.72 percent at 9 years following the primary procedure. The 95% confidence interval was (4.64, 7.04). This estimate is based on 187 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Evolution MP/Evolution MP implant combination for total knee arthroplasty (TKA) was 5.72 percent at 10 years following the primary procedure. The 95% confidence interval was (4.64, 7.04). This estimate is based on 43 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II/Genesis II implant combination for total knee arthroplasty (TKA) was 1.21 percent at 1 year following the primary procedure. The 95% confidence interval was (0.76, 1.94). This estimate is based on 1384 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II/Genesis II implant combination for total knee arthroplasty (TKA) was 1.79 percent at 2 years following the primary procedure. The 95% confidence interval was (1.21, 2.63). This estimate is based on 1358 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II/Genesis II implant combination for total knee arthroplasty (TKA) was 2.44 percent at 3 years following the primary procedure. The 95% confidence interval was (1.75, 3.40). This estimate is based on 1309 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II/Genesis II implant combination for total knee arthroplasty (TKA) was 3.20 percent at 4 years following the primary procedure. The 95% confidence interval was (2.39, 4.28). This estimate is based on 1249 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II/Genesis II implant combination for total knee arthroplasty (TKA) was 3.69 percent at 5 years following the primary procedure. The 95% confidence interval was (2.81, 4.84). This estimate is based on 1162 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II/Genesis II implant combination for total knee arthroplasty (TKA) was 3.94 percent at 6 years following the primary procedure. The 95% confidence interval was (3.02, 5.13). This estimate is based on 1034 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II/Genesis II implant combination for total knee arthroplasty (TKA) was 4.37 percent at 7 years following the primary procedure. The 95% confidence interval was (3.38, 5.64). This estimate is based on 814 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II/Genesis II implant combination for total knee arthroplasty (TKA) was 4.76 percent at 8 years following the primary procedure. The 95% confidence interval was (3.70, 6.12). This estimate is based on 551 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II/Genesis II implant combination for total knee arthroplasty (TKA) was 5.05 percent at 9 years following the primary procedure. The 95% confidence interval was (3.88, 6.56). This estimate is based on 252 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II/Genesis II implant combination for total knee arthroplasty (TKA) was 5.05 percent at 10 years following the primary procedure. The 95% confidence interval was (3.88, 6.56). This estimate is based on 61 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (CoCr)/Genesis II implant combination for total knee arthroplasty (TKA) was 0.84 percent at 1 year following the primary procedure. The 95% confidence interval was (0.38, 1.87). This estimate is based on 706 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (CoCr)/Genesis II implant combination for total knee arthroplasty (TKA) was 1.27 percent at 2 years following the primary procedure. The 95% confidence interval was (0.66, 2.42). This estimate is based on 690 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (CoCr)/Genesis II implant combination for total knee arthroplasty (TKA) was 1.86 percent at 3 years following the primary procedure. The 95% confidence interval was (1.08, 3.18). This estimate is based on 653 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (CoCr)/Genesis II implant combination for total knee arthroplasty (TKA) was 2.48 percent at 4 years following the primary procedure. The 95% confidence interval was (1.55, 3.95). This estimate is based on 611 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (CoCr)/Genesis II implant combination for total knee arthroplasty (TKA) was 2.82 percent at 5 years following the primary procedure. The 95% confidence interval was (1.81, 4.39). This estimate is based on 547 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (CoCr)/Genesis II implant combination for total knee arthroplasty (TKA) was 3.36 percent at 6 years following the primary procedure. The 95% confidence interval was (2.22, 5.08). This estimate is based on 470 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (CoCr)/Genesis II implant combination for total knee arthroplasty (TKA) was 3.36 percent at 7 years following the primary procedure. The 95% confidence interval was (2.22, 5.08). This estimate is based on 384 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (CoCr)/Genesis II implant combination for total knee arthroplasty (TKA) was 3.36 percent at 8 years following the primary procedure. The 95% confidence interval was (2.22, 5.08). This estimate is based on 286 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (CoCr)/Genesis II implant combination for total knee arthroplasty (TKA) was 3.36 percent at 9 years following the primary procedure. The 95% confidence interval was (2.22, 5.08). This estimate is based on 131 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (CoCr)/Genesis II implant combination for total knee arthroplasty (TKA) was 3.36 percent at 10 years following the primary procedure. The 95% confidence interval was (2.22, 5.08). This estimate is based on 49 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (Oxinium)/Genesis II implant combination for total knee arthroplasty (TKA) was 1.60 percent at 1 year following the primary procedure. The 95% confidence interval was (0.89, 2.86). This estimate is based on 678 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (Oxinium)/Genesis II implant combination for total knee arthroplasty (TKA) was 2.32 percent at 2 years following the primary procedure. The 95% confidence interval was (1.43, 3.76). This estimate is based on 668 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (Oxinium)/Genesis II implant combination for total knee arthroplasty (TKA) was 3.05 percent at 3 years following the primary procedure. The 95% confidence interval was (2.00, 4.65). This estimate is based on 656 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (Oxinium)/Genesis II implant combination for total knee arthroplasty (TKA) was 3.95 percent at 4 years following the primary procedure. The 95% confidence interval was (2.72, 5.70). This estimate is based on 638 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (Oxinium)/Genesis II implant combination for total knee arthroplasty (TKA) was 4.56 percent at 5 years following the primary procedure. The 95% confidence interval was (3.23, 6.43). This estimate is based on 615 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (Oxinium)/Genesis II implant combination for total knee arthroplasty (TKA) was 4.56 percent at 6 years following the primary procedure. The 95% confidence interval was (3.23, 6.43). This estimate is based on 564 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (Oxinium)/Genesis II implant combination for total knee arthroplasty (TKA) was 5.35 percent at 7 years following the primary procedure. The 95% confidence interval was (3.86, 7.39). This estimate is based on 430 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (Oxinium)/Genesis II implant combination for total knee arthroplasty (TKA) was 6.10 percent at 8 years following the primary procedure. The 95% confidence interval was (4.44, 8.35). This estimate is based on 265 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (Oxinium)/Genesis II implant combination for total knee arthroplasty (TKA) was 6.71 percent at 9 years following the primary procedure. The 95% confidence interval was (4.79, 9.36). This estimate is based on 121 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Genesis II (Oxinium)/Genesis II implant combination for total knee arthroplasty (TKA) was 6.71 percent at 10 years following the primary procedure. The 95% confidence interval was (4.79, 9.36). This estimate is based on 12 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iBalance/iBalance implant combination for total knee arthroplasty (TKA) was 2.66 percent at 1 year following the primary procedure. The 95% confidence interval was (1.61, 4.37). This estimate is based on 524 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iBalance/iBalance implant combination for total knee arthroplasty (TKA) was 6.17 percent at 2 years following the primary procedure. The 95% confidence interval was (4.39, 8.62). This estimate is based on 431 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iBalance/iBalance implant combination for total knee arthroplasty (TKA) was 8.38 percent at 3 years following the primary procedure. The 95% confidence interval was (6.21, 11.25). This estimate is based on 321 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iBalance/iBalance implant combination for total knee arthroplasty (TKA) was 8.68 percent at 4 years following the primary procedure. The 95% confidence interval was (6.46, 11.62). This estimate is based on 222 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iBalance/iBalance implant combination for total knee arthroplasty (TKA) was 10.80 percent at 5 years following the primary procedure. The 95% confidence interval was (7.99, 14.52). This estimate is based on 129 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iBalance/iBalance implant combination for total knee arthroplasty (TKA) was 11.70 percent at 6 years following the primary procedure. The 95% confidence interval was (8.54, 15.92). This estimate is based on 36 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iBalance/iBalance implant combination for total knee arthroplasty (TKA) was 11.70 percent at 7 years following the primary procedure. The 95% confidence interval was (8.54, 15.92). This estimate is based on 36 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iBalance/iBalance implant combination for total knee arthroplasty (TKA) was 11.70 percent at 8 years following the primary procedure. The 95% confidence interval was (8.54, 15.92). This estimate is based on 23 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal implant combination for total knee arthroplasty (TKA) was 1.20 percent at 1 year following the primary procedure. The 95% confidence interval was (0.63, 2.30). This estimate is based on 740 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal implant combination for total knee arthroplasty (TKA) was 2.14 percent at 2 years following the primary procedure. The 95% confidence interval was (1.31, 3.46). This estimate is based on 726 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal implant combination for total knee arthroplasty (TKA) was 2.97 percent at 3 years following the primary procedure. The 95% confidence interval was (1.97, 4.48). This estimate is based on 674 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal implant combination for total knee arthroplasty (TKA) was 3.88 percent at 4 years following the primary procedure. The 95% confidence interval was (2.70, 5.58). This estimate is based on 567 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal implant combination for total knee arthroplasty (TKA) was 4.06 percent at 5 years following the primary procedure. The 95% confidence interval was (2.84, 5.80). This estimate is based on 443 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal implant combination for total knee arthroplasty (TKA) was 4.82 percent at 6 years following the primary procedure. The 95% confidence interval was (3.40, 6.81). This estimate is based on 341 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal implant combination for total knee arthroplasty (TKA) was 4.82 percent at 7 years following the primary procedure. The 95% confidence interval was (3.40, 6.81). This estimate is based on 189 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal implant combination for total knee arthroplasty (TKA) was 6.25 percent at 8 years following the primary procedure. The 95% confidence interval was (4.12, 9.41). This estimate is based on 84 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal implant combination for total knee arthroplasty (TKA) was 6.25 percent at 9 years following the primary procedure. The 95% confidence interval was (4.12, 9.41). This estimate is based on 28 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal implant combination for total knee arthroplasty (TKA) was 6.25 percent at 10 years following the primary procedure. The 95% confidence interval was (4.12, 9.41). This estimate is based on 7 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal G2+ implant combination for total knee arthroplasty (TKA) was 1.24 percent at 1 year following the primary procedure. The 95% confidence interval was (0.65, 2.36). This estimate is based on 719 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal G2+ implant combination for total knee arthroplasty (TKA) was 2.06 percent at 2 years following the primary procedure. The 95% confidence interval was (1.25, 3.39). This estimate is based on 706 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal G2+ implant combination for total knee arthroplasty (TKA) was 2.92 percent at 3 years following the primary procedure. The 95% confidence interval was (1.91, 4.44). This estimate is based on 654 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal G2+ implant combination for total knee arthroplasty (TKA) was 3.54 percent at 4 years following the primary procedure. The 95% confidence interval was (2.41, 5.20). This estimate is based on 549 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal G2+ implant combination for total knee arthroplasty (TKA) was 3.94 percent at 5 years following the primary procedure. The 95% confidence interval was (2.71, 5.71). This estimate is based on 424 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal G2+ implant combination for total knee arthroplasty (TKA) was 4.70 percent at 6 years following the primary procedure. The 95% confidence interval was (3.27, 6.72). This estimate is based on 322 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal G2+ implant combination for total knee arthroplasty (TKA) was 4.70 percent at 7 years following the primary procedure. The 95% confidence interval was (3.27, 6.72). This estimate is based on 170 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal G2+ implant combination for total knee arthroplasty (TKA) was 4.70 percent at 8 years following the primary procedure. The 95% confidence interval was (3.27, 6.72). This estimate is based on 67 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the iTotal G2+ implant combination for total knee arthroplasty (TKA) was 4.70 percent at 9 years following the primary procedure. The 95% confidence interval was (3.27, 6.72). This estimate is based on 11 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II/Journey implant combination for total knee arthroplasty (TKA) was 1.43 percent at 1 year following the primary procedure. The 95% confidence interval was (0.90, 2.26). This estimate is based on 1165 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II/Journey implant combination for total knee arthroplasty (TKA) was 3.34 percent at 2 years following the primary procedure. The 95% confidence interval was (2.45, 4.55). This estimate is based on 982 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II/Journey implant combination for total knee arthroplasty (TKA) was 4.08 percent at 3 years following the primary procedure. The 95% confidence interval was (3.07, 5.43). This estimate is based on 789 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II/Journey implant combination for total knee arthroplasty (TKA) was 4.34 percent at 4 years following the primary procedure. The 95% confidence interval was (3.28, 5.74). This estimate is based on 543 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II/Journey implant combination for total knee arthroplasty (TKA) was 4.77 percent at 5 years following the primary procedure. The 95% confidence interval was (3.60, 6.33). This estimate is based on 372 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II/Journey implant combination for total knee arthroplasty (TKA) was 5.43 percent at 6 years following the primary procedure. The 95% confidence interval was (4.02, 7.32). This estimate is based on 216 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II/Journey implant combination for total knee arthroplasty (TKA) was 6.09 percent at 7 years following the primary procedure. The 95% confidence interval was (4.33, 8.54). This estimate is based on 93 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II/Journey implant combination for total knee arthroplasty (TKA) was 6.09 percent at 8 years following the primary procedure. The 95% confidence interval was (4.33, 8.54). This estimate is based on 19 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II/Journey implant combination for total knee arthroplasty (TKA) was 6.09 percent at 9 years following the primary procedure. The 95% confidence interval was (4.33, 8.54). This estimate is based on 1 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 1.44 percent at 1 year following the primary procedure. The 95% confidence interval was (0.91, 2.28). This estimate is based on 1157 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 3.36 percent at 2 years following the primary procedure. The 95% confidence interval was (2.46, 4.58). This estimate is based on 974 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 4.11 percent at 3 years following the primary procedure. The 95% confidence interval was (3.09, 5.47). This estimate is based on 781 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 4.37 percent at 4 years following the primary procedure. The 95% confidence interval was (3.30, 5.78). This estimate is based on 540 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 4.81 percent at 5 years following the primary procedure. The 95% confidence interval was (3.62, 6.37). This estimate is based on 372 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 5.46 percent at 6 years following the primary procedure. The 95% confidence interval was (4.04, 7.36). This estimate is based on 216 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 6.12 percent at 7 years following the primary procedure. The 95% confidence interval was (4.36, 8.57). This estimate is based on 93 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 6.12 percent at 8 years following the primary procedure. The 95% confidence interval was (4.36, 8.57). This estimate is based on 19 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 6.12 percent at 9 years following the primary procedure. The 95% confidence interval was (4.36, 8.57). This estimate is based on 1 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS/Journey implant combination for total knee arthroplasty (TKA) was 1.33 percent at 1 year following the primary procedure. The 95% confidence interval was (1.07, 1.65). This estimate is based on 5680 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS/Journey implant combination for total knee arthroplasty (TKA) was 2.66 percent at 2 years following the primary procedure. The 95% confidence interval was (2.27, 3.12). This estimate is based on 4785 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS/Journey implant combination for total knee arthroplasty (TKA) was 3.55 percent at 3 years following the primary procedure. The 95% confidence interval was (3.08, 4.08). This estimate is based on 3915 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS/Journey implant combination for total knee arthroplasty (TKA) was 4.10 percent at 4 years following the primary procedure. The 95% confidence interval was (3.59, 4.69). This estimate is based on 2867 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS/Journey implant combination for total knee arthroplasty (TKA) was 4.39 percent at 5 years following the primary procedure. The 95% confidence interval was (3.83, 5.01). This estimate is based on 2005 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS/Journey implant combination for total knee arthroplasty (TKA) was 4.82 percent at 6 years following the primary procedure. The 95% confidence interval was (4.19, 5.53). This estimate is based on 1268 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS/Journey implant combination for total knee arthroplasty (TKA) was 4.89 percent at 7 years following the primary procedure. The 95% confidence interval was (4.25, 5.63). This estimate is based on 573 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS/Journey implant combination for total knee arthroplasty (TKA) was 5.31 percent at 8 years following the primary procedure. The 95% confidence interval was (4.48, 6.29). This estimate is based on 225 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS/Journey implant combination for total knee arthroplasty (TKA) was 6.19 percent at 9 years following the primary procedure. The 95% confidence interval was (4.53, 8.44). This estimate is based on 62 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS/Journey implant combination for total knee arthroplasty (TKA) was 6.19 percent at 10 years following the primary procedure. The 95% confidence interval was (4.53, 8.44). This estimate is based on 4 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (CoCr)/Journey implant combination for total knee arthroplasty (TKA) was 0.37 percent at 1 year following the primary procedure. The 95% confidence interval was (0.12, 1.15). This estimate is based on 754 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (CoCr)/Journey implant combination for total knee arthroplasty (TKA) was 0.98 percent at 2 years following the primary procedure. The 95% confidence interval was (0.47, 2.06). This estimate is based on 589 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (CoCr)/Journey implant combination for total knee arthroplasty (TKA) was 1.15 percent at 3 years following the primary procedure. The 95% confidence interval was (0.57, 2.30). This estimate is based on 436 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (CoCr)/Journey implant combination for total knee arthroplasty (TKA) was 1.51 percent at 4 years following the primary procedure. The 95% confidence interval was (0.75, 3.05). This estimate is based on 225 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (CoCr)/Journey implant combination for total knee arthroplasty (TKA) was 1.51 percent at 5 years following the primary procedure. The 95% confidence interval was (0.75, 3.05). This estimate is based on 95 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (CoCr)/Journey implant combination for total knee arthroplasty (TKA) was 1.51 percent at 6 years following the primary procedure. The 95% confidence interval was (0.75, 3.05). This estimate is based on 36 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 1.48 percent at 1 year following the primary procedure. The 95% confidence interval was (1.18, 1.84). This estimate is based on 4926 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 2.92 percent at 2 years following the primary procedure. The 95% confidence interval was (2.48, 3.43). This estimate is based on 4196 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 3.89 percent at 3 years following the primary procedure. The 95% confidence interval was (3.37, 4.49). This estimate is based on 3479 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 4.47 percent at 4 years following the primary procedure. The 95% confidence interval was (3.90, 5.13). This estimate is based on 2642 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 4.77 percent at 5 years following the primary procedure. The 95% confidence interval was (4.16, 5.47). This estimate is based on 1910 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 5.22 percent at 6 years following the primary procedure. The 95% confidence interval was (4.54, 5.99). This estimate is based on 1232 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 5.29 percent at 7 years following the primary procedure. The 95% confidence interval was (4.60, 6.09). This estimate is based on 573 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 5.71 percent at 8 years following the primary procedure. The 95% confidence interval was (4.84, 6.73). This estimate is based on 225 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 6.59 percent at 9 years following the primary procedure. The 95% confidence interval was (4.90, 8.83). This estimate is based on 62 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Journey II BCS (Oxinium)/Journey implant combination for total knee arthroplasty (TKA) was 6.59 percent at 10 years following the primary procedure. The 95% confidence interval was (4.90, 8.83). This estimate is based on 4 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the LCS Complete/M.B.T. implant combination for total knee arthroplasty (TKA) was 1.20 percent at 1 year following the primary procedure. The 95% confidence interval was (0.77, 1.85). This estimate is based on 1581 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the LCS Complete/M.B.T. implant combination for total knee arthroplasty (TKA) was 2.44 percent at 2 years following the primary procedure. The 95% confidence interval was (1.79, 3.32). This estimate is based on 1370 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the LCS Complete/M.B.T. implant combination for total knee arthroplasty (TKA) was 3.55 percent at 3 years following the primary procedure. The 95% confidence interval was (2.73, 4.62). This estimate is based on 1230 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the LCS Complete/M.B.T. implant combination for total knee arthroplasty (TKA) was 4.14 percent at 4 years following the primary procedure. The 95% confidence interval was (3.23, 5.30). This estimate is based on 1073 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the LCS Complete/M.B.T. implant combination for total knee arthroplasty (TKA) was 4.83 percent at 5 years following the primary procedure. The 95% confidence interval was (3.81, 6.11). This estimate is based on 879 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the LCS Complete/M.B.T. implant combination for total knee arthroplasty (TKA) was 4.83 percent at 6 years following the primary procedure. The 95% confidence interval was (3.81, 6.11). This estimate is based on 623 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the LCS Complete/M.B.T. implant combination for total knee arthroplasty (TKA) was 5.06 percent at 7 years following the primary procedure. The 95% confidence interval was (3.97, 6.44). This estimate is based on 386 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the LCS Complete/M.B.T. implant combination for total knee arthroplasty (TKA) was 5.06 percent at 8 years following the primary procedure. The 95% confidence interval was (3.97, 6.44). This estimate is based on 227 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the LCS Complete/M.B.T. implant combination for total knee arthroplasty (TKA) was 5.06 percent at 9 years following the primary procedure. The 95% confidence interval was (3.97, 6.44). This estimate is based on 59 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the LCS Complete/M.B.T. implant combination for total knee arthroplasty (TKA) was 5.06 percent at 10 years following the primary procedure. The 95% confidence interval was (3.97, 6.44). This estimate is based on 5 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Legion/Genesis II implant combination for total knee arthroplasty (TKA) was 1.06 percent at 1 year following the primary procedure. The 95% confidence interval was (0.89, 1.26). This estimate is based on 11367 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Legion/Genesis II implant combination for total knee arthroplasty (TKA) was 2.19 percent at 2 years following the primary procedure. The 95% confidence interval was (1.94, 2.48). This estimate is based on 10237 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Legion/Genesis II implant combination for total knee arthroplasty (TKA) was 3.00 percent at 3 years following the primary procedure. The 95% confidence interval was (2.70, 3.33). This estimate is based on 9090 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Legion/Genesis II implant combination for total knee arthroplasty (TKA) was 3.36 percent at 4 years following the primary procedure. The 95% confidence interval was (3.03, 3.72). This estimate is based on 7550 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Legion/Genesis II implant combination for total knee arthroplasty (TKA) was 3.64 percent at 5 years following the primary procedure. The 95% confidence interval was (3.29, 4.02). This estimate is based on 5971 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Legion/Genesis II implant combination for total knee arthroplasty (TKA) was 4.01 percent at 6 years following the primary procedure. The 95% confidence interval was (3.63, 4.43). This estimate is based on 4331 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Legion/Genesis II implant combination for total knee arthroplasty (TKA) was 4.37 percent at 7 years following the primary procedure. The 95% confidence interval was (3.95, 4.83). This estimate is based on 2789 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Legion/Genesis II implant combination for total knee arthroplasty (TKA) was 4.74 percent at 8 years following the primary procedure. The 95% confidence interval was (4.26, 5.27). This estimate is based on 1645 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Legion/Genesis II implant combination for total knee arthroplasty (TKA) was 5.16 percent at 9 years following the primary procedure. The 95% confidence interval was (4.57, 5.83). This estimate is based on 597 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Legion/Genesis II implant combination for total knee arthroplasty (TKA) was 5.16 percent at 10 years following the primary procedure. The 95% confidence interval was (4.57, 5.83). This estimate is based on 167 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Pegged implant combination for total knee arthroplasty (TKA) was 1.04 percent at 1 year following the primary procedure. The 95% confidence interval was (0.50, 2.16). This estimate is based on 668 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Pegged implant combination for total knee arthroplasty (TKA) was 1.63 percent at 2 years following the primary procedure. The 95% confidence interval was (0.91, 2.92). This estimate is based on 664 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Pegged implant combination for total knee arthroplasty (TKA) was 2.07 percent at 3 years following the primary procedure. The 95% confidence interval was (1.23, 3.48). This estimate is based on 661 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Pegged implant combination for total knee arthroplasty (TKA) was 2.52 percent at 4 years following the primary procedure. The 95% confidence interval was (1.58, 4.03). This estimate is based on 628 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Pegged implant combination for total knee arthroplasty (TKA) was 2.69 percent at 5 years following the primary procedure. The 95% confidence interval was (1.70, 4.24). This estimate is based on 551 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Pegged implant combination for total knee arthroplasty (TKA) was 2.90 percent at 6 years following the primary procedure. The 95% confidence interval was (1.85, 4.51). This estimate is based on 430 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Pegged implant combination for total knee arthroplasty (TKA) was 3.13 percent at 7 years following the primary procedure. The 95% confidence interval was (2.02, 4.84). This estimate is based on 325 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Pegged implant combination for total knee arthroplasty (TKA) was 3.13 percent at 8 years following the primary procedure. The 95% confidence interval was (2.02, 4.84). This estimate is based on 244 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Pegged implant combination for total knee arthroplasty (TKA) was 3.13 percent at 9 years following the primary procedure. The 95% confidence interval was (2.02, 4.84). This estimate is based on 166 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Pegged implant combination for total knee arthroplasty (TKA) was 4.67 percent at 10 years following the primary procedure. The 95% confidence interval was (2.30, 9.35). This estimate is based on 62 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 0.33 percent at 1 year following the primary procedure. The 95% confidence interval was (0.08, 1.30). This estimate is based on 600 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.18 percent at 2 years following the primary procedure. The 95% confidence interval was (0.56, 2.46). This estimate is based on 555 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.37 percent at 3 years following the primary procedure. The 95% confidence interval was (0.68, 2.71). This estimate is based on 512 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.78 percent at 4 years following the primary procedure. The 95% confidence interval was (0.96, 3.30). This estimate is based on 456 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.78 percent at 5 years following the primary procedure. The 95% confidence interval was (0.96, 3.30). This estimate is based on 399 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.78 percent at 6 years following the primary procedure. The 95% confidence interval was (0.96, 3.30). This estimate is based on 320 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.78 percent at 7 years following the primary procedure. The 95% confidence interval was (0.96, 3.30). This estimate is based on 236 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.78 percent at 8 years following the primary procedure. The 95% confidence interval was (0.96, 3.30). This estimate is based on 201 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.78 percent at 9 years following the primary procedure. The 95% confidence interval was (0.96, 3.30). This estimate is based on 163 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.78 percent at 10 years following the primary procedure. The 95% confidence interval was (0.96, 3.30). This estimate is based on 98 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 0.38 percent at 1 year following the primary procedure. The 95% confidence interval was (0.09, 1.51). This estimate is based on 526 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.33 percent at 2 years following the primary procedure. The 95% confidence interval was (0.63, 2.76). This estimate is based on 521 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.89 percent at 3 years following the primary procedure. The 95% confidence interval was (1.02, 3.49). This estimate is based on 517 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 2.08 percent at 4 years following the primary procedure. The 95% confidence interval was (1.16, 3.73). This estimate is based on 510 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 2.28 percent at 5 years following the primary procedure. The 95% confidence interval was (1.30, 3.98). This estimate is based on 496 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 2.48 percent at 6 years following the primary procedure. The 95% confidence interval was (1.45, 4.23). This estimate is based on 486 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 2.89 percent at 7 years following the primary procedure. The 95% confidence interval was (1.75, 4.75). This estimate is based on 470 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 2.89 percent at 8 years following the primary procedure. The 95% confidence interval was (1.75, 4.75). This estimate is based on 462 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 2.89 percent at 9 years following the primary procedure. The 95% confidence interval was (1.75, 4.75). This estimate is based on 428 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS GS/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 2.89 percent at 10 years following the primary procedure. The 95% confidence interval was (1.75, 4.75). This estimate is based on 326 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 0.69 percent at 1 year following the primary procedure. The 95% confidence interval was (0.29, 1.65). This estimate is based on 718 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.38 percent at 2 years following the primary procedure. The 95% confidence interval was (0.75, 2.56). This estimate is based on 710 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 1.52 percent at 3 years following the primary procedure. The 95% confidence interval was (0.85, 2.73). This estimate is based on 705 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 2.24 percent at 4 years following the primary procedure. The 95% confidence interval was (1.38, 3.63). This estimate is based on 660 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 2.40 percent at 5 years following the primary procedure. The 95% confidence interval was (1.50, 3.83). This estimate is based on 612 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 3.08 percent at 6 years following the primary procedure. The 95% confidence interval was (2.02, 4.69). This estimate is based on 551 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 3.46 percent at 7 years following the primary procedure. The 95% confidence interval was (2.30, 5.17). This estimate is based on 466 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 3.46 percent at 8 years following the primary procedure. The 95% confidence interval was (2.30, 5.17). This estimate is based on 419 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 3.73 percent at 9 years following the primary procedure. The 95% confidence interval was (2.49, 5.55). This estimate is based on 339 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen Precoat implant combination for total knee arthroplasty (TKA) was 4.01 percent at 10 years following the primary procedure. The 95% confidence interval was (2.70, 5.95). This estimate is based on 212 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen TM implant combination for total knee arthroplasty (TKA) was 0.47 percent at 1 year following the primary procedure. The 95% confidence interval was (0.21, 1.04). This estimate is based on 1254 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen TM implant combination for total knee arthroplasty (TKA) was 0.71 percent at 2 years following the primary procedure. The 95% confidence interval was (0.37, 1.36). This estimate is based on 1200 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen TM implant combination for total knee arthroplasty (TKA) was 0.96 percent at 3 years following the primary procedure. The 95% confidence interval was (0.55, 1.68). This estimate is based on 1129 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen TM implant combination for total knee arthroplasty (TKA) was 1.14 percent at 4 years following the primary procedure. The 95% confidence interval was (0.67, 1.91). This estimate is based on 1061 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen TM implant combination for total knee arthroplasty (TKA) was 1.33 percent at 5 years following the primary procedure. The 95% confidence interval was (0.82, 2.17). This estimate is based on 998 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen TM implant combination for total knee arthroplasty (TKA) was 1.43 percent at 6 years following the primary procedure. The 95% confidence interval was (0.89, 2.30). This estimate is based on 935 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen TM implant combination for total knee arthroplasty (TKA) was 1.43 percent at 7 years following the primary procedure. The 95% confidence interval was (0.89, 2.30). This estimate is based on 863 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen TM implant combination for total knee arthroplasty (TKA) was 1.43 percent at 8 years following the primary procedure. The 95% confidence interval was (0.89, 2.30). This estimate is based on 705 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen TM implant combination for total knee arthroplasty (TKA) was 1.43 percent at 9 years following the primary procedure. The 95% confidence interval was (0.89, 2.30). This estimate is based on 470 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen LPS Option/NexGen TM implant combination for total knee arthroplasty (TKA) was 1.70 percent at 10 years following the primary procedure. The 95% confidence interval was (1.03, 2.82). This estimate is based on 238 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Option implant combination for total knee arthroplasty (TKA) was 0.31 percent at 1 year following the primary procedure. The 95% confidence interval was (0.12, 0.83). This estimate is based on 1241 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Option implant combination for total knee arthroplasty (TKA) was 0.64 percent at 2 years following the primary procedure. The 95% confidence interval was (0.32, 1.28). This estimate is based on 1207 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Option implant combination for total knee arthroplasty (TKA) was 0.97 percent at 3 years following the primary procedure. The 95% confidence interval was (0.55, 1.71). This estimate is based on 1161 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Option implant combination for total knee arthroplasty (TKA) was 1.06 percent at 4 years following the primary procedure. The 95% confidence interval was (0.62, 1.82). This estimate is based on 1077 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Option implant combination for total knee arthroplasty (TKA) was 1.16 percent at 5 years following the primary procedure. The 95% confidence interval was (0.69, 1.95). This estimate is based on 974 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Option implant combination for total knee arthroplasty (TKA) was 1.27 percent at 6 years following the primary procedure. The 95% confidence interval was (0.76, 2.10). This estimate is based on 841 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Option implant combination for total knee arthroplasty (TKA) was 1.41 percent at 7 years following the primary procedure. The 95% confidence interval was (0.86, 2.31). This estimate is based on 641 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Option implant combination for total knee arthroplasty (TKA) was 1.41 percent at 8 years following the primary procedure. The 95% confidence interval was (0.86, 2.31). This estimate is based on 410 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Option implant combination for total knee arthroplasty (TKA) was 1.41 percent at 9 years following the primary procedure. The 95% confidence interval was (0.86, 2.31). This estimate is based on 208 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Option implant combination for total knee arthroplasty (TKA) was 1.41 percent at 10 years following the primary procedure. The 95% confidence interval was (0.86, 2.31). This estimate is based on 41 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Pegged implant combination for total knee arthroplasty (TKA) was 0.81 percent at 1 year following the primary procedure. The 95% confidence interval was (0.34, 1.94). This estimate is based on 611 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Pegged implant combination for total knee arthroplasty (TKA) was 1.79 percent at 2 years following the primary procedure. The 95% confidence interval was (0.99, 3.20). This estimate is based on 605 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Pegged implant combination for total knee arthroplasty (TKA) was 2.44 percent at 3 years following the primary procedure. The 95% confidence interval was (1.48, 4.01). This estimate is based on 601 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Pegged implant combination for total knee arthroplasty (TKA) was 2.92 percent at 4 years following the primary procedure. The 95% confidence interval was (1.85, 4.60). This estimate is based on 598 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Pegged implant combination for total knee arthroplasty (TKA) was 2.92 percent at 5 years following the primary procedure. The 95% confidence interval was (1.85, 4.60). This estimate is based on 579 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Pegged implant combination for total knee arthroplasty (TKA) was 3.10 percent at 6 years following the primary procedure. The 95% confidence interval was (1.99, 4.81). This estimate is based on 505 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Pegged implant combination for total knee arthroplasty (TKA) was 3.10 percent at 7 years following the primary procedure. The 95% confidence interval was (1.99, 4.81). This estimate is based on 442 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Pegged implant combination for total knee arthroplasty (TKA) was 3.10 percent at 8 years following the primary procedure. The 95% confidence interval was (1.99, 4.81). This estimate is based on 317 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Pegged implant combination for total knee arthroplasty (TKA) was 3.45 percent at 9 years following the primary procedure. The 95% confidence interval was (2.21, 5.36). This estimate is based on 174 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Option/NextGen Pegged implant combination for total knee arthroplasty (TKA) was 3.45 percent at 10 years following the primary procedure. The 95% confidence interval was (2.21, 5.36). This estimate is based on 44 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Precoat/NextGen Precoat implant combination for total knee arthroplasty (TKA) was 0.92 percent at 1 year following the primary procedure. The 95% confidence interval was (0.38, 2.19). This estimate is based on 522 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Precoat/NextGen Precoat implant combination for total knee arthroplasty (TKA) was 1.71 percent at 2 years following the primary procedure. The 95% confidence interval was (0.89, 3.27). This estimate is based on 467 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Precoat/NextGen Precoat implant combination for total knee arthroplasty (TKA) was 1.92 percent at 3 years following the primary procedure. The 95% confidence interval was (1.04, 3.55). This estimate is based on 429 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Precoat/NextGen Precoat implant combination for total knee arthroplasty (TKA) was 2.43 percent at 4 years following the primary procedure. The 95% confidence interval was (1.38, 4.26). This estimate is based on 371 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Precoat/NextGen Precoat implant combination for total knee arthroplasty (TKA) was 2.43 percent at 5 years following the primary procedure. The 95% confidence interval was (1.38, 4.26). This estimate is based on 309 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Precoat/NextGen Precoat implant combination for total knee arthroplasty (TKA) was 2.43 percent at 6 years following the primary procedure. The 95% confidence interval was (1.38, 4.26). This estimate is based on 234 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Precoat/NextGen Precoat implant combination for total knee arthroplasty (TKA) was 2.97 percent at 7 years following the primary procedure. The 95% confidence interval was (1.66, 5.29). This estimate is based on 143 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Precoat/NextGen Precoat implant combination for total knee arthroplasty (TKA) was 2.97 percent at 8 years following the primary procedure. The 95% confidence interval was (1.66, 5.29). This estimate is based on 117 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Precoat/NextGen Precoat implant combination for total knee arthroplasty (TKA) was 2.97 percent at 9 years following the primary procedure. The 95% confidence interval was (1.66, 5.29). This estimate is based on 72 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NexGen Precoat/NextGen Precoat implant combination for total knee arthroplasty (TKA) was 2.97 percent at 10 years following the primary procedure. The 95% confidence interval was (1.66, 5.29). This estimate is based on 23 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II/NK II implant combination for total knee arthroplasty (TKA) was 0.20 percent at 1 year following the primary procedure. The 95% confidence interval was (0.05, 0.81). This estimate is based on 988 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II/NK II implant combination for total knee arthroplasty (TKA) was 0.71 percent at 2 years following the primary procedure. The 95% confidence interval was (0.34, 1.48). This estimate is based on 983 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II/NK II implant combination for total knee arthroplasty (TKA) was 1.11 percent at 3 years following the primary procedure. The 95% confidence interval was (0.62, 2.00). This estimate is based on 979 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II/NK II implant combination for total knee arthroplasty (TKA) was 1.41 percent at 4 years following the primary procedure. The 95% confidence interval was (0.84, 2.38). This estimate is based on 973 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II/NK II implant combination for total knee arthroplasty (TKA) was 1.62 percent at 5 years following the primary procedure. The 95% confidence interval was (1.00, 2.63). This estimate is based on 938 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II/NK II implant combination for total knee arthroplasty (TKA) was 1.73 percent at 6 years following the primary procedure. The 95% confidence interval was (1.08, 2.76). This estimate is based on 881 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II/NK II implant combination for total knee arthroplasty (TKA) was 1.97 percent at 7 years following the primary procedure. The 95% confidence interval was (1.26, 3.07). This estimate is based on 789 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II/NK II implant combination for total knee arthroplasty (TKA) was 1.97 percent at 8 years following the primary procedure. The 95% confidence interval was (1.26, 3.07). This estimate is based on 549 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II/NK II implant combination for total knee arthroplasty (TKA) was 2.18 percent at 9 years following the primary procedure. The 95% confidence interval was (1.40, 3.41). This estimate is based on 360 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II/NK II implant combination for total knee arthroplasty (TKA) was 2.52 percent at 10 years following the primary procedure. The 95% confidence interval was (1.58, 4.00). This estimate is based on 107 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II GS/NK II implant combination for total knee arthroplasty (TKA) was 0.37 percent at 1 year following the primary procedure. The 95% confidence interval was (0.22, 0.62). This estimate is based on 3664 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II GS/NK II implant combination for total knee arthroplasty (TKA) was 0.62 percent at 2 years following the primary procedure. The 95% confidence interval was (0.41, 0.93). This estimate is based on 3300 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II GS/NK II implant combination for total knee arthroplasty (TKA) was 0.91 percent at 3 years following the primary procedure. The 95% confidence interval was (0.64, 1.28). This estimate is based on 2989 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II GS/NK II implant combination for total knee arthroplasty (TKA) was 1.12 percent at 4 years following the primary procedure. The 95% confidence interval was (0.81, 1.53). This estimate is based on 2520 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II GS/NK II implant combination for total knee arthroplasty (TKA) was 1.34 percent at 5 years following the primary procedure. The 95% confidence interval was (0.99, 1.81). This estimate is based on 2025 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II GS/NK II implant combination for total knee arthroplasty (TKA) was 1.50 percent at 6 years following the primary procedure. The 95% confidence interval was (1.12, 2.02). This estimate is based on 1534 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II GS/NK II implant combination for total knee arthroplasty (TKA) was 1.83 percent at 7 years following the primary procedure. The 95% confidence interval was (1.36, 2.47). This estimate is based on 1064 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II GS/NK II implant combination for total knee arthroplasty (TKA) was 1.95 percent at 8 years following the primary procedure. The 95% confidence interval was (1.44, 2.65). This estimate is based on 683 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II GS/NK II implant combination for total knee arthroplasty (TKA) was 2.13 percent at 9 years following the primary procedure. The 95% confidence interval was (1.54, 2.96). This estimate is based on 341 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the NK II GS/NK II implant combination for total knee arthroplasty (TKA) was 2.13 percent at 10 years following the primary procedure. The 95% confidence interval was (1.54, 2.96). This estimate is based on 71 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for total knee arthroplasty (TKA) was 0.72 percent at 1 year following the primary procedure. The 95% confidence interval was (0.65, 0.79). This estimate is based on 54673 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for total knee arthroplasty (TKA) was 1.59 percent at 2 years following the primary procedure. The 95% confidence interval was (1.49, 1.70). This estimate is based on 45994 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for total knee arthroplasty (TKA) was 2.07 percent at 3 years following the primary procedure. The 95% confidence interval was (1.95, 2.20). This estimate is based on 39373 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for total knee arthroplasty (TKA) was 2.42 percent at 4 years following the primary procedure. The 95% confidence interval was (2.29, 2.57). This estimate is based on 31561 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for total knee arthroplasty (TKA) was 2.73 percent at 5 years following the primary procedure. The 95% confidence interval was (2.58, 2.88). This estimate is based on 24401 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for total knee arthroplasty (TKA) was 2.96 percent at 6 years following the primary procedure. The 95% confidence interval was (2.80, 3.12). This estimate is based on 17876 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for total knee arthroplasty (TKA) was 3.19 percent at 7 years following the primary procedure. The 95% confidence interval was (3.02, 3.38). This estimate is based on 11728 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for total knee arthroplasty (TKA) was 3.37 percent at 8 years following the primary procedure. The 95% confidence interval was (3.18, 3.57). This estimate is based on 6414 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for total knee arthroplasty (TKA) was 3.59 percent at 9 years following the primary procedure. The 95% confidence interval was (3.35, 3.84). This estimate is based on 2026 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for total knee arthroplasty (TKA) was 3.77 percent at 10 years following the primary procedure. The 95% confidence interval was (3.46, 4.10). This estimate is based on 18 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Scorpio/Series 7000 implant combination for total knee arthroplasty (TKA) was 1.38 percent at 1 year following the primary procedure. The 95% confidence interval was (0.72, 2.64). This estimate is based on 641 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Scorpio/Series 7000 implant combination for total knee arthroplasty (TKA) was 2.92 percent at 2 years following the primary procedure. The 95% confidence interval was (1.87, 4.54). This estimate is based on 631 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Scorpio/Series 7000 implant combination for total knee arthroplasty (TKA) was 4.00 percent at 3 years following the primary procedure. The 95% confidence interval was (2.74, 5.82). This estimate is based on 624 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Scorpio/Series 7000 implant combination for total knee arthroplasty (TKA) was 4.31 percent at 4 years following the primary procedure. The 95% confidence interval was (2.99, 6.18). This estimate is based on 622 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Scorpio/Series 7000 implant combination for total knee arthroplasty (TKA) was 4.98 percent at 5 years following the primary procedure. The 95% confidence interval was (3.55, 6.97). This estimate is based on 540 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Scorpio/Series 7000 implant combination for total knee arthroplasty (TKA) was 5.39 percent at 6 years following the primary procedure. The 95% confidence interval was (3.87, 7.47). This estimate is based on 413 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Scorpio/Series 7000 implant combination for total knee arthroplasty (TKA) was 5.39 percent at 7 years following the primary procedure. The 95% confidence interval was (3.87, 7.47). This estimate is based on 281 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Scorpio/Series 7000 implant combination for total knee arthroplasty (TKA) was 5.79 percent at 8 years following the primary procedure. The 95% confidence interval was (4.14, 8.06). This estimate is based on 170 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Scorpio/Series 7000 implant combination for total knee arthroplasty (TKA) was 7.41 percent at 9 years following the primary procedure. The 95% confidence interval was (4.93, 11.07). This estimate is based on 66 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Scorpio/Series 7000 implant combination for total knee arthroplasty (TKA) was 7.41 percent at 10 years following the primary procedure. The 95% confidence interval was (4.93, 11.07). This estimate is based on 26 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/M.B.T. implant combination for total knee arthroplasty (TKA) was 1.47 percent at 1 year following the primary procedure. The 95% confidence interval was (0.87, 2.46). This estimate is based on 927 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/M.B.T. implant combination for total knee arthroplasty (TKA) was 2.98 percent at 2 years following the primary procedure. The 95% confidence interval was (2.07, 4.29). This estimate is based on 879 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/M.B.T. implant combination for total knee arthroplasty (TKA) was 3.65 percent at 3 years following the primary procedure. The 95% confidence interval was (2.62, 5.08). This estimate is based on 843 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/M.B.T. implant combination for total knee arthroplasty (TKA) was 4.38 percent at 4 years following the primary procedure. The 95% confidence interval was (3.23, 5.92). This estimate is based on 758 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/M.B.T. implant combination for total knee arthroplasty (TKA) was 4.38 percent at 5 years following the primary procedure. The 95% confidence interval was (3.23, 5.92). This estimate is based on 661 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/M.B.T. implant combination for total knee arthroplasty (TKA) was 4.69 percent at 6 years following the primary procedure. The 95% confidence interval was (3.48, 6.30). This estimate is based on 568 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/M.B.T. implant combination for total knee arthroplasty (TKA) was 4.86 percent at 7 years following the primary procedure. The 95% confidence interval was (3.62, 6.51). This estimate is based on 453 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/M.B.T. implant combination for total knee arthroplasty (TKA) was 5.35 percent at 8 years following the primary procedure. The 95% confidence interval was (3.98, 7.17). This estimate is based on 362 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/M.B.T. implant combination for total knee arthroplasty (TKA) was 5.64 percent at 9 years following the primary procedure. The 95% confidence interval was (4.19, 7.57). This estimate is based on 193 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/M.B.T. implant combination for total knee arthroplasty (TKA) was 7.24 percent at 10 years following the primary procedure. The 95% confidence interval was (4.44, 11.70). This estimate is based on 44 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/Sigma implant combination for total knee arthroplasty (TKA) was 1.49 percent at 1 year following the primary procedure. The 95% confidence interval was (1.00, 2.22). This estimate is based on 1561 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/Sigma implant combination for total knee arthroplasty (TKA) was 2.40 percent at 2 years following the primary procedure. The 95% confidence interval was (1.75, 3.28). This estimate is based on 1468 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/Sigma implant combination for total knee arthroplasty (TKA) was 2.94 percent at 3 years following the primary procedure. The 95% confidence interval was (2.21, 3.90). This estimate is based on 1436 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/Sigma implant combination for total knee arthroplasty (TKA) was 3.14 percent at 4 years following the primary procedure. The 95% confidence interval was (2.38, 4.13). This estimate is based on 1394 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/Sigma implant combination for total knee arthroplasty (TKA) was 3.72 percent at 5 years following the primary procedure. The 95% confidence interval was (2.88, 4.79). This estimate is based on 1291 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/Sigma implant combination for total knee arthroplasty (TKA) was 3.95 percent at 6 years following the primary procedure. The 95% confidence interval was (3.08, 5.06). This estimate is based on 1178 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/Sigma implant combination for total knee arthroplasty (TKA) was 4.13 percent at 7 years following the primary procedure. The 95% confidence interval was (3.23, 5.27). This estimate is based on 959 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/Sigma implant combination for total knee arthroplasty (TKA) was 4.23 percent at 8 years following the primary procedure. The 95% confidence interval was (3.32, 5.39). This estimate is based on 778 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/Sigma implant combination for total knee arthroplasty (TKA) was 4.69 percent at 9 years following the primary procedure. The 95% confidence interval was (3.62, 6.05). This estimate is based on 340 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma/Sigma implant combination for total knee arthroplasty (TKA) was 4.69 percent at 10 years following the primary procedure. The 95% confidence interval was (3.62, 6.05). This estimate is based on 42 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma implant combination for total knee arthroplasty (TKA) was 0.67 percent at 1 year following the primary procedure. The 95% confidence interval was (0.45, 0.99). This estimate is based on 3519 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma implant combination for total knee arthroplasty (TKA) was 1.30 percent at 2 years following the primary procedure. The 95% confidence interval was (0.97, 1.73). This estimate is based on 3363 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma implant combination for total knee arthroplasty (TKA) was 1.93 percent at 3 years following the primary procedure. The 95% confidence interval was (1.52, 2.45). This estimate is based on 3142 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma implant combination for total knee arthroplasty (TKA) was 2.29 percent at 4 years following the primary procedure. The 95% confidence interval was (1.84, 2.85). This estimate is based on 2887 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma implant combination for total knee arthroplasty (TKA) was 2.50 percent at 5 years following the primary procedure. The 95% confidence interval was (2.02, 3.09). This estimate is based on 2605 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma implant combination for total knee arthroplasty (TKA) was 2.71 percent at 6 years following the primary procedure. The 95% confidence interval was (2.20, 3.32). This estimate is based on 2260 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma implant combination for total knee arthroplasty (TKA) was 2.84 percent at 7 years following the primary procedure. The 95% confidence interval was (2.32, 3.48). This estimate is based on 1939 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma implant combination for total knee arthroplasty (TKA) was 2.95 percent at 8 years following the primary procedure. The 95% confidence interval was (2.41, 3.61). This estimate is based on 1570 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma implant combination for total knee arthroplasty (TKA) was 3.33 percent at 9 years following the primary procedure. The 95% confidence interval was (2.69, 4.11). This estimate is based on 848 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma implant combination for total knee arthroplasty (TKA) was 3.33 percent at 10 years following the primary procedure. The 95% confidence interval was (2.69, 4.11). This estimate is based on 181 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma PFC All-Poly implant combination for total knee arthroplasty (TKA) was 0.73 percent at 1 year following the primary procedure. The 95% confidence interval was (0.28, 1.94). This estimate is based on 541 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma PFC All-Poly implant combination for total knee arthroplasty (TKA) was 1.10 percent at 2 years following the primary procedure. The 95% confidence interval was (0.50, 2.43). This estimate is based on 532 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma PFC All-Poly implant combination for total knee arthroplasty (TKA) was 1.29 percent at 3 years following the primary procedure. The 95% confidence interval was (0.62, 2.70). This estimate is based on 497 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma PFC All-Poly implant combination for total knee arthroplasty (TKA) was 1.29 percent at 4 years following the primary procedure. The 95% confidence interval was (0.62, 2.70). This estimate is based on 456 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma PFC All-Poly implant combination for total knee arthroplasty (TKA) was 1.29 percent at 5 years following the primary procedure. The 95% confidence interval was (0.62, 2.70). This estimate is based on 376 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma PFC All-Poly implant combination for total knee arthroplasty (TKA) was 1.29 percent at 6 years following the primary procedure. The 95% confidence interval was (0.62, 2.70). This estimate is based on 276 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma PFC All-Poly implant combination for total knee arthroplasty (TKA) was 1.29 percent at 7 years following the primary procedure. The 95% confidence interval was (0.62, 2.70). This estimate is based on 191 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma PFC All-Poly implant combination for total knee arthroplasty (TKA) was 1.29 percent at 8 years following the primary procedure. The 95% confidence interval was (0.62, 2.70). This estimate is based on 114 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma PFC All-Poly implant combination for total knee arthroplasty (TKA) was 1.29 percent at 9 years following the primary procedure. The 95% confidence interval was (0.62, 2.70). This estimate is based on 50 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Sigma PFC/Sigma PFC All-Poly implant combination for total knee arthroplasty (TKA) was 1.29 percent at 10 years following the primary procedure. The 95% confidence interval was (0.62, 2.70). This estimate is based on 7 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon implant combination for total knee arthroplasty (TKA) was 0.88 percent at 1 year following the primary procedure. The 95% confidence interval was (0.79, 0.98). This estimate is based on 33826 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon implant combination for total knee arthroplasty (TKA) was 1.54 percent at 2 years following the primary procedure. The 95% confidence interval was (1.41, 1.67). This estimate is based on 28688 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon implant combination for total knee arthroplasty (TKA) was 1.95 percent at 3 years following the primary procedure. The 95% confidence interval was (1.81, 2.11). This estimate is based on 24089 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon implant combination for total knee arthroplasty (TKA) was 2.24 percent at 4 years following the primary procedure. The 95% confidence interval was (2.08, 2.42). This estimate is based on 18432 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon implant combination for total knee arthroplasty (TKA) was 2.49 percent at 5 years following the primary procedure. The 95% confidence interval was (2.32, 2.68). This estimate is based on 14314 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon implant combination for total knee arthroplasty (TKA) was 2.68 percent at 6 years following the primary procedure. The 95% confidence interval was (2.49, 2.88). This estimate is based on 10153 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon implant combination for total knee arthroplasty (TKA) was 2.86 percent at 7 years following the primary procedure. The 95% confidence interval was (2.65, 3.08). This estimate is based on 6514 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon implant combination for total knee arthroplasty (TKA) was 3.01 percent at 8 years following the primary procedure. The 95% confidence interval was (2.78, 3.27). This estimate is based on 3673 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon implant combination for total knee arthroplasty (TKA) was 3.12 percent at 9 years following the primary procedure. The 95% confidence interval was (2.84, 3.41). This estimate is based on 1337 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon implant combination for total knee arthroplasty (TKA) was 3.59 percent at 10 years following the primary procedure. The 95% confidence interval was (3.08, 4.18). This estimate is based on 224 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon TS implant combination for total knee arthroplasty (TKA) was 0.91 percent at 1 year following the primary procedure. The 95% confidence interval was (0.81, 1.03). This estimate is based on 25887 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon TS implant combination for total knee arthroplasty (TKA) was 1.74 percent at 2 years following the primary procedure. The 95% confidence interval was (1.59, 1.91). This estimate is based on 22794 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon TS implant combination for total knee arthroplasty (TKA) was 2.22 percent at 3 years following the primary procedure. The 95% confidence interval was (2.05, 2.41). This estimate is based on 20065 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon TS implant combination for total knee arthroplasty (TKA) was 2.52 percent at 4 years following the primary procedure. The 95% confidence interval was (2.33, 2.72). This estimate is based on 16764 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon TS implant combination for total knee arthroplasty (TKA) was 2.84 percent at 5 years following the primary procedure. The 95% confidence interval was (2.64, 3.07). This estimate is based on 13175 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon TS implant combination for total knee arthroplasty (TKA) was 3.17 percent at 6 years following the primary procedure. The 95% confidence interval was (2.94, 3.41). This estimate is based on 9805 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon TS implant combination for total knee arthroplasty (TKA) was 3.38 percent at 7 years following the primary procedure. The 95% confidence interval was (3.13, 3.65). This estimate is based on 6615 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon TS implant combination for total knee arthroplasty (TKA) was 3.60 percent at 8 years following the primary procedure. The 95% confidence interval was (3.33, 3.90). This estimate is based on 4065 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon TS implant combination for total knee arthroplasty (TKA) was 3.95 percent at 9 years following the primary procedure. The 95% confidence interval was (3.60, 4.32). This estimate is based on 1789 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Triathlon/Triathlon TS implant combination for total knee arthroplasty (TKA) was 4.08 percent at 10 years following the primary procedure. The 95% confidence interval was (3.70, 4.51). This estimate is based on 525 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim implant combination for total knee arthroplasty (TKA) was 0.81 percent at 1 year following the primary procedure. The 95% confidence interval was (0.70, 0.93). This estimate is based on 21644 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim implant combination for total knee arthroplasty (TKA) was 1.55 percent at 2 years following the primary procedure. The 95% confidence interval was (1.39, 1.72). This estimate is based on 20319 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim implant combination for total knee arthroplasty (TKA) was 2.07 percent at 3 years following the primary procedure. The 95% confidence interval was (1.88, 2.27). This estimate is based on 19014 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim implant combination for total knee arthroplasty (TKA) was 2.39 percent at 4 years following the primary procedure. The 95% confidence interval was (2.19, 2.61). This estimate is based on 17177 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim implant combination for total knee arthroplasty (TKA) was 2.67 percent at 5 years following the primary procedure. The 95% confidence interval was (2.46, 2.90). This estimate is based on 14629 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim implant combination for total knee arthroplasty (TKA) was 2.96 percent at 6 years following the primary procedure. The 95% confidence interval was (2.73, 3.21). This estimate is based on 11578 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim implant combination for total knee arthroplasty (TKA) was 3.23 percent at 7 years following the primary procedure. The 95% confidence interval was (2.98, 3.50). This estimate is based on 8131 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim implant combination for total knee arthroplasty (TKA) was 3.41 percent at 8 years following the primary procedure. The 95% confidence interval was (3.14, 3.70). This estimate is based on 5032 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim implant combination for total knee arthroplasty (TKA) was 3.43 percent at 9 years following the primary procedure. The 95% confidence interval was (3.16, 3.72). This estimate is based on 2550 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim implant combination for total knee arthroplasty (TKA) was 3.54 percent at 10 years following the primary procedure. The 95% confidence interval was (3.23, 3.87). This estimate is based on 716 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim Mono-Lock implant combination for total knee arthroplasty (TKA) was 0.57 percent at 1 year following the primary procedure. The 95% confidence interval was (0.27, 1.19). This estimate is based on 1207 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim Mono-Lock implant combination for total knee arthroplasty (TKA) was 1.57 percent at 2 years following the primary procedure. The 95% confidence interval was (1.01, 2.46). This estimate is based on 1131 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim Mono-Lock implant combination for total knee arthroplasty (TKA) was 2.03 percent at 3 years following the primary procedure. The 95% confidence interval was (1.36, 3.01). This estimate is based on 1020 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim Mono-Lock implant combination for total knee arthroplasty (TKA) was 2.55 percent at 4 years following the primary procedure. The 95% confidence interval was (1.78, 3.66). This estimate is based on 855 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim Mono-Lock implant combination for total knee arthroplasty (TKA) was 3.05 percent at 5 years following the primary procedure. The 95% confidence interval was (2.17, 4.28). This estimate is based on 711 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim Mono-Lock implant combination for total knee arthroplasty (TKA) was 3.69 percent at 6 years following the primary procedure. The 95% confidence interval was (2.66, 5.11). This estimate is based on 543 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim Mono-Lock implant combination for total knee arthroplasty (TKA) was 3.69 percent at 7 years following the primary procedure. The 95% confidence interval was (2.66, 5.11). This estimate is based on 412 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim Mono-Lock implant combination for total knee arthroplasty (TKA) was 4.19 percent at 8 years following the primary procedure. The 95% confidence interval was (3.01, 5.83). This estimate is based on 269 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim Mono-Lock implant combination for total knee arthroplasty (TKA) was 4.72 percent at 9 years following the primary procedure. The 95% confidence interval was (3.27, 6.79). This estimate is based on 132 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard/Maxim Mono-Lock implant combination for total knee arthroplasty (TKA) was 5.49 percent at 10 years following the primary procedure. The 95% confidence interval was (3.62, 8.29). This estimate is based on 60 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard XP/Vanguard XP implant combination for total knee arthroplasty (TKA) was 2.56 percent at 1 year following the primary procedure. The 95% confidence interval was (1.52, 4.28). This estimate is based on 533 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard XP/Vanguard XP implant combination for total knee arthroplasty (TKA) was 7.31 percent at 2 years following the primary procedure. The 95% confidence interval was (5.42, 9.84). This estimate is based on 507 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard XP/Vanguard XP implant combination for total knee arthroplasty (TKA) was 9.87 percent at 3 years following the primary procedure. The 95% confidence interval was (7.65, 12.69). This estimate is based on 493 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard XP/Vanguard XP implant combination for total knee arthroplasty (TKA) was 10.79 percent at 4 years following the primary procedure. The 95% confidence interval was (8.47, 13.71). This estimate is based on 450 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard XP/Vanguard XP implant combination for total knee arthroplasty (TKA) was 11.64 percent at 5 years following the primary procedure. The 95% confidence interval was (9.21, 14.66). This estimate is based on 382 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard XP/Vanguard XP implant combination for total knee arthroplasty (TKA) was 12.15 percent at 6 years following the primary procedure. The 95% confidence interval was (9.65, 15.25). This estimate is based on 314 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard XP/Vanguard XP implant combination for total knee arthroplasty (TKA) was 12.15 percent at 7 years following the primary procedure. The 95% confidence interval was (9.65, 15.25). This estimate is based on 291 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard XP/Vanguard XP implant combination for total knee arthroplasty (TKA) was 12.52 percent at 8 years following the primary procedure. The 95% confidence interval was (9.94, 15.70). This estimate is based on 220 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Vanguard XP/Vanguard XP implant combination for total knee arthroplasty (TKA) was 12.52 percent at 9 years following the primary procedure. The 95% confidence interval was (9.94, 15.70). This estimate is based on 78 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Oxford/Oxford implant combination for unicompartmental knee arthroplasty (UKA) was 1.79 percent at 1 year following the primary procedure. The 95% confidence interval was (1.38, 2.33). This estimate is based on 2970 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Oxford/Oxford implant combination for unicompartmental knee arthroplasty (UKA) was 3.86 percent at 2 years following the primary procedure. The 95% confidence interval was (3.22, 4.61). This estimate is based on 2771 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Oxford/Oxford implant combination for unicompartmental knee arthroplasty (UKA) was 4.85 percent at 3 years following the primary procedure. The 95% confidence interval was (4.14, 5.69). This estimate is based on 2580 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Oxford/Oxford implant combination for unicompartmental knee arthroplasty (UKA) was 6.03 percent at 4 years following the primary procedure. The 95% confidence interval was (5.22, 6.97). This estimate is based on 2265 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Oxford/Oxford implant combination for unicompartmental knee arthroplasty (UKA) was 6.96 percent at 5 years following the primary procedure. The 95% confidence interval was (6.07, 7.98). This estimate is based on 1920 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Oxford/Oxford implant combination for unicompartmental knee arthroplasty (UKA) was 7.98 percent at 6 years following the primary procedure. The 95% confidence interval was (7.00, 9.09). This estimate is based on 1526 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Oxford/Oxford implant combination for unicompartmental knee arthroplasty (UKA) was 9.19 percent at 7 years following the primary procedure. The 95% confidence interval was (8.08, 10.45). This estimate is based on 1019 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Oxford/Oxford implant combination for unicompartmental knee arthroplasty (UKA) was 10.28 percent at 8 years following the primary procedure. The 95% confidence interval was (8.99, 11.74). This estimate is based on 540 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Oxford/Oxford implant combination for unicompartmental knee arthroplasty (UKA) was 12.19 percent at 9 years following the primary procedure. The 95% confidence interval was (10.38, 14.30). This estimate is based on 243 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Oxford/Oxford implant combination for unicompartmental knee arthroplasty (UKA) was 13.10 percent at 10 years following the primary procedure. The 95% confidence interval was (10.71, 15.97). This estimate is based on 78 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for unicompartmental knee arthroplasty (UKA) was 1.27 percent at 1 year following the primary procedure. The 95% confidence interval was (0.89, 1.80). This estimate is based on 2087 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for unicompartmental knee arthroplasty (UKA) was 2.23 percent at 2 years following the primary procedure. The 95% confidence interval was (1.69, 2.94). This estimate is based on 1674 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for unicompartmental knee arthroplasty (UKA) was 2.83 percent at 3 years following the primary procedure. The 95% confidence interval was (2.19, 3.66). This estimate is based on 1255 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for unicompartmental knee arthroplasty (UKA) was 3.22 percent at 4 years following the primary procedure. The 95% confidence interval was (2.49, 4.15). This estimate is based on 595 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the Persona/Persona implant combination for unicompartmental knee arthroplasty (UKA) was 3.22 percent at 5 years following the primary procedure. The 95% confidence interval was (2.49, 4.15). This estimate is based on 111 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RESTORIS-MCK/RESTORIS-MCK implant combination for unicompartmental knee arthroplasty (UKA) was 1.12 percent at 1 year following the primary procedure. The 95% confidence interval was (0.89, 1.42). This estimate is based on 5727 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RESTORIS-MCK/RESTORIS-MCK implant combination for unicompartmental knee arthroplasty (UKA) was 2.42 percent at 2 years following the primary procedure. The 95% confidence interval was (2.05, 2.85). This estimate is based on 4935 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RESTORIS-MCK/RESTORIS-MCK implant combination for unicompartmental knee arthroplasty (UKA) was 3.16 percent at 3 years following the primary procedure. The 95% confidence interval was (2.73, 3.66). This estimate is based on 4311 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RESTORIS-MCK/RESTORIS-MCK implant combination for unicompartmental knee arthroplasty (UKA) was 4.03 percent at 4 years following the primary procedure. The 95% confidence interval was (3.52, 4.62). This estimate is based on 3453 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RESTORIS-MCK/RESTORIS-MCK implant combination for unicompartmental knee arthroplasty (UKA) was 4.68 percent at 5 years following the primary procedure. The 95% confidence interval was (4.11, 5.33). This estimate is based on 2449 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RESTORIS-MCK/RESTORIS-MCK implant combination for unicompartmental knee arthroplasty (UKA) was 5.22 percent at 6 years following the primary procedure. The 95% confidence interval was (4.58, 5.96). This estimate is based on 1620 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RESTORIS-MCK/RESTORIS-MCK implant combination for unicompartmental knee arthroplasty (UKA) was 5.87 percent at 7 years following the primary procedure. The 95% confidence interval was (5.10, 6.76). This estimate is based on 830 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RESTORIS-MCK/RESTORIS-MCK implant combination for unicompartmental knee arthroplasty (UKA) was 7.41 percent at 8 years following the primary procedure. The 95% confidence interval was (6.07, 9.03). This estimate is based on 255 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RESTORIS-MCK/RESTORIS-MCK implant combination for unicompartmental knee arthroplasty (UKA) was 8.12 percent at 9 years following the primary procedure. The 95% confidence interval was (6.32, 10.40). This estimate is based on 99 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the RESTORIS-MCK/RESTORIS-MCK implant combination for unicompartmental knee arthroplasty (UKA) was 12.59 percent at 10 years following the primary procedure. The 95% confidence interval was (7.53, 20.65). This estimate is based on 36 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the ZUK/ZUK implant combination for unicompartmental knee arthroplasty (UKA) was 1.08 percent at 1 year following the primary procedure. The 95% confidence interval was (0.77, 1.51). This estimate is based on 3024 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the ZUK/ZUK implant combination for unicompartmental knee arthroplasty (UKA) was 2.26 percent at 2 years following the primary procedure. The 95% confidence interval was (1.79, 2.85). This estimate is based on 2927 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the ZUK/ZUK implant combination for unicompartmental knee arthroplasty (UKA) was 3.04 percent at 3 years following the primary procedure. The 95% confidence interval was (2.49, 3.72). This estimate is based on 2761 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the ZUK/ZUK implant combination for unicompartmental knee arthroplasty (UKA) was 3.52 percent at 4 years following the primary procedure. The 95% confidence interval was (2.91, 4.24). This estimate is based on 2505 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the ZUK/ZUK implant combination for unicompartmental knee arthroplasty (UKA) was 4.00 percent at 5 years following the primary procedure. The 95% confidence interval was (3.35, 4.78). This estimate is based on 2225 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the ZUK/ZUK implant combination for unicompartmental knee arthroplasty (UKA) was 4.29 percent at 6 years following the primary procedure. The 95% confidence interval was (3.60, 5.10). This estimate is based on 1882 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the ZUK/ZUK implant combination for unicompartmental knee arthroplasty (UKA) was 4.69 percent at 7 years following the primary procedure. The 95% confidence interval was (3.95, 5.56). This estimate is based on 1412 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the ZUK/ZUK implant combination for unicompartmental knee arthroplasty (UKA) was 5.12 percent at 8 years following the primary procedure. The 95% confidence interval was (4.31, 6.08). This estimate is based on 933 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the ZUK/ZUK implant combination for unicompartmental knee arthroplasty (UKA) was 5.57 percent at 9 years following the primary procedure. The 95% confidence interval was (4.64, 6.69). This estimate is based on 449 primary cases at risk.
The Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI) reported in its 2023 annual report that the ZUK/ZUK implant combination for unicompartmental knee arthroplasty (UKA) was 5.93 percent at 10 years following the primary procedure. The 95% confidence interval was (4.82, 7.29). This estimate is based on 99 primary cases at risk.